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Breast cancer is by far the most common cancer in European and North American women.1 In 
the Netherlands, 13,257 women were diagnosed with breast cancer in 2010.2 Due to earlier 
diagnosis and improved treatment, the five year relative survival has increased from 77% for 
women diagnosed in 1989 - 1993 to 86% for women diagnosed in 2004 – 2008. This leads to an 
increasing number of patients requiring follow-up care. 
Breast cancer follow-up care
Breast cancer follow-up care focuses on three elements, the primary purpose of which is early 
detection of loco-regional recurrences or a second primary tumour, in order to start immediate 
potentially curative therapy and prolong survival. Other reasons for providing follow-up care 
are the detection of side-effects of treatment and the provision of psychosocial support. In 
the Netherlands, national guidelines for breast cancer follow-up care have existed since 1999, 
suggesting a standard follow-up schedule lasting of 5 years for all breast cancer patients.3 Until 
the arrival of the newest version of the guideline in 2012, the guideline recommended patients 
visit the hospital every 3 months in the first year after breast cancer treatment, every 6 months 
in the second year and annually during the subsequent 3 years (Figure 1a). During these visits, 
a physical examination was performed, supported by an annual mammogram. After the first 
5 years of follow-up, annual in-hospital follow-up continued until the age of 60. Patients older 
than 60 were referred to the general practitioner if treated with breast conserving surgery (a 
mammogram is performed biennially in hospital) or to the national screening programme if 
treated with ablative surgery. In the national screening programme, women between 50 and 
75 years old underwent a standard biennial screening mammogram. For patients older than 75 
no follow-up care was recommended. 
Due to the increasing burden for health professionals and the doubtful benefits of routine 
follow-up visits4-7, debate continues about the frequency and duration of follow-up, who 
should provide follow-up care and which diagnostic tests should be performed. There is also a 
lack of knowledge about the daily practice of follow-up care. Since the opinions of patients and 
health professionals will strongly influence (non) adherence to the guidelines, it is important 
to evaluate the adherence to the guideline and to explore their opinions, before changes can 
be made to optimise follow-up.
Risk of relapse
The early detection of loco-regional recurrences and second primary tumours is the primary 
purpose of follow-up care. In the Netherlands, 3% of all the patients who received breast 
conserving therapy developed a recurrence within 5 years.8 Inadequate surgical margins 
resulted in an increased risk of local recurrences.9,10 The majority of studies report positive 
resection margins in 20% to 40% of the patients who underwent breast-conserving therapy.11 
Although previous studies have shown that there are several factors related to the risk of 
positive surgical margins, there is no practical tool for professionals to estimate the risk of 
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A: < 60 years of age annual visit and mammogram continue
B: 60 - 75 years of age patients are referred to the general practitioner (biennial 
mammogram in hospital) or national screening programme 
C: > 75 years of age consider to end follow-up care
follow-up year
follow-up year
Frequency of follow-up visits + annual mammogram
a: until 2012
Follow-up schedule
b: since 2012
Personal follow-up care plan
1 2 3 4 5
Frequency of follow-up visits + annual mammogram
1 2 3 4 5
A
B
C
A
B
C
Figure 1 Follow-up schedules according the national guideline a: until 2012 b: since 2012. 
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positive margins. Besides positive surgical margins, risk factors for loco-regional recurrences 
are younger age, higher tumour stage, higher grade, negative hormone receptor status and 
lack of adjuvant treatment. Although with inconsistent results, some studies have also reported 
that lobular breast cancer is a prognostic factor for better disease free survival. 
Distant metastases after breast cancer treatment are generally considered incurable. Early 
detection of metastases results in no improvement in survival or quality of life and is therefore 
not a specific goal of follow-up. The median survival after the diagnosis of metastases 
ranges between 18 and 30 months.12,13 However, metastatic breast cancer patients form a 
heterogeneous group and survival varies greatly from a few months to several years. Various 
studies investigating prognostic factors for survival after distant metastases show that older 
age, initial higher tumour grade and negative hormone receptor status, a shorter metastasis 
free interval and multiple sites of metastases are important prognostic factors for worse 
survival.12-17 However, hormone receptor status is related to the other prognostic factors and 
information about the interaction between hormone receptor status and other prognostic 
factors remains poor.
Women with a history of breast cancer have a 2-3 fold higher risk of developing a contralateral 
breast cancer as compared with the general female population.18-21 Besides an elevated risk of 
contralateral breast cancer, several studies revealed that women with a primary breast cancer 
have an increased risk of developing a subsequent non-breast cancer. Increased risks were most 
consistently found for tumours of the ovary, endometrium, soft tissue and for leukaemia.18-23 
Even so, information about the risk of subsequent cancer after bilateral breast cancer is lacking. 
Population-based information on prognostic factors for the risk of recurrences and survival 
after distant metastasis could further improve breast cancer follow-up care and may assist 
physicians in making clinical decisions. 
Objective of the thesis
The objective of this thesis is twofold. The first is to evaluate current follow-up practice. In 
order to do so, adherence to follow-up guidelines is evaluated, the relation between in-hospital 
follow-up visits and the national screening programme is investigated, and the opinions of health 
professionals and patients about the follow-up guidelines are explored. The second objective, 
to evaluate prognostic factors for the risk of relapse, is achieved by identifying prognostic 
factors for positive surgical margins after breast conserving therapy. We determined whether 
histological type is an independent prognostic factor; the risk of third non breast cancer after 
bilateral breast cancer was investigated; and we investigated independent prognostic factors 
for the survival after distant metastasis.
Chapter  1
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Outline of the thesis
This thesis consists of two sections. In the first section, we focus on the follow-up practice. 
Chapter 2 provides an evaluation of the adherence to follow-up guidelines for women diagnosed 
with breast cancer in two top clinical hospitals and factors associated with the adherence are 
described. Since 1996 a population-based breast cancer screening programme has been fully 
implemented in the Netherlands. As the relation between the in-hospital follow-up and the 
screening programme is not well established, Chapter 3 provides results for breast cancer 
patients attending the screening programme during their in-hospital follow-up (overlap) and the 
(re-)attendance to the screening programme after more than 5 years of in-hospital follow-up. 
Adherence to follow-up guidelines is shown to be dependent on the opinions from health care 
professionals and patients. Chapter 4 presents results of a qualitative study exploring opinions 
and preferences of health care professionals and patients about different aspects of follow-up, 
including the purpose of follow-up, the duration and frequency, which examinations should be 
done and by whom.
In the second section of this thesis, we present studies about the risk of relapse. These find that 
early detection of loco-regional recurrences and subsequent breast cancer is an important goal 
of follow-up care, and that positive margins after breast-conserving surgery are a significant 
risk factor for local recurrences. Chapter 5 examines prognostic factors for positive surgical 
margins after breast conserving therapy, and provides a nomogram, which can be used by 
professionals to estimate the risk of surgical margins. However, whether histological type is a 
prognostic factor for the risk of loco-regional recurrences and distant metastases, independent 
of other risk factors remains unclear. In Chapter 6 we determine whether histological type is an 
independent prognostic factor. Next, the risk of a third non-breast cancer after bilateral breast 
cancer is investigated, and the results are presented in Chapter 7. Although metastatic breast 
cancer is considered incurable, outcomes vary so Chapter 8 considers whether age, stage, 
metastatic-free interval and site of distant metastases are independent prognostic factors. 
Since the revision of the guideline in 2012, for the first 5 years, follow-up visits for physical 
examination have been restricted to an annual visit (figure 1b). In addition, a personal follow-up 
care plan is to be set up, tailor-made to the needs of the patient. In the general discussion 
(Chapter 9) we focus on the implementation of the revised follow-up guideline and discuss the 
opportunities for individualised follow-up schedules. 
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follow-up practice
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Evaluation of the adherence to follow-up care guidelines for 
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Abstract
Purpose
To evaluate adherence with follow-up criteria as suggested by the national guideline for breast 
cancer patients.
Method
Patients diagnosed with breast cancer in 2003 in two hospitals were identified from 
the Netherlands Cancer Registry (n=198). Compliance with the guideline was assessed 
retrospectively by extracting follow-up care data from patient files for a period of five years.
Results
Follow-up data were available for 196 patients. In the first year of follow-up, fewer 
consultations were performed compared to guideline standards. In the second through the 
fifth year of follow-up, more consultations were performed, with nearly double the number of 
consultations in the third until the fifth year compared to the guideline (p < 0.05). This excess 
usage was mainly associated with the fact that women had received radiotherapy (p < 0.01). 
Physical examinations were performed during 97 percent of consultations. Mammograms 
were performed slightly less often than suggested.
Conclusions
Among women receiving follow-up care after breast cancer, more consultations were provided 
compared to the guideline recommendations. Mammograms were performed slightly less 
often than recommended. With regard to the performance of physical examinations, the 
guideline was followed. 
Chapter  2
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Background
Breast cancer is the most frequently occurring cancer among women in the Netherlands.1 In 
1989, 7,704 women were diagnosed with invasive breast cancer, a number which increased 
to 13,005 new cases in 2008.2 Due to improved treatment and early diagnosis, the five 
year relative survival has increased from 76% for women diagnosed in 1988-1992 to 85% 
for women diagnosed in 2003.2,3 The first choice of treatment for invasive breast cancer is 
surgery, either breast conserving or mastectomy. Adjuvant treatment for breast cancer can 
include radiotherapy, chemotherapy, immunotherapy and/or hormone therapy depending on 
patient and tumour characteristics.4 Consequently, four disciplines are often involved in the 
care process of breast cancer patients: the general practitioner, surgeon, medical oncologist 
and the radiation oncologist.5
Women who received curative treatment for breast cancer are entitled to follow-up care. The 
period of follow-up starts after treatment of the primary tumour, which can include chemo- 
and radiotherapy. The follow-up has several aims, the main one of which is detection of 
recurrent curative treatable tumours, either local or regional, or a second primary tumour 
(ipsi-/contralateral).6 In the Netherlands, 3% of all the patients that received breast conserving 
therapy developed a recurrence within five years.7 Literature indicates that the majority of the 
recurrences can be observed within the first five years of follow-up. A peak in time of diagnosis 
of these recurrences can be observed at 24 months and possibly also at 60 months.8 There 
is no screening for asymptomatic distant metastases, since early detection and subsequent 
treatment does not improve survival.8,9 Except for the yearly mammogram, advanced 
diagnostic imaging is therefore not recommended in asymptomatic women.9 Other aims of 
follow-up include early detection and the treatment or monitoring of treatment side-effects, 
psychosocial counselling and recognizing serious mental problems.6
There are different strategies for follow-up: follow-up comprising clinical visits and a yearly 
mammogram or a more intense follow-up including laboratory and radiology testing. In a 
review, Rojas et al.10 suggest that, with regard to the detection of malignancies, the less intense 
follow-up (regular physical examinations and an annual mammography) is as effective as the 
more intense follow-up (regular execution of laboratory and instrumental examinations). 
In the Netherlands, a national guideline has been developed by the National Breast Cancer 
Consideration Netherland (NABON) for the follow-up procedures after the treatment of breast 
cancer.4 This guideline states that women should receive follow-up care for a minimum of 
five years. The frequency of visits changes over the years: in the first year the woman should 
be seen four times, in the second year twice, and thereafter once a year. During these visits 
women receive a physical examination and once a year a mammogram. In 2008 the guidelines 
have been revised.
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Due to the increase in incidence of breast cancer and the higher rate of survival, the burden 
on caregivers for breast cancer treatment and follow-up is growing. This can result in problems 
with regard to the number of follow-up consultations the breast cancer centre can conduct.11 
Few information is available about the follow-up care provided and adherence to the national 
guideline in the daily life setting. The aim of this paper is to evaluate adherence with follow-up 
criteria as suggested by the national guideline and to determine the factors that influence the 
adherence to this guideline.
Patients and Methods
Study population
Patients were identified from the database of the Netherlands Cancer Registry. Based on 
pathological notification through the PALGA (automated pathology archive) system, trained 
registration clerks gather data concerning patient, tumour and treatment characteristics from 
the patients files. The topography and morphology are coded according to the International 
Classification of Diseases for oncology (ICD-O). Staging is coded according to the tumour, node, 
and metastasis system (TNM) classification.12
Inclusion criteria were: women diagnosed in 2003 with invasive breast cancer, and curatively 
treated by means of surgery (breast conserving or mastectomy) in the Deventer Hospital 
(DH) (Deventer, the Netherlands) and the Medical Spectrum Twente (MST) (Enschede, the 
Netherlands). Exclusion criteria were: metastases at diagnosis and a simultaneous tumour in 
the other breast. In total 198 patients were selected.
Data collection
Additional patient-, tumour- and specific follow-up information were acquired from the patient 
files and the electronic patient records in the two teaching hospitals. In the MST, data regarding 
radiotherapeutic treatment and follow-up were obtained from theradiotherapeutic department 
within the hospital and, for the DH, from the radiotherapeutic centre “Radiotherapeutisch 
Instituut Stedendriehoek en Omstreken” (RISO, Deventer, the Netherlands). Data were 
collected from 2003 for a period of five years. This timeframe was chosen to determine the 
consistency with the 5-year follow-up guideline. Ethical approval was obtained through the 
Committee of Privacy of the Cancer Registry.
During the study period, the 2002 NABON guideline was available for the follow-up of breast 
cancer patients. Adherence to this guideline was determined by the frequency of follow-up 
consultations and the performance of the annual mammogram. This study includes the follow-up 
consults with the surgeon and the radiation oncologist (including the consultations performed 
by interns, nurse practitioners, physician assistants and breast care nurses), because these 
health professionals were actively involved in the follow-up care in both hospitals. The “start of 
the follow-up period” was defined as the date of the end of the treatment, which was the date 
of surgery or the end date of adjuvant treatment (radiotherapy and/or chemotherapy) plus ten 
Chapter  2
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weeks. The ten weeks were added because it was difficult to distinguish routine post-treatment 
visits (e.g. wound control) and follow-up care in the first period after treatment. A distinction 
was made between women who received fewer consultations and/or mammograms (including 
routine MRI’s for the mamma) compared to the guideline and women who received more 
consultations compared (excess use) to the guideline. During every consultation the women 
should receive a physical examination. The following were recorded: the performer of the 
consultation, patient complaints, additional diagnostics and the outcome of the consultation. 
To determine the rate of recurrent malignancies, the local and regional recurrences, metastases 
as well as secondary tumours were recorded. Besides this, the caregiver who requested the 
test leading to the diagnosis was determined (the surgeon or radiation oncologist versus other 
disciplines). A distinction was made between malignancies found by the yearly mammogram 
or as an outcome of a consultation.
Statistical analysis
To compare the actual performance of follow-up care with their commendations in the 
national guideline, the Pearson χ2 test was used. When the number of patients was too 
small, the Fisher’s exact test was applied. To compare means, the Student’s t-test was used. 
In case an observed mean was compared to expected means as indicated by the guideline, 
a one-sample t-test was conducted. A one-way analysis of variance (ANOVA) was performed 
to determine if significant differences between means of follow-up consultations were found 
by subgroups of patient, tumour or treatment characteristics. For these comparisons several 
independent variables were used, age was collapsed into three categories (0-45, 46-60, 60+), 
stage in stage I, II, III or unknown, the different adjuvant treatments in either radiotherapy or 
none, chemotherapy or none and/or hormone therapy or none. Complaints were collapsed 
into 4 categories based on the total number of consultations in which a woman experienced 
complaints (0-25%, 25-50%, 50-75% or 75-100%). Both hospitals were also compared. The 
dependent variable was the number of follow-up consultations in the second through fifth 
year. Consequently, in this analysis only patients who completed the full five years of follow-up 
were included, since otherwise an average of these years could not be taken (N = 142).
In addition, a multiple linear regression analysis was performed to determine the independent 
association of factors that influence and predict the frequency of the follow-up consultations. 
The dependent variable was the number of follow-up consultations in the second through the 
fifth year. The independent variables were age, stage and the different adjuvant treatments. 
Both hospitals were also included. In modelling the multiple linear regression, variables were 
considered confounders and included in the model when the regression coefficient of the 
variable of interest changed by more than 10%. Analyses were performed in STATA version 
10.1. The significance level was set at p = 0.05.
The endpoints of the follow-up period were: completion of five years of follow-up, a disease 
relapse (local/regional recurrence, metastases and/or a second primary tumour), when the 
patient died or if the woman was lost to follow-up. Only complete years of follow-up were 
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included. If a patient experienced a relapse for example in the third month of the fourth 
follow-up year, only the first three completed follow-up years were included. With regard to 
the adherence to the recommendation of the annual mammogram, women who underwent a 
prophylactic mastectomy of the contra-lateral breast were excluded.
Results
Patient characteristics
Of the 198 women, two women were excluded based on findings during the additional data 
collection. Reasons for exclusion were: not curatively treated (1 record) and one patient with 
a total of 46 follow-up consultations. This led to a total of 196 women. Table 1 presents the 
overall patient characteristics and the characteristics per hospital for these 196 patients. The 
mean age (±SD) was 57.5 (13.3) years. Women from the MST were somewhat younger than 
women treated in the DH; 55.7 (13.5) years compared to 59.2 (12.9) years (p = 0.07). The 
MST had the highest percentage of women that received a mastectomy (65%). With regard to 
additional therapy: nearly 70% of the patients in the DH received radiotherapy, while just under 
60% of women at the MST received radiotherapy. For chemotherapy and hormone therapy, no 
statistical differences were found between the hospitals.
Table 1 Patient characteristics (per hospital and total)
MST DH  Total
N % N % N % P value 
Total 97 99 196
Age mean (SD), (in years) 55.7 (13.5) 59.2 (12.9) 57.5 (13.3) 0.07
0-45 22 23 13 13 35 18
46-60 43 44 43 43 86 44
60+ 32 33 43 43 75 39
Stage
I 31 32 38 38 69 35 0.49 
II 54 56 46 46 100 51
III 12 12 14 14 26 13
Unknown 0 0 1 1 1 1
Treatment 
Surgery
Ablation/Mastectomy 63 65 51 52 114 58 0.06
Breast conserving 34 35 48 48 82 42 0.06
Adjuvant
Chemotherapy 45 46 41 41 86 44 0.48
Radiotherapy 56 58 69 69 125 64  0.08
Hormone therapy 49 51 52 53 101 52 0.78
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Table 2 Average number of follow-up consultations and mammograms per follow-up year per hospital
MST 
NABON N Mean SD
Less than 
recommended 
As recommended
More than 
recommended      
N % N % N %
Consultation(s)
Year 1 4 95 2,80* 0,92 81 86 9 10 5 4
Year 2 2 90 2,64* 0,95 6 7 39 43 45 50
Year 3 1 87 2,05* 0,79 2 2 15 18 70 80
Year 4 1 80 1,89* 0,67 3 4 13 16 64 80
Year 5 1 69 1,81* 0,83 3 4 19 28 47 68
Mammogram** 93
Year 1 1 91 0,67* 0,52 32 35 57 63 2 2
Year 2 1 86 0,92 0,44 12 14 69 80 5 6
Year 3 1 84 0,85* 0,42 15 18 67 80 2 2
Year 4 1 78 0,91 0,46 11 14 64 82 3 4
Year 5 1 67 0,88* 0,41 10 15 55 82 2 3
DH
NABON N Mean SD
Less than 
recommended 
As recommended
More than 
recommended      
N % N % N %
Consultation(s)
Year 1 4 95 3.07* 0.70 74 78 18 19 3 3
Year 2 2 89 2.61* 0.89 6 7 37 41 46 52
Year 3 1 86 2.15* 0.68 2 2 5 6 79 92
Year 4 1 80 1.78* 0.62 3 4 16 20 61 76
Year 5 1 73 1.71* 0.68 2 3 24 33 47 64
Mammogram** 96
Year 1 1 92 0.86* 0.38 14 15 77 84 1 1
Year 2 1 86 0.85* 0.47 17 20 65 75 4 5
Year 3 1 84 0.96 0.42 9 11 69 82 6 7
Year 4 1 78 0.88* 0.36 10 13 67 86 1 1
Year 5 1 72 0.97 0.5 9 13 57 79 6 8
*A significant difference between the mean and the recommended number of consultations and mammograms as stated in the 
guideline, by means of a one sample t-test
**Total number of patients is 189 due to excluding patients who underwent a prophylactic mastectomy and have not received a 
mammogram for that reason
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Adherence to the follow-up guidelines
Number of consultations and mammograms
A total of 54 patients did not complete the full five years of follow-up. Of these 54 women, 34 
had a recurrence, 7 died, 4 women were dismissed from the follow-up, 2 stopped the follow-up 
on their own request, 1 woman returned to the national screening program before the five 
year of follow-up period was ended and 6 women stopped early due to other reasons (i.e. 
moved to other city, medical reasons not related to the cancer).
A significant difference between the actual number of consultations compared with the 
recommendations in the guideline can be seen for every year (p≤0.05, Table 2). Fewer 
consultations than recommended were observed in the first year, particularly in the MST. In 
the second till the fifth year, more follow-up consultations were given in both hospitals (p < 
0.05). This excess use (more consultations than recommended) is mainly evident in the third, 
fourth and fifth year where nearly a double number of follow-up consultations was performed 
compared to the guideline. During 97% of the consultations, women received a physical 
examination. On average, mammograms were performed slightly less often than once a year.
Since excess use was observed in the second until the fifth year of follow-up, we tried to 
identify if differences in subgroups were found on the number of follow-up consultations in 
these years. The one-way ANOVA showed that subcategories in age, tumour stage, complaints, 
having received chemotherapy or hormone therapy did not significantly influence the number 
of follow-up consultations in both hospitals (Table 3). However, the difference between having 
received radiotherapy or not was significant (p < 0.01). In the MST, women not receiving 
radiotherapy had, on average, 7.7 consults in the second until the fifth year, compared to 
9.3 consultations for women receiving radiotherapy. In the DH, these numbers were 6.7 
consultations compared to 8.9 consultations respectively. In the DH a near significant difference 
can be seen between the number of complaints and the number of follow-up consultations 
(p = 0.06). Not much difference was noticed between women who experience complaints in 
25-50% of the number of consultations and women having complaints in 50-75% complaints 
of the cases. However, women with complaints in more than 75% of the total number of 
consultations, had, on average, more consults than women without complaints. 
In addition a multiple linear regression analysis was performed to determine the factors 
associated with the number of consultations in the second until the fifth year of follow-up 
(results not shown). Based on before set entry and exit criteria, the model resulted in a final 
linear regression that only included having received radiotherapy. Compared to women 
who received no radiotherapy, women who received radiotherapy have, on average, 1.8 
more consultations in the second until the fifth year of follow-up (95% CI = 1.2-2.4). Since 
the coefficient in the model did not change more than 10% with the inclusion of the other 
variables, no confounders were found. The final model showed an R2 value of 0.19.
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Table 3 Average number of follow-up consultations in the second until the fifth follow-up year per 
hospital
MST DH
N=142
N
Number of 
follow-up 
consults P value* N
Number of 
follow-up 
consults P value*
Age category 0.15 0.48
0-45 30 8.8 32 8.5
46-60 18 8.9 10 7.7
60+ 21 7.8 31 8.2
Tumour stage 0.96 0.35
I 26 8.5 27 8.5
II 35 8.5 36 7.9
III 8 8.8 9 9.1
Unknown 0 - 1 8.0
Radiotherapy <0.01 <0.01
No 31 7.7 22 6.7
Yes 38 9.3 51 8.9
Chemotherapy 0.10 0.90
No 35 8.1 42 8.3
Yes 34 9.0 31 8.2
Hormone therapy 0.48 0.90
No 35 8.4 31 8.2
Yes 34 8.7 42 8.3
Complaints 0.49 0.06
0-25% of consultations 30 8.2 26 7.5
25-50% of consultations 19 8.8 23 8.8
50-75% of consultations 11 9.3 18 8.4
75-100% of consultations 9 8.2 6 9.2
*P value between subgroup categories performed by an ANOVA. Bold indicates statistical significance.
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Discipline
Overall, the majority of the consultations were performed by the surgeon, in the MST (53%) 
and the DH (37%). In the MST, about a quarter of the consultations were provided by the 
radiation oncologist and the additional quarter by the residents or other caregivers. In 
the DH the radiation oncologists performed approximately a third of the consultations. A 
prominent shift in performance of the consultations can be observed in the DH. Over the five 
years, the physician assistant, nurse practitioner and breast care nurse gradually performed 
more consultations. This increased from 0.7% to 26% in five years. This led to a decrease in 
consultations performed by the surgeon.
Local, regional recurrences, metastases and second primary tumours. 
During the five year follow-up period, a total of 34 recurrences were found in both hospitals 
(17%). Twenty women had distant metastatic disease. Four local recurrences were found and 
two regional recurrences. One local recurrence was found after breast conserving therapy 
(1/82 = 1.2%). The remaining three local recurrences occurred after a mastectomy (3/114 = 
2.6%). In eight women, a second primary tumour was detected. Six of these second primary 
tumours were located in the (ipsi- or contralateral) breast, one in the lung and one in an ovary.
Of these 34 recurrences, 23 were found by the regular follow-up care involving the surgeon 
and radiation oncologist (including interns, residents, nurse practitioners, physician assistants 
and breast care nurses). The regular mammogram detected 6 malignancies, the other 17 were 
found during a consultation. Eleven malignancies were found outside the regular follow-up by 
other disciplines (e.g. medical oncologist, general practitioner), of which ten involved distant 
metastatic disease.
Discussion
This study evaluated the follow-up care of breast cancer patients in two clinical teaching 
hospitals to determine whether care was delivered according to the recommendations in the 
national guideline and to determine the factors influencing this adherence. Evaluation of this 
part of the care process is important. Women should be given evidence based care, while the 
capacity of medical resources needs to be taken into consideration.
The most important finding of this study was that women with breast cancer received more 
follow-up consultations than suggested in the guideline. This excess use is seen in the second 
until the fifth year of follow-up. In the third, fourth and fifth year, nearly double the number 
of recommended consultations is performed. Excess use was mainly associated with the fact 
that a woman received radiotherapy in addition to other treatments, leading to follow-up 
visits by both the surgeon and the radiation oncologist. Although not significantly proven, the 
more complaints a woman has, the more follow-up complaints she tends to have. However, 
with regard to the performance of physical examinations (performed in 97% of consultations) 
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the guideline was followed. Mammograms are performed, on average, slightly less often than 
once a year. This research also revealed an interesting shift in which discipline performed 
the follow-up consultations, mainly in the DH: within a period of five years, a quarter of 
consultations were performed by the physician assistant, nurse practitioner and breast care 
nurses instead of the surgeon. This shift indicates that pressure can be taken off the load of 
the surgeon, and more consultations can be performed by other members of the mamma-care 
team. A study performed by Kimman et al.13 revealed that although women prefer follow-up 
consultations performed by the medical specialist, alternating between a breast care nurse 
and a medical specialist was also accepted. A quarter of the women favoured follow-up care 
performed only by a breast care nurse. This reflects that the shift noticed in this study may be 
positively experienced by the women that undergo follow-up care.
The average age at diagnosis in this study was 57.5 years, which is similar to the average age at 
diagnosis of breast cancer in the Netherlands.14 In this study, 2.0% developed a local recurrence 
within 5 years, which is under the Dutch average.7 A local recurrence after breast conserving 
therapy was seen in 1.2% of the women, whereas 2.6% of women after breast mastectomy 
suffered a local recurrence. These percentages are low compared to the literature in which 
3.0% of women experience a local recurrence within five years after breast conserving therapy 
and 3.5% after a mastectomy. Eleven malignancies were found by disciplines other than the 
surgeon or radiation oncologist. Ten of these eleven were metastases, which are not actively 
searched for in the follow-up care.6
The findings of this study should be interpreted cautiously. First, the interpretation of the 
number of follow-up consultations; on average fewer consultations than recommended were 
performed in the first year, but this may be influenced by the fact that our cut-off point was 
at ten weeks and consultations during these ten weeks were not included in the analysis, 
but might have been performed as follow-up consultations. It is also possible that a woman 
receives two consultations in one year, in the beginning and at the end, and therefore none in 
the following year. Furthermore, the beginning and end of the first year of follow-up was not 
described clearly in the guideline. Clinicians of both hospitals consider the first mammogram, 
one year after diagnosis, the end of the first year of follow-up. Relating this to the definition of 
the start of the follow-up in this study (ten weeks after completing the primary treatment), this 
could result in a short first year of follow-up in case a woman received surgery, chemotherapy 
and radiotherapy. In the opinion of the clinicians, the second follow-up year begins after this 
first mammogram. If this interpretation would be applied to our data, the averages would 
increase from the second year onward because the follow-up years shift forward. Besides, 
the medical oncologist was not included in this follow-up study. If included, the number of 
follow-up consultations would be even higher. The number of mammograms is slightly lower 
than suggested in the guideline. Second, with regard to the external validity of this research, 
the total number of patients is relatively small. However, this is one of the first studies that 
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evaluates the follow-up care for breast cancer patients based on patient chart data. Third, 
in the DH, all patient information was available digitally, leading to a higher level of detail of 
the data collected compared to patient reports interpreted from handwritten reports, as in 
the MST. Certain variables were difficult to interpret from both the charts and the electronic 
patient records, for example complaints, these might therefore have been taken too generally 
in this study. Fourth, there might be factors influencing the number of follow-up consultations 
that were not included in the current linear regression model. Other factors that could be 
considered are certain patient characteristics (for example education level, patient wishes and 
the amount of fear). For the ANOVA and the multiple linear regression analysis only patients 
were included that completed the full five years of follow-up, this might result in bias because 
the patients with a malignancy or other reasons for stopping the follow-up early were not 
included.
The demand on our health care system for breast cancer specialists is already high due to 
the increasing incidence in breast cancer patients and the rising survival rate.11 The findings 
from this study show that this demand has increased because women receive more follow-up 
care than needed. This was mainly the case in women where both the surgeon and radiation 
oncologist were involved. It would be interesting to determine why more consultations are 
given if both specialists are involved and the reasons for doing so. Furthermore, research that 
also includes the medical oncologist in the follow-up care is needed.
Based on the results of our study we can recommend that a better coordination between the 
surgery and radiotherapy department is necessary. Improved communication may be achieved 
by using a joint electronic patient record. However, if the disciplines involved have valid reasons 
for a more discipline tailored follow-up in patients with treatment including radiotherapy, the 
guideline should provide advice on this.
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Abstract
Background
In the Netherlands, breast cancer patients are treated and followed at least 5 years after 
diagnosis. Furthermore, all women aged 50-74 are invited biennially for mammography by the 
nationwide screening programme. The relation between the outpatient follow-up (follow-up 
visits in the outpatient clinic for 5 years after treatment) and the screening programme is not 
well established and attending the screening programme as well as outpatient follow-up is 
considered undesirable. This study evaluates potential factors influencing women to attend the 
screening programme during their outpatient follow-up (overlap) and the (re-)attendance to 
the screening programme after 5 years of outpatient follow-up.
Patients and Methods
Data of breast cancer patients aged 50-74 years, treated for primary breast cancer between 
1996 and 2007 were selected from the Netherlands Cancer Registry and linked to the National 
Breast Cancer Screening Programme in the Northern region. Cox regression analyses were 
used to study women (re-)attending the screening programme over time, possible overlap with 
the outpatient follow-up and factors influencing this. 
Results
In total 11,227 breast cancer patients were included, of whom 19% attended the screening 
programme after breast cancer treatment, 4.4% within 5 years and 15.4% after more than 5 
years. Factors that independently influenced attendance within 5 years as well as more than 
5 years after treatment were: interval tumours (HR 0.77; 95%CI 0.61-0.97 and HR 0.69; 95%CI 
0.53-0.88, ref: screen-detected tumours), receiving adjuvant radiotherapy (HR 0.65; 95%CI 
0.47-0.90 and HR 0.66; 95%CI 0.47-0.93; ref: none) and diagnosis of in-situ tumours (HR 1.67; 
95%CI 1.25-2.23 and HR 1.39; 95%CI 1.05-1.85; ref: stage I tumours). Non-screen related 
tumours (HR 0.41; 95%CI 0.29-0.58) and recent diagnosis (HR 0.89 per year; 95%CI 0.86-0.92) 
were only associated with attendance within 5 years after treatment.
Conclusion
The interrelation between outpatient follow-up and screening should be improved to avoid 
overlap and low attendance to the screening programme after outpatient follow-up. Breast 
cancer patients should be informed that attending the screening programme during the 
outpatient follow-up is not necessary.
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Background
Breast cancer is the most common type of cancer in women in the Netherlands, with an incidence 
of 16,000 new cases in 2011 (www.cancerregistry.nl).1 In the Netherlands a population-based 
breast cancer screening programme has been fully implemented since 1996. Women aged 
50-74 (70-74 since 1999) are invited biennially for mammography.2 Due to the implementation 
of this screening programme, breast cancer is diagnosed at an earlier stage. Together with 
improved treatment options, this has lead to an increasing number of women surviving five 
years and more after diagnosis. Although the optimal follow-up after breast cancer treatment is 
still unknown, women frequently attend scheduled outpatient follow-up visits (follow-up visits 
in the outpatient clinic for 5 years after treatment), including mammography.3-10 
Women attending outpatient follow-up after breast cancer diagnosis aged 50-74 can also attend 
the screening programme which is considered undesirable. In the guideline for breast cancer, 
recommendations are given about outpatient follow-up after treatment of breast cancer for 
the first 5 years.11 These visits focus on wound healing, adverse effects of the treatment, the 
need for psychosocial care and the early detection of second primary tumours. From the 
revision of 2008 onwards, the Dutch guideline for breast cancer states that breast cancer 
patients treated with mastectomy could, after 5 years of outpatient follow-up and then 60-74 
years of age, be referred to the screening programme.12 Nevertheless, little is known about the 
relation between the outpatient follow-up and the attendance to the screening programme 
after treatment for breast cancer, and which factors influence the screening participation. 
The objective of this population-based study was to determine whether breast cancer patients 
attended the screening programme during their outpatient follow-up (overlap) and the (re-)
attendance to the screening programme after more than 5 years of outpatient follow-up, 
and which factors (method of detection, tumour characteristics and primary and adjuvant 
treatment) influenced this attendance.
Patients and Methods  
Patients
Women with breast cancer were selected from the population-based Netherlands Cancer 
Registry (NCR) of the Comprehensive Cancer Centre the Netherlands (IKNL). The NCR contains 
data on patient and tumour characteristics, stage and treatment of all newly diagnosed 
malignancies.13 The National Breast Cancer Screening Programme invites women 50-74 years 
of age (70-74 since 1999). All women aged 50-74 at the time of their first invasive or in-situ 
breast cancer between 1996 and 2007 were selected (N=12,010). Women with metastases at 
diagnosis (N=497) and women without primary treatment (N=46) were excluded, as well as 
women with bilateral mastectomy (N=240). In total 11,227 women were included in this study. 
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For the analyses of women attending the screening programme after more than 5 years of 
outpatient follow-up, women aged 50-69, diagnosed between 1996 and 2004, not attending 
screening within 5 years after treatment were included (N=6,251).
Relation to screening
Data of the NCR were merged with the data of the National Breast Cancer Screening 
Programme, region North, covering an area of 3.3 million inhabitants comprising 1.6 million 
women. Thereafter only data from he NCR covering the same area as the screening programme 
were selected, to ensure that all breast cancer patients had the chance to be invited by the 
National Breast Cancer Screening Programme, region North. Dutch legislation states that the 
breast screening programme is obliged to invite all women aged 50-74 (70-74 since 1999), even 
after breast cancer treatment. Women do have the option to return a non-attender form on 
which they can state that they are in follow-up after breast cancer treatment in the hospital. 
The data of the screening programme include the date of attendance and the screening result. 
Three groups were defined: the first group comprised of women with a suspect mammography 
by breast cancer screening who were subsequently diagnosed with breast cancer within 12 
months (“screen-detected tumour”). The second group comprised of women who developed 
breast cancer within 24 months after a normal mammogram by breast screening (“interval 
tumour”). The third group comprised of women with breast cancer without a relation to the 
screening programme (“non-screen related tumours”). This group included women who never 
attended the screening programme before their breast cancer diagnosis and women diagnosed 
with breast cancer more than 24 months after the last biennial screening mammography. Data 
until 31 December 2009 were available. 
Statistical analysis
Chi-squared analysis was used to compare categorical variables. The time period between 
diagnosis and attendance to the screening programme was defined as the date of pathological 
confirmation and the first screen mammography afterwards. Patients were censored at the 
date of a new primary breast tumour, death, date when a woman reached the age of 75, or end 
of the study period (31 December 2009). The percentage of women attending the screening 
programme was calculated using Kaplan Meijer analysis. Multivariable Cox regression analyses 
were used to identify independent prognostic factors for the chance of attending the screening 
programme. Factors considered were: age, year of diagnosis, stage, type of surgery and 
adjuvant therapy (radio-, chemo- and/or endocrine). Analyses were performed using the STATA 
software package, version 12.0 for Windows (Stata Corporation LP, College Station, TX, USA).
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Table 1 Characteristics of the total study population 
Total (n=11 227) N % N % 
Detection Surgery 
Screen-detected 6,002 53.5 BCS 6,315 56.2
Interval 3,328 29.6 Mastectomy 4,706 41.9
Non-screen relateda 1,897 16.9 Other 206 1.8
Age at diagnosis Radiotherapy
50-54 2,595 23.1 No 3,953 35.2
55-59 2,310 20.6 Yes 7,274 64.8
60-64 2,222 19.8 Chemotherapy
65-69 2,117 18.9 No 8,922 79.5
70-74 1,983 17.7 Yes 2,305 20.5
Year of diagnosis Endocrine therapy
1996-1998 1,757 15.6 No 7,630 68.0
1999-2001 2,831 25.2 Yes 3,597 32.0
2002-2004 2,926 26.1 Hospital type
2005-2007 3,213 28.6 Non-teaching 5,282 47.0
Stage Teaching 5,945 53.0
Stage I 4,772 42.5
Stage II 4,303 38.3
Stage III 969 8.6
In-Situ 1,183 10.5
a non-screen related tumours include women who never attended the screening programme, and women 
diagnosed with breast cancer more than 24 months after the last screen; BCS: breast conserving surgery
Results
Attendance to the screening programme within 5 years after 
treatment 
In total 11,227 breast cancer patients were included in the study and tumour and treatment 
characteristics are shown in Table 1. In total 19% attended the screening programme after 
breast cancer treatment. Of 11,227 breast cancer patients, 4.4% attended the screening 
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programme within 5 years after treatment. Of the screen-detected cases, 5.2% attended the 
screening programme within 5 years. Furthermore, 4.0% of women with an interval tumour and 
2.7% of women with a non-screen related tumour attended the screening programme within 
5 years after treatment. Figure 1a shows the results of multivariable analysis for attending 
screening within 5 years after treatment. Breast cancer patients with interval and non-screen 
related cancer attended the screening programme after breast cancer treatment less often 
than breast cancer patients with screen-detected tumours (HR 0.77; 95%CI 0.61-0.97 and 0.41; 
95%CI 0.29-0.58 resp.; Table 2), as well as later year of diagnosis (HR 0.89 per year; 95%CI 0.86-
0.92) and breast cancer patients who received adjuvant radiotherapy (HR 0.65; 95%CI 0.47-
0.90 compared to patients without adjuvant radiotherapy). Breast cancer patients with in-situ 
tumours (HR 1.67; 95%CI 1.25-2.23) were more likely to attend the screening programme than 
patients with stage I tumours. 
Attendance to the screening programme after more than 5 years after 
treatment
Of 6,251 women, 15.4% attended the screening programme more than 5 years after 
treatment. Of women with screen-detected tumours 15.4% of patients attended the screening 
programme more than 5 years after treatment, compared to 13.0% and 18.3% women with an 
interval tumour and women with a non-screen related tumour, respectively. In multivariable 
analysis for attending screening more than 5 years after treatment, breast cancer patients with 
interval tumours attended the screening programme after breast cancer treatment less often 
than breast cancer patients with screen-detected tumours (HR 0.69; 95%CI 0.53-0.88; Table 2; 
Figure 1b). Furthermore, breast cancer patients who received adjuvant radiotherapy attended 
less often than patients without adjuvant radiotherapy (HR 0.66; 95%CI 0.47-0.93). Breast 
cancer patients with in-situ tumours (HR 1.39; 95%CI 1.05-1.85) were more likely to attend the 
screening programme more than 5 years after treatment than patients with stage I tumours.
Discussion
Of the breast cancer patients, 4.4% attended the breast screening programme within 5 
years after breast cancer treatment, followed by another 15.4% of patients attending the 
programme more than 5 years after treatment. Factors associated with a lower attendance to 
the screening programme within 5 years after treatment were interval tumours and non-screen 
related tumours (compared to screen-detected tumours), higher age, later year of diagnosis, 
and receiving adjuvant radiotherapy (compared to none). Diagnosis with in-situ tumours was 
related to a higher attendance to the screening programme compared to women with stage 
I tumours. Breast cancer patients with interval tumours and patients who received adjuvant 
radiotherapy were also less likely to attend the screening programme more than 5 years after 
treatment, patients with in-situ tumours were more likely to attend.
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Table 2 Hazard ratios (HR) and associated 95% Confidence Intervals (CI) for attending screening within 5 
years after breast cancer treatment and more than 5 years after treatment.
attending screening <5 years attending screening >=5 years
N HR 95% CI P value N HR 95% CI P value
Detection  <0.001 0.014
Screen-detected 6,002 Ref. 3,353 Ref.
Interval 3,328 0.77 0.61  - 0.97 0.026 1,862 0.69 0.53  - 0.88 0.004
Non-screen related 1,897 0.41 0.29  - 0.58 <0.001 1,036 0.91 0.70  - 1.18 0.478
Age
by year 11,227 0.99 0.97  - 1.00 0.133 6,251 1.01 0.99  - 1.03 0.227
Year of diagnosis
by year 11,227 0.89 0.86  - 0.92 <0.001 6,251 1.00 0.95  - 1.05 0.882
Stage 0.002 0.015
Stage I 4,772 Ref. 2,584 Ref.
Stage II 4,303 1.17 0.87  - 1.56 0.300 2,567 0.76 0.57  - 1.02 0.065
Stage III 969 1.69 1.01  - 2.82 0.044 480 0.82 0.40  - 1.67 0.582
In-Situ 1,183 1.67 1.25  - 2.23 0.001 620 1.39 1.05  - 1.85 0.021
Surgery 0.413 0.095
BCS 6,315 Ref. 3,400 Ref.
Mastectomy 4,706 0.90 0.65  - 1.25 0.539 2,731 0.79 0.56  - 1.11 0.175
Other 206 1.37 0.68  - 2.78 0.381 120 0.15 0.02  - 1.12 0.065
Radiotherapy
No 3,953 Ref. 2,248 Ref.
Yes 7,274 0.65 0.47  - 0.90 0.009 4,003 0.66 0.47  - 0.93 0.017
Chemotherapy
No 8,922 Ref. 4,959 Ref.
Yes 2,305 0.96 0.69  - 1.34 0.798 1,292 0.72 0.49  - 1.07 0.107
Endocrine therapy
No 7,630 Ref. 4,356 Ref.
Yes 3,597 0.88 0.67  - 1.17 0.389 1,895 1.14 0.85  - 1.54 0.391
BCS: breast conserving surgery. Bold indicates statistical significance.
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Figure 1 Factors influencing the attendance to the screening programme for (a) attending screening < 5 
year after treatment and (b) attending screening ≥ 5 year after treatment, multivariable Cox regression 
analyses. * Indicates statistical significance.
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Breast cancer patients with screen-detected tumours were more likely to return to the 
screening programme, which may be caused by more trust in the programme. Women with 
in-situ tumours were also more likely to attend the screening programme. It is known that 
these women have a lower risk of local recurrence.14 Due to this lower risk, specialists might be 
more willing to refer these patients to the screening programme. Breast cancer patients with 
an interval tumour, which either did not exist at the time of the screening or was undetected, 
may have been disappointed and therefore reluctant to re-enter the programme. 
Breast cancer patients receiving adjuvant radiotherapy were less likely to attend the screening 
programme. A study by Grandjean et al.15 revealed that women who had received radiotherapy 
had follow-up by both the surgeon and the radiation oncologist and therefore received more 
outpatient follow-up than recommended by the guidelines. This might reduce the urge for 
women to attend the regular screening programme. 
Besides the specialists in the hospital, the patient’s needs and preferences are important 
factors. These factors should be taken into account when discussing follow-up. De Bock et al.16 
studied the needs of patients during follow-up and showed that patients have widely different 
needs and preferences. Furthermore, there is an ongoing debate about the effectiveness of 
routine follow-up including an annual mammography. De Bock et al. showed that still 40% of 
recurrences were detected in an asymptomatic stage during routine follow-up visits or tests. A 
simulation study found that patients aged 50 years with standard follow-up examinations had 
only 2 months gain in life expectancy compared to patients without follow-up examinations. 
For older patients the benefit was even less.17 On the other hand, several studies reported that 
most patients prefer frequent follow-up visits for a long, even a life-long period.3,6,10 Patients 
indicated that the main benefit attending follow-up visits was the perceived reassurance they 
gained.18,19 This might be an important reason why women will attend the screening programme 
when invited, while still attending outpatient follow-up.
After breast cancer diagnosis and treatment, women frequently attend scheduled outpatient 
follow-up visits.11 According to guidelines, in the first year the breast cancer patients are seen 
four times, in the second year twice , and thereafter once a year. During these visits women 
receive a physical examination, and annually a mammography. Until 2008, after a follow-up 
of 5 years, annual or biennial mammography was recommended, and the optimal length of 
follow-up given was to be decided individually by specialist and the breast cancer patient. 
In specific situations, depending on age and treatment, the option was to be referred to 
the screening programme after 10 years of follow-up.20,21 As no explicit recommendations 
were made about referral to the screening programme, this might have resulted in the low 
percentage of breast cancer patients attending the screening programme after treatment. In 
2008 the Dutch guideline for breast cancer was revised and since then a clear recommendation 
is given about referral to the screening programme after curative treatment: after 5 years 
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outpatient follow-up, female patients over 60 years of age and treated with mastectomy should 
be referred to the screening programme.11,12,22 This might result in more women attending the 
screening programme after treatment However, surgeons and radiologists might not be willing 
to refer a patient to the screening programme for many different reasons. 
Furthermore, screen radiologists are probably not so eager to include breast cancer patients 
who underwent BCS in the screening programme, as these mammographies are more difficult 
to analyse. After surgery and/or radiotherapy the women’s breast will change in appearance 
and density. On mammography scar tissue from the operation and radiotherapy may have 
an appearance similar to a second breast tumour.23 For the screen radiologist a comparison 
is difficult, as he has only the screen mammographies made before diagnosis or none at all. 
Therefore, screen radiologists are more likely to refer the women for further diagnostics. In the 
future it may become more feasible to exchange digital images from hospitals to the screening 
programme, enabling screen radiologists to interpret mammographies over time. 
To reduce overlap, breast cancer patients should be informed by their specialist that attending 
the screening programme in the first 5 years of follow-up is unnecessary and the interrelation 
between the outpatient follow-up and the screening programme should be improved. The 
recommendation in the national guideline that breast cancer patients can be referred to the 
screening programme 5 years after mastectomy is the first step in creating a more efficient 
follow-up. The effect of this recommendation should be seen in the forthcoming years. 
Conclusion
In conclusion, 4.4% of the breast cancer patients attended the breast screening programme 
within 5 years after breast cancer treatment, followed by another 15.4% of patients attending 
the programme after 5 years after treatment. Women with screen-detected breast cancer, 
in-situ tumours, and women treated without adjuvant radiotherapy were more likely to return 
to the screening programme. In the future, improving the interrelation between the outpatient 
follow-up and the screening programme is desirable to avoid overlap and low attendance to the 
screening programme after outpatient follow-up. Breast cancer patients should be informed 
by their specialist that attending the screening programme during the outpatient follow-up is 
not necessary. 
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Abstract
Increased breast cancer incidence and better survival have raised the number of patients 
requiring follow-up care. Despite guidelines, there is controversy about appropriate breast 
cancer follow-up. Therefore, semi-structured interviews were conducted in 2 hospitals with 23 
patients and 18 health professionals (HPs) in order to explore opinions and preferences about 
the purpose, the duration and frequency of breast cancer follow-up and which examinations 
should be done, by whom. The transcripts were inductively analysed and coded into pre-
identified themes. Patients were followed more intensively than guidelines recommend. HPs 
mentioned three major reasons; patient preferences, each discipline wanting to observe the 
patient, and financial incentives. For patients and HPs the most important purpose of follow-up 
was early detection of new malignancies. A highly valued aspect of follow-up mentioned by HPs 
was the psychosocial support which was rarely mentioned by patients. Patient’s expectations 
about the benefits of follow-up and additional examinations were sometimes unrealistic. 
Patients and HPs were positive about nurse-practitioner-led follow-up, but less positive about 
general-practitioner-led follow-up. Important barriers to current guideline adherence were 
revealed and should be taken into account by implementing new individualised guidelines. 
Furthermore, patients should be better informed about the benefits of follow-up to prevent 
unrealistic expectations.
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Background
More than 13,000 women are diagnosed annually with breast cancer in the Netherlands.1 
The 5-year relative survival of breast cancer patients increased over the years, from 77% for 
patients diagnosed in 1989-1993 to 86% for patients diagnosed in 2003-2008. This leads to 
an increasing number of patients requiring follow-up care. The primary purpose of follow-up 
is the early detection of loco-regional recurrences or a second primary tumour, in order to 
start immediate potentially curative therapy and prolong survival.2 Other reasons for providing 
follow-up care are detecting side-effects of treatment and providing psychosocial support. 
Since 1999 evidence based follow-up guidelines exist in the Netherlands, although compliance 
with these guidelines is not obligatory. As a result, follow-up practices vary between hospitals 
in the Netherlands and patients attend the hospital for follow-up visits more often than 
guidelines recommend.3 Due to the doubtful benefits of routine follow-up visits and the 
increasing burden for health professionals, the debate about the frequency and duration of 
follow-up is ongoing. Who should provide follow-up care and which diagnostic tests should be 
performed?4-6 Several studies investigating patient preferences have shown that patients tend 
to have a strong preference for intensive follow-up by a specialist.7,8 However, little is known 
about the opinions and preferences of health professionals (HP). Previous reports show that 
HPs are likely to follow a large group of patients longer and more intensive than guidelines 
advise and many different HPs are involved in follow-up.9,10 In optimising breast cancer 
follow-up and understanding the heterogeneity in compliance, it is important to gain insight 
into the attitudes, experiences and preferences of HPs and patients. After all, their opinions 
will strongly influence (non) adherence to the guidelines. Therefore, the present qualitative 
study was conducted, to explore the opinions and preferences of both HPs and patients about 
the current follow-up guideline and different aspects of follow-up, including the purpose of 
follow-up, the duration and frequency, which examinations should be done and by whom.
Patients and Methods
Semi-structured interviews were conducted with breast cancer patients and with HPs 
involved in breast cancer follow-up at two top clinical teaching hospitals in the Netherlands. 
Both hospitals have mamma care centres, in which multidisciplinary teams perform the 
diagnostic examinations, treatment and follow-up of patients with a breast lesion. In 2009, 432 
women were diagnosed with breast cancer in both hospitals. Depending on the treatment, 
the follow-up in these hospitals was performed by one or more HPs: a surgeon, a medical 
oncologist, a radiation oncologist or a nurse practitioner (NP).
Participants 
In 2009, patients at different ages and with different time intervals since diagnosis, who fulfilled 
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the inclusion criteria were asked to participate in the study. In total 26 curatively treated breast 
cancer patients were asked to participate. The following inclusion criteria were applied: (1) 
patients had not suffered an earlier tumour and were free of loco-regional recurrences or 
metastases, (2) patients were physically and emotionally able to participate and (3) patients 
had sufficient knowledge of the Dutch language. All patients received a letter from their 
surgeon with detailed information about the study. After a week, patients were called and 
invited to participate. Three patients refused to participate. In the end 10 and 13 patients 
from each hospital took part in the study. The median age of the patients was 51 years (range 
43.9-80.6 years) and the median time after diagnosis was 2.5 years (range 0.3-5.6 years). All 
patients were treated surgically (70% mastectomy), 50% received adjuvant chemotherapy and 
50% received adjuvant radiotherapy. Endocrine therapy was given to 14 patients (64%) at time 
of the study inclusion. 
Health professionals (n=20) were selected on the basis of their involvement in the treatment 
and follow-up of the patient and their field of interest. They were informed by letter and asked 
to participate by phone. Two HPs (1 medical oncologist and 1 surgeon) refused to participate. 
In total 18 HPs agreed to participate in the study: 5 surgeons, 2 medical oncologists, 3 radiation 
oncologists, 1 gynaecologist, 5 NPs and 2 GPs. The NPs had a masters degree in Advanced 
Nursing Practice or an in-hospital training to become a mammacare specialist. The medical 
specialists all followed a specialisation in oncology. The years of experience ranged from 2 to 
26 years. Two-thirds of the HPs were men. 
Follow-up guidelines
In the Netherlands, national guidelines for breast cancer care have existed since 1999. During 
the study period the 2008 NABON guideline was available, suggesting a standard follow-up 
schedule lasting of 5 years for all breast cancer patients.11 Patients should visit the hospital 
every 3 months in the first year, every 6 months in the second year and annually during the 
subsequent 3 years. During these visits a physical examination is performed, supported by an 
annual mammogram. The annual follow-up continues until the age of 60, patients older than 
60 are referred to the general practitioner (GP) or to the national screening programme. In 
the national screening programme, women between 50 and 75 years old undergo a standard 
biennial screening mammogram. It should be made clear to the patient and the GP who 
coordinates the follow-up, this could be the NP, surgeon, medical oncologist or radiation 
oncologist.
Data collection
Semi-structured, face to face, interviews were conducted by the same person ABGK (who was 
trained to do semi-structured interviews). Interviews were audiotaped after consent of the 
participant. Patients were interviewed at their homes, and the interviews lasted between 30 
and 90 minutes. Each patient interview started with some general questions about how breast 
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cancer was detected, how it was treated, how follow-up was organised and how satisfied 
they were with the current follow-up. HPs were interviewed at the hospital or their practice. 
For the HPs the interview started by asking how follow-up was organised and what specific 
contribution they had in it. Subsequently, both patients and HPs were asked to reflect freely 
about the following issues: purpose of follow-up, preferred duration and frequency, preferred 
diagnostic examinations and involved HPs.
Ethical considerations
According to local regulations in the Netherlands (WMO), the study did not need approval of 
the ethical review board, only (non-intervention) studies with high burden for patients have 
to be reviewed. The following precautions were taken to protect the participants. Participants 
were informed about the purpose of the research, the procedure and how data will be used. 
Furthermore, patients were informed that participation was completely voluntary and that 
their decision about participation did not have any consequences for treatment and follow-up 
care. Patients were also informed that none, neither their doctors, will be informed about the 
participation in the study and content of the interviews. The field notes and transcripts did not 
contain personal identifiers and were kept locked or password protected. Data was only shared 
with the three investigators.
Data analysis 
The audiotapes were transcribed verbatim. All three investigators separately read all transcripts 
to familiarize themselves with the data. The principle investigator (ABGK) selected all citations 
that were relevant to the research questions, and coded these into 5 pre-identified themes: 1) 
implementation of the current follow-up guidelines, 2) main purpose of follow-up, 3) preferred 
frequency and duration, 4) which examinations should be conducted and 5) who should 
perform the follow-up care. Next, the citations within each theme were further analysed and 
arranged into subcategories by three investigators (ABGK, CHCD & SS) independently, using 
an inductive process, meaning that themes and categories arise from the data.12 During this 
phase the coders met on several occasions to discuss their findings. Differences were discussed 
until consensus was reached on the final subcategories (as presented in the results section). 
Finally, one coder (ABGK) examined the raw data again to ensure the robustness of the 
analytical process and to confirm that all data were indeed reflected in the coding. Although 
the qualitative nature of the study does not allow for any conclusions regarding the numbers 
of HPs that held a particular opinion, the frequencies of the number of citations within each 
subcategory was used to assist in determining their importance in our interpretation of the 
answers of the interview questions.
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Results
The results describe the perceptions of HPs and patients regarding the current follow-up 
practice and opinions and preferences regarding diverse follow-up items: the purpose of 
follow-up, frequency and duration, which diagnostic examinations should be used and who 
should perform follow-up visits. 
Perceptions regarding the current follow-up
The interviews started by asking in general how the current follow-up was organised and how 
satisfied patients were with current follow-up. Almost all HPs mentioned that current follow-up 
guidelines were used. However, subsequently about half of the HPs indicated that patients 
often were followed longer and more frequently than recommended. Several reasons for more 
intensive follow-up emerged from the interviews. The first reason that emerged from the data 
was that HPs felt that patients prefer a more intensive or longer follow-up, and HPs complied 
with their requests. This was illustrated by a nurse practitioner in the following quote:
For the patient, the follow-up visits are very important, therefore it is hard to end the 
follow-up period. [HP: nurse practitioner]
The second reason was that some HPs indicated that each involved discipline (surgeon, 
radiation oncologist and medical oncologist) wants to follow the patient themselves, because 
they want to monitor side-effects relevant for their own specialty. A radiation oncologist said: 
Patients are examined for late treatment effects, in order to know what the treatment will 
cause in future patients. [HP: radiation oncologist]
The final reason was that financial incentives for longer follow-up periods appeared to play a 
role in continuing the follow-up. The following extract illustrates this point:
Because of budgetary reasons patients are seen for 10 years instead of 5 years. [HP: surgeon]
Patients were generally satisfied about how the follow-up was organised and particularly 
about the accessibility of the HPs. Patients agree that follow-up is often more intense than 
recommended by the guideline. Some patients indicated that they were seen every year by 
a surgeon or NP, a radiation oncologist and a medical oncologist. Therefore they visited the 
hospital up to 3 times a year, whereas one visit should have been sufficient. Moreover some 
patients were dissatisfied about the many different faces they have seen during the follow-up 
period, as illustrated by the following citation:
Sometimes it isn’t possible, but I prefer to see the same doctor during the follow-up period. 
Than you don’t need to tell your story again and again. Sometimes I wondered myself 
whether they read my dossier before the follow-up visit. 
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Table 1 Follow-up goals: reported by health professionals and patients
Health professionals Patients
Often mentioned
•  Early detection of recurrences and 
second tumours
•  Examination of the breast 
•  Psychosocial support •  Reassurance
•  Guidance, information and referral •  Guidance of patients; answering 
questions
Occasionally mentioned
• Evaluation of treatment and treatment 
side-effects
•  Evaluation of treatment and treatment 
side-effects
•  Early detection of metastases •  Psychosocial support
•  Clinical trials; building own database
Opinions and preferences regarding different follow-up items
What should be the main purpose of follow-up?
Table 1 shows an overview of the mentioned goals of the follow-up according to the HPs and 
patients. 
For almost all HPs, the most important goal of follow-up was the early detection of a recurrence 
or a second primary tumour. Yet some HPs questioned whether early detection of recurrence 
is a realistic goal:
You catch almost nothing, those patients come in between the regular visits. It’s more about 
the social talk. [HP: surgeon]
Furthermore, HPs mentioned that psychosocial support becomes a more and more important 
purpose of follow-up. Patients, however, rarely mentioned psychosocial support as follow-up 
goal in itself. 
For patients one of the main purposes of follow-up was examination of the breast. Hardly 
none of the patients explicitly mentioned early detection of recurrences. Another important 
purpose for patients was reassurance and guidance. 
I think it is reassuring, after the follow-up visit you are less tense for the next year. Although, 
a month later you can have problems again, you are never sure about that. [Patient]
It was noted by HPs that the views of patients regarding “reassurance” were sometimes 
unrealistic. As some patients seemed to think that they could not get breast cancer, as long as 
they were in the follow-up programme, which is illustrated by the following citation: 
I prefer follow-up visits as long as possible, 2 times a year. As they just make a mammogram 
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every half year, than you can be sure that you never get it again. Of course, I know that you 
can get the disease elsewhere, but at least no longer in the breast. 
Half of the HPs mentioned to experience a discrepancy between the expectations of the patient 
and the ability of the HPs. This was illustrated by the following point:
We tell the patient that we see no signs of disease, the patient interprets that as: I am 
healed. [HP: gynaecologist]
Monitoring long term side-effects of radiation therapy was particularly important for the 
radiation oncologist. The medical oncologist evaluated the effects of endocrine therapy in order 
to adapt therapy if necessary. They also keep patients in follow-up because of participation in a 
clinical trial. The NPs were mainly concerned about the wounds and the effects of the resection 
of lymph nodes. 
What should be the frequency and duration of follow-up?
In table 2 we present arguments for the duration and frequency of follow-up, categorised into 
less intensive than, more intensive than, or according to the current guidelines. 
About half of the HPs indicated that the frequency and duration of follow-up could be tailored 
depending on patient and tumour characteristics (such as age at diagnosis, stage and positive 
lymph nodes). As a result, the follow-up could be shorter and less frequent for some patients. 
Most patients were, however, uncomfortable with the idea that follow-up could become 
shorter than 5 years. Many patients preferred an even longer follow-up period (until life-
long) than currently offered. Reasons for this were: anxiety for recurrent distant metastases, 
the need for guidance and reassurance, or the fact that the national screening programme 
only starts at age 50. Only a few patients indicated that the duration of follow-up could be 
shortened. Also about a third of the HPs felt that follow-up should be continued after 5 years 
for certain patients. They mentioned several reasons for this, including: patients’ expectations, 
the ongoing increased risk of a second primary tumour, the duration of hormonal treatment, 
and financial reasons. It appeared from the interviews that some patients took 5 years literally 
to mean they were declared cured. It finally should be noted that the question about required 
duration of follow-up was difficult for some patients, as they felt that the doctors are the 
experts and they should decide how long the follow-up should take. 
Regarding the preferred frequency of visits, almost all patients and HPs agreed with the 
recommended frequency according to the guidelines. More frequent visits at the beginning 
of the follow-up period were experienced to be pleasant by most patients, because there is a 
lot uncertainty short after the treatment period. Three HPs mentioned that less frequent visits 
should be sufficient, especially for older patients. Also, a few patients mentioned that they 
prefer less frequent visits, because it was too much or with the consequence that they could 
stay under control for a longer period. 
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Table 2 Opinions about the duration of follow-up and frequency of visits of health professionals and 
patients
Duration of follow-up Health professionals Patients
According to current 
guidelines...
(5 years)
•  because the guidelines are scientifically 
based 
•  because that is the standard (then you are 
free of cancer)
•  because, after a while, patient’s life 
should return to normal 
•  because you can return to the national 
screening programme
•  because patients can always contact 
the hospital, even after 5 years
•  because it is no longer necessary 
Shorter than guidlines...
(<5 years)
•  for low risk patients (low tumour stage, 
elderly patients )
•  because you can call yourself if something 
is wrong
•  because the usefulness of follow-up is 
not proven
•  because it requires a lot of health care 
time
•  because 2-3 years is sufficient for 
psychosocial and recurrence control
•  because follow-up visits evoke anxiety 
for the patient
Longer than guidelines... 
(>5 years)
•  because patients expect more and feel 
abandoned if follow-up ends 
•  because of the anxiety of a metastasis
•  because there still can be problems 
after 5 years (second primary tumours)
•  for younger patients, because screening 
starts at the age of 50 
•  because the duration of hormonal 
treatment is often longer 
•  because it is pleasurable and gives 
reassurance and you don’t have to return to 
the national screening programme 
•  because of financial benefits 
•  for high-risk patients (node-positive 
patients) 
•  for younger patients, because 
screening starts at the age of 50 
Other 
•  because it depends on the patient, no 
fixed number of years
•  the doctor decides
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Table 2 continued
Frequency of follow-up 
visits Health professionals Patients
According to current 
guidelines... 1
•  because at the beginning there is a 
need for regular control and information
•  because at first there is a need for security 
and the possibility to ask questions
•  because in the first years the probability 
of a recurrence is the highest 
•  because in the course of time your life can 
return to normal and if there are problems 
you can always call
•  because visits become less frequent and 
you know you are getting better
Less than current 
guidelines…1
•  for older patients, a minimum number 
of visits is desirable
•  particularly in the first years, it is very tough 
•  because an annual fixed control 
visit with additional visits based on 
complaints would be sufficient
•  as long as it is possible to stay under control 
for a long time 
More than current 
guidelines…1
•  for patients treated by different 
disciplines: when a specialist sees a 
patient less often than once a year it 
makes no sense
•  because waiting for one year takes too long
1Current guidelines prescribe every 3 months in the first year, every 6 months in the second year and annually during the subsequent 
3 years.
Which diagnostic examinations should be performed during follow-up? 
Table 3 shows an overview of the opinions of HPs and patients for different diagnostic 
examinations. The annual mammography was seen as the primary diagnostic tool by HPs. 
However, some HPs mentioned that for a certain age group a mammogram could also be 
performed by the national screening programme instead of in the hospital. Patients also 
indicated that the mammogram was more valuable than the physical examinations. However, 
some women were not reassured by a mammogram only. Especially if nothing had been 
seen at the mammogram at the time of their initial diagnosis. Almost a quarter of the HPs 
and patients questioned the value of physical examinations. Experience is needed and even 
experienced HPs cannot find everything by physical examinations. About a third of the patients 
were disappointed that additional tests, such as blood tests or a total body scan, were not 
performed. They felt that you could never be sure that something is wrong elsewhere, without 
a total body scan. Only a few patients were aware that total body scans do not add value, or they 
did not want to search for trouble. Health professionals recognised the demand for additional 
blood tests and scans from patients. But they were not convinced about the additional value, 
and stressed the importance of good education.
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Table 3 Opinions about which diagnostic examinations should be performed of health professionals and 
patients
Diagnostic examinations Health professionals Patients
Mammography
+ * This is the most important control + This is the most important control
+ After 5 years women could take part in 
the national screening programme
+ After 5 years women could take part in the 
national screening programme
- Patients have to wait too long for the 
outcome
- It is unpleasant
- Sometimes cancer cannot be detected by a 
mammogram
Physical examination
+ For women with a lobular tumour + When nothing is seen on the mammogram
- Expertise is needed for physical 
examination 
- It is not possible to find everything with 
physical examination
- You cannot find everything with a 
physical examination
- Seems unnecessary, when mammograms 
are made
Additional examinations 
(body scan, MRIǂ, blood 
tests)
+ MRI for young patients + MRI, when there is nothing to see on the 
mammogram
+ MRI, when the tumour is not visible on a 
mammogram 
+ You remain uncertain, if no total body 
check or blood tests are done
- Blood tests and body scans: almost 
impossible to find metastasis 
- If a blood test is useful, they would have 
used it 
- Early detection of metastases does not 
affect your life expectancy
- Early detection of metastases does not 
affect your life expectancy 
- No need to search for trouble: If you don’t 
know, it will not hurt 
* +: advantage of the diagnostic examination, - : disadvantage of the diagnostic examination  ǂMRI: Magnetic resonance imaging
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Who should perform the follow-up visits?
Table 4 presents an overview of the opinions of HPs and patients on the perceived advantages 
and disadvantages of the different follow-up care providers. No more than a quarter of the 
women had most confidence in the surgeon. Other patients indicated that they saw no extra 
value in a check-up by the surgeon. NPs indicated that surgeons are responsible for follow-up 
care and make care policy, however other disciplines could perform the follow-up care. 
In general NPs were seen as a valuable addition to the surgical department by both patients 
and HPs. Reasons included that NPs were easily accessible to the patient; had more time for 
the patient; were more socially empathic to the patient; saved time for the specialists and 
were cheaper than specialists. However, some surgeons in particular doubted the usefulness 
of the NPs, and questioned whether NPs would recognise recurrence of the disease. They were 
concerned about the efficiency because more diagnostic examinations might be performed by 
a NP and because the patient was often seen by the surgeon as well. 
Opinions about the GP were divided. Initially, patients saw no role for the GP during follow-up. 
However, when hospital follow-up ends, they want to return to the GP. Other patients saw no
reason to go to the hospital when no mammogram will be performed. HPs doubted if GPs have 
enough time to see breast cancer patients, whether they have enough experience and as a 
result might request diagnostic examinations too often. Both GPs stressed that they would like 
to take part in follow-up, but that the patient’s preference would be important here. 
From the interviews it appeared that currently, different disciplines were often involved in the 
follow-up. Primary, patients are under control by the surgeon or NP. Radiation- and medical 
oncologists found it important to see the patient during follow-up because of the treatment 
effects. Patients and HPs did not always fully understand why patients were seen by different 
care providers. Patients and HP’s mentioned both advantages and disadvantages of this. The 
most frequently mentioned advantage of seeing different HPs was the second opinion. A 
disadvantage was the lack of continuity, i.e. seeing the same HP. Another disadvantage was 
the insufficient communication between the different disciplines, which sometimes resulted in 
inadequate sharing of information with the patient and in lack of coordination. A few surgeons 
and NPs mentioned that they could take over the follow-up care of the radiation- and medical 
oncologists.
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Table 4 Health professionals’ and patients’ opinions about the advantages and disadvantages of various 
follow-up care providers
Care provider Health professionals Patients
Surgeon
+ The surgeon is always responsible + The surgeon is trained / specialised 
+ For more complex patients + more confidence in the surgeon than in other 
disciplines
- The surgeon makes care policy, but 
implementation can be done by
- It is an expensive waste of time 
 another caregiver, e.g. a NP - The surgeon does the surgery, not the 
follow-up
Nurse 
practitioner
+ They can save time for the specialist + They have more time for the patient 
+ They have more time for the patient than the 
specialist
+ They are as good as the surgeon 
+ They are easily accessible and can trace 
psychosocial problems earlier 
+ They have more empathy
+ Cheaper care + They act as coach for questions and problems
- They should always be supervised by the 
specialist 
- Doubt whether they have enough experience 
- They are inclined to do more diagnostics - They are not specialised enough
Radiation 
oncologist
+ For the control of long-term radiation effects + They do more extensive physical examinations
+ They know how the patient was treated with 
radiotherapy
+ More frequent contact with the patients 
during treatment
- The reason for the involvement of a radiation 
oncologist is unknown 
- The reason for involvement of a radiation 
oncologist is unknown 
Medical 
oncologist
+ For patients participating in trials 
+ For the control of endocrine treatment effects
- Not all perform a physical examination
General 
practitioner
+ It is cheaper care + For support for psychosocial problems
- They have not enough expertise, which quickly 
creates commotion 
+ When hospital follow-up is ended
- They do not see enough breast cancer patients 
to guarantee good care
+ Then you are not required to go to the 
hospital anymore
- This is asking too much of the GPs - The GP is too busy 
- They refer you to the hospital anyway
- They are not specialised enough
* +: advantage of the particular care provider -: disadvantage of the particular care provider 
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Discussion
To our knowledge, this is one of the first studies on breast cancer follow-up identifying a broad 
overview of opinions and preferences of both HPs and patients on breast cancer follow-up. 
Due to the qualitative and explorative design of the study new insights were revealed. 
Purpose of follow-up
Health professionals mentioned that psychosocial support becomes a more and more important 
aspect of follow-up care. The same findings were reported in a Dutch study about professionals’ 
opinion on follow-up by van Hezewijk et al.10 In this study 83% of the HPs mentioned detecting 
psychological problems as a purpose of follow-up. Remarkably, the present study showed 
that only a few patients mentioned psychosocial support as an important goal of follow-up. In 
agreement with results from a study of Beaver et al.13 patients are satisfied with examination 
of the breast and with reassurance of the HP that everything is still gone. Furthermore van 
Hezewijk et al.14 showed that consultation by a psychologist or social worker was less valued 
by breast cancer patients. A reason could be that the available time for psychosocial support 
during a routine follow-up visit is limited and therefore not always appropriate.15-17 Although 
HPs mentioned that psychosocial support becomes a more important aspect, in daily practice 
control visits are still focused on physical symptoms, which could retain patients to talk about 
other problems. Since 2012 the NABON guideline is revised, advising to make a personal 
follow-up care plan with the patient during the first year of follow-up.18 The personal follow-up 
care plan describes the physical and psychological impact of the disease and treatment, how 
frequently the patient should receive a follow-up visit and which diagnostic tests should be 
performed during these visits. The introduction of the personal follow-up care plan could help 
recognizing psychosocial problems in an early stage, so that the patient can be referred to 
specialists.
In our study HPs doubted the primary goal of follow-up: early detection of recurrences. Their 
doubts are supported by literature: a meta-analysis found that 41% of recurrences had been 
diagnosed outside routine visits or routine tests.6 A few HPs mentioned that early detection of 
metastases is a goal of follow-up. Van Hezewijk et al.10 showed that 6 out of 10 HPs still indicate 
that detecting metastases is a follow-up goal. This is remarkable since previous studies have 
shown that early detection of metastases gives no improvement in survival or quality of life.19
Several misconceptions about follow-up persist among patients, underlining the need for 
better patient education. For example some patients believe that follow-up care can prevent 
new malignancies, others expected blood tests and total body scans, believing that finding 
metastases in an early stage can improve prognosis. Indeed, a recent study by Montgomery 
et al.20 has shown that education can eliminate misunderstandings and could influence 
women’s preference for the nature of follow-up (regular mammograms versus more intensive 
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follow-up). However, van Hezewijk et al.14 saw no differences in expectations about additional 
investigations between a written informed group and a non-informed group. An explanation 
could be that the written information was not well understood. Given the improved survival 
of cancer patients and the involvement of many disciplines for treatment and follow-up care, 
there is need for better coordination and information sharing. In response, the revised NABON 
guideline developed the personal follow-up care plan describing treatment and follow-up care 
to the patient and involvement of the patient's HP. However, it is still unknown how often 
these plans are implemented. A study performed with American cancer survivors showed that 
approximately one third reported receiving cancer treatment summaries and 44% reported 
receiving written follow-up care instructions.21
Frequency and duration
The results of the present study presume that current follow-up is more intensive in terms of 
frequency and duration than the guidelines recommend. Patients preferred prolonged and 
frequent follow-up and found it hard to end follow-up. These findings agree with earlier studies, 
which concluded that more than half of the patients questioned preferred lifetime follow-up.8,14 
Our study showed that this preference is one of the main reasons why HPs keep patients under 
observation for a longer period than stated in the guideline. This is also illustrated in the study 
of Beaver et al.13, on request of the patient, HPs prolong follow-up care. However it is known 
that when follow-up schedules change, patients adjust to the new system and appreciate it. 
An earlier clinical trial showed that a less frequent follow-up schedule is well appreciated by 
breast cancer patients.22 However, this is a small study with a possible bias in patient selection. 
Patients selected for this study were of older age, had positive tumour characteristics and had 
a positive attitude towards less intensive follow-up. Other trials evaluated reduced follow-up 
strategies by nurse-led telephone follow-up17,23 and point-of-need access to specialist care24, 
and found that most patients were satisfied with these alternative strategies.
A second reason why more frequent follow-up visits were offered than recommended was that 
each discipline wanted to observe the results of their therapy. These findings agree with the 
results from van Hezewijk et al.10 who found that the coordination of follow-up was most often 
done by multiple specialists and ongoing hormone therapy was a reason for longer follow-up. 
Geurts et al.25 showed that follow-up frequency increased with the number of medical 
disciplines involved in routine follow-up.
Finally, financial incentives were thought as to play an important role. According to the Dutch 
guidelines patients older than 60 years can be referred to the GP or the national screening 
programme after 5 years of in-hospital follow-up.18 In the national screening programme a 
standard biennial mammogram will be performed, patients who will visit the GP should 
still make a biennial mammogram at the hospital. However, according to the current Dutch 
reimbursement schemes, surgical and radiation departments receive a yearly reimbursement 
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for each patient who visits the department. A phone call about the outcome of the mammogram 
does not suffice and therefore departments continue inviting patients for follow-up visits.
All these reasons together ensure that many patients are seen too frequently, by different 
disciplines, and for a long period. Recently, the American Society of Clinical Oncology (ASCO) 
performed a systemic review for the update of the 2006 guideline for breast cancer follow-up.26 
They did not find enough evidence to change the guideline. Examinations should be performed 
every 3 to 6 months for the first 3 years, every 6 to 12 months for years 4 and 5, and annually 
thereafter. On the other hand, the revised NABON guideline advises an annual follow-up visit 
combined with a mammogram for the first 5 years of follow-up, because for early detection of 
relapse a mammogram is more effective than only clinical follow-up.18
Considering the above mentioned results, we do not expect that the revised follow-up guideline 
in the Netherlands will be implemented in clinical practice automatically. The revised guideline 
requires changes in patients’ behaviour, better collaboration among clinical disciplines and 
changes in the organisation of follow-up care.
Follow-up care provider
The number of patients attending breast cancer follow-up is increasing. Costs have increased 
and a shortage of personnel has occurred.27 Furthermore, patients were dissatisfied about the 
many different faces they sometimes see during the follow-up period. This raises questions 
about whether follow-up can be optimised. In literature, there is continued interest in GP-led 
follow-up care. Grunfeld et al.28 showed that GP-led care is as effective as specialist care, while 
being considerably cheaper than hospital care. The results of our study showed limited support 
for GP-led care. Both patients and HPs were concerned about the lack of experience of the GP. 
They also felt that GPs are too busy and will refer the patient to the hospital anyway. In the study 
of van Hezewijk et al.10 the HPs agree that the GP should play a minor role in follow-up, only 
8% indicated that the GP should always be involved. However it is known that when patients 
are informed about the usual care, they have a preference for what they know best.29 Patients 
and HPs are unfamiliar with follow-up care provided by a GP. Follow-up care provided by a NP 
is well implemented, and highly appreciated by both HPs and patients. NP’s would be cheaper 
than specialists and be time-saving for the specialist. McCaughan and McSorley30 concluded in 
their qualitative study that doctors were enthusiastic about nurse-led follow-up care because 
it would free valuable time for medical consultants. From literature it is known that nurse-led 
follow-up is as effective as specialist care in terms of detection of cancer recurrence31, and that 
nurses are more likely to detect psychological distress in breast cancer patients.32 Pennery and 
Mallet15 found that 54% of the patients preferred a breast cancer nurse (more supportive) and 
38% a surgeon (most qualified, most up to date knowledge). In the present study disadvantages 
of nurse-led follow-up were also mentioned: some HPs emphasised that a NP should always 
be supervised by a specialist which takes extra time and some HPs were worried that NPs 
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would be inclined to do more diagnostics. Koinberg et al.33 indeed revealed a higher rate of 
mammograms among NPs, but requests for other imaging and laboratory evaluations were 
similar to those of specialists. 
Study limitations 
Some limitations have to be discussed. Although we felt that we have reached data saturation (no 
new information was being obtained during the 3 final interviews), and as a result the overview 
of relevant issues and opinions is likely to be complete, we should take the small sample size 
of our study into account and results should be interpreted with caution. Furthermore, the 
study took place in two hospitals in the eastern part of the Netherlands. The findings therefore 
may not be representative to other hospitals. However, due to the qualitative and explorative 
design of the study new insights were revealed. This is of great importance, because it enables 
changing the follow-up, thus tackling the increasing burden due to increasing incidence and 
survival.
Conclusion
This study gave insight into barriers for the implementation of adjusted follow-up schedules. 
Beside patient preferences also the collaboration of involved specialists play an important role 
even as the financial incentives. Implementation of new follow-up schedules might be more 
successful when taking these barriers into account. The implementation should therefore be 
active through education of both the HP and the patients.
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Abstract
Background
Breast-conserving therapy, consisting of lumpectomy and adjuvant radiotherapy, is considered 
standard treatment for early-stage breast cancer. One of the most important risk factors of local 
recurrence is the presence of positive surgical margins following lumpectomy. We aimed to 
develop and validate a predictive model (nomogram) to predict for positive margins following 
the first attempt at lumpectomy as a preoperative tool for clinical decision-making.
Patients and Methods
Patients with clinical T1-2N0-1Mx-0 histology-proven invasive breast carcinoma who underwent 
BCT throughout the North-East region of The Netherlands between June 2008 and July 2009 
were selected from the Netherlands Cancer Registry (n = 1,185). Results from multivariate 
logistic regression analyses served as the basis for development of the nomogram. Nomogram 
calibration and discrimination were assessed graphically and by calculation of a concordance 
index, respectively. Nomogram performance was validated on an external independent dataset 
(n = 331) from the University Medical Center Groningen.
Results
The final multivariate regression model included clinical, radiological, and pathological 
variables. Concordance indices were calculated of 0.70 (95% CI: 0.66-0.74) and 0.69 (95% CI: 
0.63-0.76) for the modeling and the validation group, respectively. Calibration of the model was 
considered adequate in both groups. A nomogram was developed as a graphical representation 
of the model. Moreover, a webbased application (http://www.breastconservation.com) was 
build to facilitate the use of our nomogram in a clinical setting.
Conclusion
We developed and validated a nomogram that enables estimation of the preoperative risk 
of positive margins in breast-conserving surgery. Our nomogram provides a valuable tool for 
identifying high-risk patients who might benefit from preoperative MRI and/or oncoplastic 
surgery.
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Background
Breast-conserving therapy (BCT), consisting of lumpectomy and adjuvant radiotherapy, is 
considered standard treatment for early stage breast cancer.1,2 The presence of a positive 
(surgical) margin, usually defined as tumor cells being present at the inked margin of the 
lumpectomy specimen, has been reported to be the most consistent risk factor for local 
recurrence (LR) following BCT.3,4 The percentage of patients with positive margins following the 
first attempt at lumpectomy ranges from 20 to 40% in the majority of studies.5 To reduce the 
risk of LR in the case of positive margins, additional surgery and/or radiotherapy are required 
with adverse affects on cosmesis, psychological distress, and health costs.6 
Previous studies reported large tumor size, lobular histological type, positive N-stage, 
multifocal disease, lymphovascular invasion, co-existing ductal carcinoma in situ (DCIS), 
microcalcifications on mammography, and young age to be independent risk factors associated 
with positive margins following lumpectomy (Supplemental Table 1). To allow for simultaneous 
consideration of multiple risk factors, statistical tools can be applied to calculate the overall 
probability of a specific outcome.7 These so-called nomograms are tailored to the profile of an 
individual patient.8 User-friendly graphical interfaces and web-based calculators can facilitate 
the use of nomograms in clinical practice.
Several nomograms have been developed in the field of breast cancer, including one for 
predicting the risk of positive surgical margins after BCT.9 However, this study was based and 
validated on single-center data, which might impair generalizability of the model. The aims 
of the current study were: i) to develop a userfriendly graphical and web-based nomogram 
based on multicenter data to predict individual probability of positive margins following the 
first attempt at lumpectomy based on clinicopathological variables and ii) to validate the 
nomogram in an independent dataset.
Patients and Methods
Patient population
A modeling and a validation group were constituted for development and validation of the 
nomogram, respectively. The modeling group consisted of breast cancer patients selected from 
the Netherlands Cancer Registry (NCR). Based on pathological notification through the PALGA 
(automated pathology archive) system,10 trained registration clerks gathered data concerning 
patient, tumor, and treatment characteristics from the patient files. Additionally, the NCR 
registered surgical margin status following lumpectomy between June 2008 and July 2009. 
During this time frame, data was collected from 1,495 patients who underwent BCT in one of 
24 institutions throughout the North-East region of the Netherlands. 
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Supplemental radiological and clinical variables were collected retrospectively for 1349 
patients from 20 out of 24 institutions. Three institutions were excluded due to a relatively 
limited contribution to the NCR database (<15 patients). One institution did not participate 
because of a change in the preoperative work-up during the investigated time frame, which 
might have influenced surgical outcome. Approval was obtained from the institutional review 
board of all participating institutions prior to initiation of the study. 
Women with clinical T1-2N0-1Mx-0 histology-proven invasive breast carcinoma who 
underwent BCT were included in the study. Patients with unconfirmed malignancy prior to 
surgery, undefined margin status, neo-adjuvant treatment, or absence of reported radiological 
tumor size were excluded. A total of 1,185 out of 1,349 patients (88%) were eligible for the 
modeling group.
The validation group consisted of 439 patients who underwent BCT at the University Medical 
Center Groningen (UMCG), Groningen, The Netherlands between July 2004 and June 2008 or 
July 2009 and May 2011. Patients who underwent BCT between June 2008 and July 2009 were 
assigned to the modeling group as they were part of the NCR database. Inclusion and exclusion 
criteria were identical to those applied in the modeling group. A total of 331 patients (75%) 
were eligible for the validation group.
Clinicopathological evaluation
The following variables were incorporated from the NCR database: surgical margin status, 
age, preoperative N-stage, preoperative T-stage, tumor location, histological type, histological 
grade, estrogen receptor (ER) status, progesterone receptor (PR) status, Her2/neu receptor 
status, and presence of co-existing DCIS. 
Positive surgical margin status was defined as microscopically confirmed invasive carcinoma 
(IC) and/or DCIS at the inked margin of the lumpectomy specimen following the first attempt at 
lumpectomy. Staging was performed according to the fifth edition of the TNM atlas. Preoperative 
T-stage was based on the maximum tumor diameter as measured on MRI (if available) or 
ultrasonography. Preoperative N-stage was based on clinical and/or radiological examination 
as well as preoperative histological examination (if available) of the axillary region. Topography 
and morphology were coded according to the International Classification of Diseases for 
Oncology (ICD-O).11 Grading of invasive carcinoma was scored according to the Nottingham 
(Elston-Ellis) modification of the Scarf-Bloom-Richardson grading system. Positivity of estrogen 
and progesterone receptors was defined as at least 10% of immunostained nuclei of tumor 
cells. HER2/neu status was considered positive in case of Her2/neu 3+ (strong and complete 
membranous expression in >30% of tumor cells) or Her2/neu 2+ (weak complete membranous 
expression in >10% of tumor cells) confirmed with positive fluorescence in situ hybridization. 
Co-existing DCIS was defined as the presence of any DCIS component. All pathological variables 
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were assessed on final pathology due to the fact that no preoperative core needle biopsy (CNB) 
was routinely performed in the vast majority of patients.
The NCR database was supplemented with data collected from patient files at the participating 
institutions, including clinical (family history, referral from screening, palpability, breast cup size, 
and prior surgery to the ipsilateral breast), and radiological variables (BI-RADS classification, 
suspicion of multifocality, preoperative MRI, microcalcifications, density of the breast, and 
area of the breast on the preoperative digital mammogram). Family history was recorded as 
negative, first-degree (FDR), or second-degree relatives (SDR). Tumors were classified as non-
palpable if a needle-localization procedure was required for excision. BI-RADS classification was 
recorded according to the fourth edition of the Breast Imaging Reporting and Data System.12 
Suspicion of multifocalitywas defined as the presence of two or more tumor foci within the 
same quadrant of the ipsilateral breast as assessed on MRI (if available) or radiography. The 
presence of microcalcifications was assessed on mammography and reported as present or 
absent. Density of the breast was assessed on mammograms and reported as one out of 
four BI-RADS categories: mostly fatty (0-25% dense), scattered fibroglandular tissue (25-50% 
dense), heterogeneously dense (50-75% dense), and extremely dense (75-100% dense).12 Area 
of the breast was determined in square millimeters by manually delineating the breast on 
the lateral projection of the preoperative digital mammogram. Calculations were performed 
using the default radiological software package available at each hospital. Last, postoperative 
variables were scored for the purpose of describing patient and tumor characteristics, including 
postoperative T-stage, postoperative N-stage, weight of the excised lump, and tumor-to-lump 
index (defined as the maximum tumor diameter in millimeters divided by the weight of the 
excised lump in grams).
Within the validation group, clinicopathological variables were collected from patient files in 
the UMCG database. Variables were scored identically to those in the modeling group.
Statistical analysis
The primary outcome for this study was the proportion of positive surgical margins following 
lumpectomy. Multivariate logistic regression analysis (MVA) was used to test the association 
between clinicopathological variables and the likelihood of positive margins. Stepwise 
backward variable selection was performed to determine informative variables based on 
the corrected Akaike’s Information Criterion (AICc).13 The nested model with the lowest AICc 
value was used to construct a graphical nomogram. A corresponding web-based calculator 
was developed. Moreover, a second calculator was developed including solely clinical and 
radiological variables, which can be applied in the absence of a preoperative CNB.
Model performance was quantified in both the modeling group and the validation group with 
respect to discrimination and calibration. Discrimination was assessed by calculating the area 
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under the receiver-operating characteristic (AUROC) curve, resulting in a so-called concordance 
index (c-index). Calibration was studied graphically after grouping patients into deciles with 
respect to their predicted probabilities and plotting the mean predicted probabilities against 
the mean observed probabilities. Bootstrapping was applied to calculate 95% confidence 
intervals. Overall fit of the model was evaluated using the Hosmer-Lemeshow goodness-of-fit 
test. Reported P-values are two-sided with alpha 5%.
Statistical analyses were performed using the statistical packages SPSS (SPSS for Windows, 
version 18.0.3, SPSS Inc., Chicago, IL) and STATA Software, version 10.0 (StataCorp, College 
Station, TX). Graphs were created using GraphPad Prism (GraphPad Prism for Windows, version 
5.00, GraphPad Software, San Diego, CA).
Results
Patient and tumor characteristics of the modeling and the validation group are listed in  Table 
1. Positive margins in BCT were present in 19.7% and 24.5% of the patients in the modeling 
and validation group, respectively (Supplemental Table 2). Marked differences between 
the modeling and the validation group were observed with respect to age, weight of the 
excised lump, tumor location, pN-stage, prior surgery to the breast, family history, BI-RADS 
classification, and presence of DCIS.
Margin positivity ranged from 11% to 38% throughout the 20 institutions that constituted 
the modeling group. No difference was observed between positive surgical margin rates from 
university-affiliated and community hospitals (P = 0.883). Moreover, no significant difference in 
the occurrence of positive margins was observed between individual hospitals when evaluated 
using MVA (P = 0.282). Of the 233 patients with positive margins in the modeling group, 92 
(39.5%) patients had a relumpectomy with clear margins, 2 (0.9%) patients had a second 
lumpectomy with persistent positive margins, 16 (6.9%) patients underwent mastectomy, and 
123 (52.8%) patients had no further surgery despite positive margins. Data on further surgical 
management were available for all 233 (100%) patients.
Data on breast cup size was available for only 101 out of 1,185 patients (8.5%) in the modeling 
group and 45 out of 331 patients (13.6%) in the validation group (data not shown). We 
therefore used the area of the breast on the digital mammogram to substitute for cup size, as 
the correlation between both variables was strong (Spearman’s rho: 0.893, P < 0.0001).
MRI was performed in 122 patients (10.3%) in the model group for preoperative tumor 
assessment. Ultrasonography was performed in the remaining 1,064 patients (89.7%). In the 
validation group, preoperative MRI was performed in 31 patients (9.4%), while the remaining 
300 patients (90.6%) had ultrasonography. Sentinel lymph node biopsy was performed in the 
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Table 1 Patient and tumor characteristics for the modeling and the validation group.
Modeling group Validation Group
N % N % P value
No. of patients 1,185 100 331 100
Age (years)
Mean (±SE) 59.8 (±0.31) 56.5 (±0.63) <0.001a
Median 60.3 56.0
Range 27 – 95 26 – 91 <0.001b
 ≤ 40 39 3.3 28 8.5
41-69 919 77.6 255 77.0
≥70 227 19.2 48 14.5
Tumor size (mm)
Mean (±SE) 15.6 (±0.22) 15.2 (±0.48) 0.107c
Median 14.0 13.0
Range 1.5 – 58.5 2.1 – 57.9 0.087
pT
1a
54 4.6 22 6.6
pT
1b
243 20.5 81 24.5
pT
1c
599 50.5 164 49.5
pT
2
284 24.0 62 18.7
pT
3
5 0.4 2 0.6
Area on mammogram (mm2)
Mean (±SE) 17916 (±6807) 17575 (±6937) 0.617
Median 17163 16498
Range 3551 - 46895 5212 - 50619 0.396
≤ 15000 450 38.0 138 42.4
15000-25000 554 46.8 142 44.7
≥ 25000 181 15.3 45 13.8
Weight excised lump (gram)
Mean (±SE) 62.5 (±39.7) 56.3 (±40.0) 0.027
Median 53.0 47.0
Range 6 - 277 6 - 299 0.044
 ≤ 50 270 44.5 167 51.0
51-99 172 28.3 78 23.9
 ≥ 100 165 27.2 82 25.1
(continued on next page)
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Table 1 continued
Modeling group Validation Group
N % N % P value
Tumor-to-lump index
Mean (±SE) 0.338 (±0.012) 0.354 (±0.020)        0.503
Median 0.266 0.288
Range 0.02 - 3.67 0.02 - 4.41    0.132
≤ 0.25 278 45,8 121 39.2
0.25-0.50 228 37.6 135 43.7
≥ 0.50 101 16.6 53 17.2
Palpability 0.104
Palpable 637 53.8 195 58.9
Non-palpable 548 46.2 136 41.1
Tumor location <0.001
LOQ 122 10.3 42 12.7
UOQ 535 45.1 170 51.4
UIQ 189 15.9 50 15.1
LIQ 150 12.7 26 7.9
Central 103 8.7 6 1.8
Histological type 0.062
Ductal 957 80.8 286 86.4
Lobular 119 10.0 23 6.9
Specifiedd 109 9.2 22 6.6
Histological grade 0.214
Grade I 330 28.1 107 32.8
Grade II 531 45.2 133 40.7
Grade III 313 26.6 86 26.5
ER status 0.661
Positive 1,002 85.3 276 84,4
Negative 172 14.7 51 15.6
PR status 0.443
Positive 750 71.4 226 69.1
Negative 300 28.5 101 30.9
Her2neu receptor status 0.486
Positive 125 10.7 40 12.3
Multifocal disease 0.170
Yes 47 4.0 19 5.7
No 1,138 96.0 312 94.3
Negative 1,041 89.3 290 87.7
(continued on next page)
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Table 1 continued
Modeling group Validation Group
N % N % P value
pN-stage 0.004
Positive 310 26.2 113 34.4
Negative 875 73.8 218 65.6
Prior surgery to the breast <0.001
Yes 46 3.9 34 10.3
No 1,139 96.1 297 89.7
Family history <0.001
FDR 91 8.9 75 22.8
SDR 188 18.2 56 17.0
Negative 749 72.9 199 60.2
Referred from screening 0.755
Yes 578 49.1 158 47.7
No 601 50.9 172 52.3
BI-RADS classification 0.001
IIe 3 0.3 8 2.5
III 93 8.1 31 9.7
IV 611 52.9 155 48.3
V 447 38.7 127 39.5
Preoperative MRI 0.680
Yes 122 10.3 31 9.4
No 1,063 89.7 302 90.6
Microcalcifications
Yes 245 20.8 74 22.4 0.542
No 937 79.2 257 77.6
DCIS component present <0.001
Yes 529 44.6 188 56.8
No 656 55.4 143 43.2
Breast density 0.816
0-25 % 323 31.0 101 31.2
25-50% 467 44.9 146 45.0
50-75% 217 20.8 70 21.6
75-100% 34 3.3 7 2.2
Institution -
University-affiliated 642 54.2 331 100
Community hospital 543 45.8 - -
Abbreviations: ER, estrogen receptor; FDR, first-degree relative; LIQ, lower inner quadrant; LOQ, lower outer quadrant; MRI, magnetic 
resonance imaging; PR, progesterone receptor; SDR, second-degree relative; UIQ, upper inner quadrant; UOQ, upper outer quadrant.
a Independent-samples t-test.  b Fisher’s exact test. c Independent-samples t-test following logarithmic transformation to promote data 
normality. d Specified histological types included mucinous, medullary, tubular, and papillary carcinomas. e BI-RADS classification II with 
malignancy proven by fine needle aspiration or core needle biopsy. Bold indicates statistical significance.
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vast majority of patients, including 1,113 (93.9%) patients from the modeling group and 307 
(92.7%) from the validation group. Axillary lymph node dissection (ALND) was performed 
in 293 (24.7%) and 87 patients (26.3%), respectively. A total of 221 (18.6%) and 63 (19.0%) 
patients received an ALND in addition to an SLNB procedure.
Multivariate analysis
The nested MVA model with the lowest AICc (959.6) was selected. Clinicopathological 
variables constituting the final model were microcalcifications, preoperative MRI, suspicion 
of multifocality, palpability, preoperative N-stage, preoperative T-stage, density of the breast, 
histological type, histological grade, ER status and presence of DCIS. Corresponding odds ratios 
are listed in Table 2. Nonsignificant variables were included if they improved accuracy of the 
model. 
Predictor Odds ratio 95% CI P value
Suspicion of multifocal disease (vs. unifocal) 2.81 1.30-6.06 0.008
Preoperative MRI scan absent (vs. available) 1.80 1.02-3.18 0.043
Positive preoperative N-stage (vs. negative) 1.73 0.97-3.07 0.062
Non-palpable tumor (vs. palpable) 1.51 1.07-2.13 0.020
Microcalcifications on mammogram (vs. none) 1.37 0.95-2.00 0.094
Preoperative T2 stage (vs. T1) 1.33 0.87-2.02 0.185
Breast density on mammogram 1.22 1.00-1.49 0.053
Presence of DCIS component (vs. absence) 3.11 2.19-4.42 <0.001
Lobular histological type (vs. other) 2.90 1.71-4.91 <0.001
Positive ER status (vs. negative) 1.80 1.04-3.13 0.037
Elston III grade (vs. Elston I/II) 1.44 0.96-2.16 0.082
Reported odds ratios indicate a ratio of the probability of positive margins following lumpectomy versus the 
probability of negative margins. Bold indicates statistical significance.
Evaluation of the model
The model fitted the data according to the Hosmer-Lemeshow goodness-of-fit test (Χ2 = 2.733, 
8 degrees of freedom, P = 0.950). Discrimination (Figuire 1) and calibration (Figure 2) were 
first assessed for the modeling group. The c-index was calculated to be 0.70 (95% CI 0.66-0.74, 
P < 0.001). Calibration was considered adequate. External validation on the UMCG dataset 
resulted in a c-index of 0.69 (95% CI 0.63-0.76, P < 0.001; Figure 1). Calibration was considered 
acceptable (Figure 2).
Table 2 Preoperative clinical, radiological, and pathological variables included in the final model.
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Figure 1 Discrimination of the final model for the modeling and validation group. The area under the 
receiver-operating characteristic (AUROC) curve, comparable to the concordance index, indicates the 
discriminative power of the model. The reference line indicates an AUROC value of 0.5, for which the 
probability of positive surgical margins is equal to the toss of a coin. An AUROC value of 1.0 would 
resemble perfect discrimination.
Figure 2 Calibration of the final model in the modeling and validation group. All patients were grouped 
into deciles (blue triangles and orange dots) based on their predicted probabilities. Mean predicted 
probabilities were plotted against the actual incidence of positive margins for each decile. Moreover, 
95% confidence intervals are shown for both groups. The reference line represents perfect equality of 
observed frequencies and predicted probabilities. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.)
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Figure 3 Nomogram including clinical, radiological, and pathological variables for predicting positive 
surgical margins following the first attempt at lumpectomy. Instructions for use: Locate the patient’s 
status on the ‘preoperative MRI’ axis. Draw a line straight upward to the ‘points’ axis to determine how 
many points are assigned to the individual patient. Repeat this process for the axes below. Sum the points 
achieved for each variable and locate this sum on the ‘total points’ axis. From here, draw a line straight 
downward to obtain the probability of positive surgical margins following lumpectomy for the individual 
patient. Note: Due to the relatively high frequency of false negative findings when assessing the presence 
of co-existing DCIS in a core needle biopsy (CNB), absence of DCIS should be interpreted with caution. 
We therefore recommend to determine a suitable probability interval by calculating the probability of 
positive surgical margins for both true and false negative outcomes. A user-friendly web-based version of 
the nomogram is available at www.breastconservation.com.
Nomogram and web-based calculators
A graphical nomogram was developed based on the results of MVA (Figure 3). The underlying 
statistical formula was also implemented in a web-based calculator, accessible at http://www.
breastconservation.com. Additionally, a second web-based calculator was developed including 
solely clinical and radiological variables that can be used in the absence of a preoperative CNB. 
Discrimination of this model ranged from 0.62 to 0.64 for the modeling and validation group, 
respectively (Supplemental Figure 1). Calibration was considered acceptable for both groups 
(Supplemental Figure 2). Both calculators provide the user with a patient-tailored estimation 
of the preoperative risk of positive margins, stratified as low (<15%), intermediate (15-25%), or 
high (>25%) risk. The calculators support Internet Explorer, Safari, Firefox, and Google Chrome. 
An example on how to use the online nomogram is provided on the website.
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Discussion
We developed a nomogram and corresponding web-based calculators to estimate the risk of 
positive margins following lumpectomy using clinicopathological variables. Variables predicting 
for positive surgical margins on MVA included microcalcifications on mammogram (OR 1.37, 
P = 0.094), absence of preoperative MRI (OR 1.80, P = 0.043), suspicion of multifocality (OR 
2.81, P = 0.008), nonpalpable tumor (OR 1.51, P = 0.020), positive preoperative N-stage (OR 
1.73, P = 0.062), large tumor size (OR 1.33, P = 0.185), high density of the breast (OR 1.22, P 
= 0.053), lobular histological type (OR 2.90, P < 0.001), high histological grade (OR 1.44, P = 
0.082), positive ER status (OR 1.80, P = 0.037) and presence of DCIS (OR 3.11, P < 0.001). In 
the absence of preoperative pathological variables (e.g. no CNB available), a second online 
calculator is available at http://www.breastconservation.com that solely includes clinical and 
radiological variables.
Assessment of pathological variables in the current study was based on final pathology due to 
the fact that fine needle aspiration biopsy instead of CNB was performed in the vast majority 
of patients. Nonetheless, CNB may provide important information on preoperative prognostic 
factors and shows good correlation with findings on final pathology.14 Histological type can be 
accurately predicted on CNB and is reported to be concordant with the subsequent surgical 
specimen in 93-100% of the cases.15 For ER status, reported concordance rates between CNB 
and the surgical specimen range from 86% to 100%.16-18 Current evidence shows that histological 
grade can be assessed on CNB and is concordant with final pathology in approximately 75% 
of the cases.19 The highest level of agreement is achieved in high-grade carcinomas, with an 
associated concordance rate of 84%.14 The presence of co-existing DCIS can also be assessed 
on CNB and is associated with an increased risk of positive margins.20-22 However, false negative 
findings reported in the literature range from 36% to 54%, indicating that the absence of DCIS 
in the CNB should be interpreted with caution.21,23 The risk for false negative results of CNB 
can be minimized by accurate targeting, sufficient biopsy size, and obtaining a larger number 
of cores.20 Jimenez et al.21 reported that CNB predicts the presence of co-existing DCIS in the 
subsequent surgical specimen with a sensitivity and specificity of 54% and 92%, respectively. 
The corresponding negative and positive predictive values were 70% and 85%. To account 
for the relatively high-risk of false negative findings, we recommend determining a suitable 
probability interval by calculating the probability of positive margins for both true and false 
negative outcomes when using our nomogram (Figure 3). The web-based calculator will 
automatically provide the user with such a probability interval if applicable. 
The ability to estimate the preoperative risk of positive margins following lumpectomy could 
support clinicians in counseling patients regarding the likelihood of requiring further surgery, 
allowing for a more patient-tailored approach. Although broadly supported for positive 
margins, some authors have also reported an increased risk for LR in the case of close surgical 
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margins.4,24 However, the importance of close margins is still a matter of debate.25,26 Moreover, 
consensus over what is the most appropriate margin is lacking, with definitions of close margins 
ranging from <1 mm to <5 mm distance to the inked margin.27 Because the clinical implications 
of close margins are uncertain, they were not taken into account in the current study. 
In patients identified as high-risk (>25%), we advise to perform a preoperative MRI to assist 
the clinician in defining the extent of local disease and detect areas of co-existing high-grade 
DCIS that are occult on mammography. Indeed, preoperative MRI was reported to reduce 
the risk of inadequate tumor excision.28 In the current study, MRI was performed in those 
patients with preoperative suspicion of multifocal disease or with BRCA1 of BRCA2 mutations. 
Despite correction for these factors, MRI was found to significantly decrease the risk of positive 
margins (P = 0.043; Table 2). However, the true value of MRI in reducing the risk of inadequate 
tumor excision in patients preoperatively identified as high-risk needs to be assessed in future 
studies. 
In addition, high-risk patients might benefit from a more extensive surgical excision. Lovrics et 
al.29 reported the amount of breast parenchyma excised during BCS to be inversely correlated 
with the likelihood of positive margins. In the current study, we also found a significant 
association between low tumor-to-lump index (i.e. relatively small lump compared to size of 
the tumor) and positive surgical margins (P = 0.002). However, although excising relatively 
voluminous specimens is more accurate in predicting margin status than any predictive model, 
it has profound repercussions on cosmesis. To allow for relatively extensive excisions while 
maintaining adequate cosmetic results, oncoplastic surgery was suggested as a technique 
to minimize breast deformities by immediate reconstruction of large resection defects.30 
The technique might be of particular value for those patients identified as high-risk with our 
nomogram, although further studies are needed to address this topic.
The rate of positive margins observed in the modeling (19.7%, range: 11-38%) and the 
validation group (24.5%) are in line with positivity rates reported in the literature.5 The slightly 
higher positive margin rate in the validation group can partially be explained by the high rate of 
co-existing DCIS (56.8% vs. 44.6% in the modeling group, P < 0.001), which is known to increase 
the risk of positive margins.31 
Very recently, Shin et al.9 reported on a nomogram for predicting positive surgical margins 
after BCT. The nomogram was based on retrospective single-center data derived from 1034 
Korean breast cancer patients with invasive or in situ breast carcinoma. MVA indicated 
microcalcifications (OR 1.57, P = 0.034), dense breasts (OR 4.52, P = 0.005), 0.5 cm difference 
in tumor size between MRI and ultrasonography (OR 10.00, P < 0.001), presence of DCIS (OR 
1.58, P = 0.044), and lobular histological type (OR 3.99, P = 0.015) to be independent predictors 
for positive surgical margins. Validation was performed on an independent cohort of 563 
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patients. The concordance indices of the modeling and the validation groups were reported to 
be 0.82 (95% CI: 0.79-0.86) and 0.85 (95% CI: 0.80-0.89), respectively. Although the reported 
concordance indices are relatively high when compared to the current multicenter study, this 
difference may partly be explained by the relative lack of heterogeneity in single-institution 
data, impairing generalizability of the model.8 Our nomogram was constructed based on 
multicenter data derived from 20 institutions, including community-based and university-
affiliated hospitals. Validation was performed in an independent dataset that showed marked 
differences when compared to the modeling group, providing sufficient data heterogeneity to 
assess generalizability of the nomogram.
Several other nomograms are available in the field of breast cancer, including nomograms 
for predicting the likelihood of cancer spread to the sentinel lymph nodes,32 cancer spread to 
nonsentinel lymph nodes,33 and the benefit of systemic adjuvant therapy (Adjuvant! Online).34 
Moreover, Rudloff et al.35 developed a nomogram (c-index: 0.704) for predicting the 5- and 
10-year probability for ipsilateral breast tumor recurrence after BCT for ductal carcinoma in 
situ. The nomogram was developed on the basis of unicenter data derived from 1,681 patients 
and included ten clinical, pathological, and treatment variables (age at diagnosis, family 
history, initial presentation, radiation, adjuvant endocrine therapy, nuclear grade, necrosis, 
margins, number of excisions, and year of surgery). Sanghani et al.36 constructed a web-based 
nomogram for predicting the probability of ipsilateral breast tumor recurrence after BCT. Data 
was derived from 7,811 patients and included both clinical and pathological variables (adjuvant 
RT or endocrine therapy, age, margin status, number of excisions, and treatment time period). 
Werkhoven et al.37 developed a comparable nomogram (c-index: 0.68) based on data from 
1,603 patients. Rouzier et al.38 developed several nomograms that can be applied to predict the 
probability of successful BCT in patients who underwent neo-adjuvant treatment.
We acknowledge that there are certain limitations to our study. First, our study is subject to 
limitations that are inherent to retrospective data collection. Second, as discussed earlier, 
pathological variables were obtained on final pathology due to the fact that preoperative 
CNB was not routinely performed in the vast majority of patients. We were therefore unable 
to evaluate the concordance between pathological variables as assessed on CNB and final 
pathology. However, numerous studies have evaluated this topic with the majority of studies 
reporting good concordance rates. Third, we used surgical margin status after the first 
lumpectomy attempt as a primary endpoint. Although information on positive margin rate 
after a second lumpectomy might be of particular clinical interest, the absolute number of 
patients with positive surgical margins after a second lumpectomy in our study was considered 
insufficient to obtain adequate sample size for nomogram development. Larger patient 
cohorts are therefore needed to address this topic. Last, our nomogram is based on female 
Dutch inhabitants, who are primarily Caucasian women. We therefore advise caution against 
extrapolation of the nomogram to different populations.
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Conclusion
We developed and validated a nomogram to predict the probability of positive surgical margins 
following lumpectomy using clinicopathological variables. Our nomogram could support 
clinicians in identifying high-risk patients who might benefit from preoperative MRI and/or 
oncoplastic surgery.
Appendix A Supplementary data
Supplementary data related to this article can befound at 
http://dx.doi.org/10.1016/j.breast.2013.01.010.
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Abstract 
Background 
Invasive lobular breast cancer (ILC) is less common than invasive ductal breast cancer (IDC) 
and appears to have a distinct biology. Inconsistent findings regarding disease-free survival 
(DFS) are probably due to the fact that histologic type is related to hormone receptor status. 
This study aims to determine whether the type of the primary breast cancer histology is an 
independent prognostic factor for disease-free survival (DFS), the risk pattern of loco-regional 
recurrences (LRR) and distant metastases (DM), and whether it is a prognostic factor for the 
site of DM.
Patients and Methods 
All Dutch women diagnosed between 2003-2005 with ILC (n=2,949) or IDC (n=22,378) were 
selected from the Netherlands Cancer Registry. DFS was assessed using proportional hazard 
regression analysis.
Results 
Compared to patients with IDC, those with ILC were significantly older and more likely to have 
more than 3 positive lymph nodes and have larger, better differentiated, more multifocal and 
hormone receptor positive tumors (all P<0.001). ILC was more likely to metastasize to the 
gastrointestinal organs and bones and less likely to the lung, central nervous system and lymph 
nodes. Within the ER+PR+ and ER+PR- subgroups ILC was still more likely to metastasize to 
gastrointestinal organs and less likely to the lung. The timing of recurrence was correlated to 
hormone receptor status, independent of histological type. Highest risks were observed among 
ER-PR- patients within two years of surgery. Multivariable analysis showed that histological 
type is not an independent significant prognostic factor of DFS for the first 3 years post-surgery 
and thereafter (<3years HR=0.91, 95%CI:0.78-1.06, >3years HR=1.07, 95%CI:0.88-1.30). 
Conclusion 
Histological type should not be considered an important prognostic factor for the risk and risk 
pattern of recurrences. 
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Background
Carcinoma of the breast is a diverse group of tumors with different types of histology and 
variable response to treatment. The most common type is invasive ductal cancer (IDC), 
accounting for about 75% to 80% of all invasive breast tumors, and invasive lobular cancer (ILC) 
is the second most common type of this, accounting for 8-14%.1-3 Positive hormone receptor 
status for estrogen (ER) and progesterone (PR) is known to be more common in ILC than in 
IDC.1,4-6 Reported long-term clinical outcomes for ILC versus IDC vary. Since histological type is 
related to hormone receptor status, and hormone receptor status is an important independent 
prognostic factor for disease-free survival (DFS) and overall survival (OS), the independent 
prognostic value may be overestimated when not corrected for hormone receptor status. 
However, studies analyzing the effect of histological type by correcting for hormone receptor 
status show inconsistent results, with some supporting a better DFS and OS for ILC compared 
to IDC5,6, and others revealing no differences1,7, or finding that the effect of histology on risk 
of recurrence or death changed over time, with a better DFS and OS for patients with ILC 
compared to IDC in the first 6 to 10 years and a worse DFS and OS thereafter.8 Moreover, 
preferential sites for distant metastases (DM) for ILC have been found to be different from those 
for IDC. Metastases to the bones, gastrointestinal organs, peritoneum and ovaries are most 
common for ILC, whereas metastases to the lung, liver and central nervous system (CNS) are 
more common for IDC.1,5,7-11 Similar observations were found when ER positive were compared 
with ER negative patients, with metastases to the bones more common in ER positive patients 
and metastases to visceral organs more common in ER negative patients.12-14
The aim of this study is to define whether type of histology is an independent prognostic factor 
for DFS and the risk pattern of local-regional recurrences (LRR) and DM, and whether it is a 
prognostic factor for the site of DM.
Patients and methods
Netherlands Cancer Registry
Patients were selected from the nationwide population-based Netherlands Cancer Registry 
(NCR), which registers data about all newly diagnosed in situ and invasive tumors since 1989. 
Information on patient characteristics, tumor characteristics, treatment and follow-up is 
recorded by specially trained registration clerks directly from the patient files. Topography 
and histology are coded according to the International Classification of Diseases for oncology 
(ICD-O)15, and staging is coded according to the tumor, node, and metastasis system (TNM) 
classification.16 Hormone receptor status has been registered since the beginning of 2004, 
with tumors with at least 10% positive tumor cells for estrogen receptors (ER) or progesterone 
receptor (PR) defined as having a positive receptor status: ER+ or PR+. Information on the 
occurrence of LRR (located at the treated breast, chest wall or axilla) and DM within at least 
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five years after diagnosis was derived retrospectively from the patients files for all patients 
diagnosed between 2003 to 2005.
Patients
From the NCR, women diagnosed with primary invasive breast cancer (pathological T stage 
1-3) between 2003 to 2005, without distant metastases at diagnosis and treated with curative 
intent were selected (N=29,848), excluding those who received neo-adjuvant systemic therapy 
(n=1,278), were ER- and PR+ (n=265), were not tumor-free after initial treatment (n=97), were 
treated with breast-conserving treatment without adjuvant radiotherapy (n=364) or when 
follow-up information was incomplete (n=459). Of the selected breast cancer patients, 82% 
were diagnosed with IDC and 11% with ILC. Patients with special histological types (mucinous, 
medullary or apocrine) or mixed ILC and IDC were excluded (n=2,049), leading to a total of 
25,336 patients for analysis. 
Statistical analyses
Analyses were performed using STATA version 12. The clinical and biological tumor characteristics 
and treatment modalities are reported as frequencies and compared using χ2 tests. Differences 
in distribution of metastatic sites among patients with a DM were tested by χ2 tests and Fisher’s 
exact tests. First, the patterns of LRR and DM were studied using the life-table method to 
observe the occurrence pattern of LRR and DM, i.e. the conditional probabilities of manifesting 
recurrence in subsequent time intervals, given that the patient is free of recurrence at the 
beginning of each interval. These hazard rates are displayed graphically using smoothed curves 
obtained with kernel density estimation. Disease-free survival was defined as the time between 
the date of surgery and the date of first recurrence (LRR or DM). Patients were censored at the 
date of a new primary cancer, death or end of study period (5 years after surgery). 
Proportional hazard regression modeling was used to identify independent prognostic factors 
for DFS. Hazards in different subgroups of variables were tested for proportionality using 
graphical (Kaplan Meier plots) and the Schoenfeld residuals test. Factors included in the model 
were age (≤50 years, >50 years), tumor size (≤2 cm, >2 and ≤5 cm, >5 cm, other), nodal status 
(negative, 1-3 positive, >3 positive), tumor grade (I, II, III), hormone receptor status (ER-PR-, 
ER+PR-, ER+PR+), multifocality (no, yes), microscopic positive margins (no, yes) and surgery with/
without radiotherapy (breast conserving with radiotherapy, mastectomy with radiotherapy, 
mastectomy without radiotherapy), chemotherapy (yes, no) and endocrine therapy (yes, 
no). The percentage of missing values varied between 0 and 35%. In total, 11,830 of 25,336 
records (47%) were incomplete for one or more variables. The hormone receptor status has 
been registered on a national basis since 2004, and women with a small tumor size had more 
missing data. Due to the large percentage of missing data, multiple imputation, which assumes 
that data are missing at random (MAR), was performed17 under Fully Conditional Specification, 
using the MI command in STATA version 12, with 100 iterations. Fifty datasets were generated 
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using a model that included all variables used in the regression analysis and all variables 
predictive of missing values. This model consisted of ER and PR status, grade, clinical nodal 
status, pathological tumor size and nodal status, multifocality, microscopic positive margins, 
year of diagnosis, age, histology, surgery, radiotherapy, chemotherapy, endocrine therapy, LRR, 
DM, site of DM, time from surgery to first recurrence and the log time from surgery to first 
recurrence. Convergence of the imputations was checked graphically18 and, for each imputed 
dataset, the Proportional Hazard regression model was separately estimated. The estimates 
and their standard errors were combined using Rubin’s rules. For comparative purposes, the 
proportional hazard models were built using both the imputed dataset and a dataset restricted 
to cases with complete data. 
A p-value of 0.05 was considered to be statistically significant.
Results
Patient and tumor characteristics
Table 1 summarizes the patient and tumor characteristics according to histological type. 
Compared to IDC, ILC was significantly (p<0.001) more likely to occur in older patients, to 
be larger, more often had >3 positive lymph nodes, was better differentiated and was more 
frequently multifocal. Only 4.6% of the patients with ILC had an ER-PR- receptor status, while 
20% of the patients with IDC had an ER-PR- status (p<0.001). As such, the proportion of patients 
with mastectomy was higher in ILC and endocrine therapy was more often given to patients 
with ILC. Adjuvant chemotherapy was less often given to patients with ILC. 
Site of distant metastasis
The site of first DM according to histological type and hormone receptor status are listed in 
Table 2. Gastrointestinal organs (including peritoneum and pleura) and bone involvement 
were more frequently observed in ILC patients, whereas lung, CNS, lymph nodes and skin 
involvement were more frequently observed in IDC patients. However, different patterns of 
metastatic dissemination were also observed between hormone receptor subgroups, with 
bone involvement more frequently observed in patients with ER+PR- or ER+PR+ tumors, and 
lung, CNS and lymph node involvement more frequently observed in patients with ER-PR- 
tumors. Consequently, we analyzed whether a difference remained between histological type 
within the hormone receptor subgroups (Table 2), finding that, within the ER+PR- and ER+PR+, 
ILC was still significantly more likely to metastasize to gastrointestinal organs. Within the 
ER-PR- subgroup, differences between histological type remained significant for metastases to 
the lymph nodes and lung. 
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Table 1 Patient and tumor characteristics by invasive lobular and ductal carcinomas before and after 
multiple imputation
Ductal Lobular Total After multiple  imputation
N % N % P   value N % % 95% CI
Total 22,387 2.949 25,336
Year of diagnosis 0.557
2003 7,449 33.3 981 33.3 8,430 33.3
2004 7,526 33.6 966 32.8 8,492 33.5
2005 7,412 33.1 1,002 34.0 8,414 33.2
Grade <0.001
I 4,577 21.6 516 21.8 5,093 21.6 22.0 21.5 - 22,6
II 8,994 42.4 1,580 66.8 10,574 44.9 44.9 44.3 - 45,5
III 7,632 36.0 271 11.5 7,903 33.5 33.1 32.5 - 33,7
Unknown 1,184 582 1,766
Age <0.001
Median (25%-75%) 57 49-68 61 51-71 58 49-68
≤50 5,955 26.6 590 20.0 6,545 25.8
>50 16,432 73.4 2,359 80.0 18,791 74.2
Tumor size <0.001
<=2cm 14,052 62.8 1,424 48.3 15,476 61.1
>2and<=5cm 7,846 35.1 1,280 43.4 9,126 36.0
>5cm 489 2.2 245 8.3 734 2.9
Lymph node status <0.001
negative 13,592 61.1 1,702 58.1 15,294 60.8 60.9 60.3 - 61,5
1-3 positive 6,237 28.0 777 26.5 7,014 27.9 27.8 27.3 - 28,4
>3 positive 2,415 10.9 452 15.4 2,867 11.4 11.3 10.9 - 11.7
unknown 143 18 161
Hormone receptor status <0.001
ER- & PR-* 3,004 20.1 91 4.6 3,095 18.2 18.6 18.0 - 19.2
ER+ & PR- 2,301 15.4 392 19.6 2,693 15.9 16.3 15.7 - 16.9
ER+ & PR+ 9,662 64.6 1,515 75.8 11,177 65.9 65.0 64.3 - 65.8
unknown 7,420 951 8,371
Multifocal <0.001
No 12,429 85.9 1,498 78.3 13,927 85.0 85.5 85.0 - 86.1
Yes 2,049 14.2 415 21.7 2,464 15.0 14.5 13.9 - 15.0
unknown 8,359 1,123 8,945
Surgery + radiotherapy <0.001
BCS≠ +RT¥ 12,879 57.5 1,228 41.6 14,107 55.7
Amputation +RT 2,230 10.0 538 18.2 2,768 10.9
Amputation -RT 7,278 32.5 1,183 40.1 8,461 33.4
Residual tumor <0.001
No 20,911 96.6 2,657 94.0 23,568 96.3 96.3 96.0 - 96.5
Yes 731 3.4 169 6.0 900 3.7 3.7 3.5 - 4.0
unknown 745 123 868
Chemotherapy <0.001
No 14,216 63.5 2,128 72.2 16,344 64.5
Yes 8,171 36.5 821 27.8 8,992 35.5
Endocrine therapy <0.001
No 13,323 59.5 1,479 50.2 14,802 58.4
Yes 9,064 40.5 1,470 49.9 10,534 41.6
* ER Estrogen receptor, PR Progesterone receptor; ≠ BCS Breast conserving surgery.  ¥ RT radiotherapy;± within 5 years after surgery. Bold indicates statistical 
significance.
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Risk of loco-regional recurrences and distant metastasis
The median follow-up time for the total population was 4.9 years (interquartile range (IQR): 
4.2-5), for patients with a LRR (3.5%) the median follow-up was 2.6 years (IQR: 1.5-3.6) and for 
patients with DM (9.3%) this was 2.4 years (IQR: 1.4-3.6). The hazard rate curve for LRR (Figure 
1) shows an early peak for the IDC cohort but, after 3 years, the rate among the ILC cohort 
was higher. Similarly, the hazard rate curve for DM (Figure 1) shows an earlier appearance for 
the IDC cohort, whereas, after 3 years, the rate for DM is lower in the IDC cohort. Since the 
patterns of LRR and DM appeared to be remarkably similar, both endpoints were combined for 
further analyses. A subset of the patients, those for whom ER and PR status was known, was 
further analyzed, stratified by hormone receptor status (Figure 2). The resulting curves show 
that the timing of recurrence was correlated to receptor status independent of histological 
type. The hazard rates for both ILC and IDC patients in the ER-PR- subgroup show an early peak 
between 1 and 2 years after surgery (Figure 2a). For ER+PR- and ER+PR+ subgroup, the highest 
hazards were observed 1.5 years after surgery and a considerable decline was not observed 
until 5 years after diagnosis, although the highest hazard was much lower than for the ER-PR- 
subgroup (Figure 2b, c). These results suggest a time-dependent effect of hormone receptor 
status for the risk of LRR and DM. 
 Figure 1 Hazard rates for loco-regional recurrences and distant metastases by histological type
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Figure 2 Hazard rates for loco-regional recurrences and distant metastasis combined (a) for ER- and PR- 
patients by histological type(n=3,095) (b) for ER+ and PR- patients by histological type (n=2,693) (c) for 
ER+ and PR+ patients by histological type (n=11,177)
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A multivariable Cox regression model was built with all co-variables defined in the method 
section. As expected, statistical analyses provided strong evidence of non-proportionality for 
hormone receptor status so Cox regression models were performed for two time periods, 
before and after 3 years of follow-up. No significant risk differences of a recurrence between 
the histological types was seen before (hazard ratio (HR)=0.91, 95%CI:0.78-1.06) and after 
(HR=1.06, 95%CI:0.88-1.29) 3 years (Table 3). Before and after 3 years, patients with an 
ER+PR+ tumor had a significantly lower risk of a recurrence compared to those with an 
ER-PR- tumor (<3 years HR= 0.42, 95%CI:0.36-0.49 and >3 years HR= 0.77, 95%CI:0.61-0.98), 
whereas patients with an ER+PR- tumor only had a lower risk during the first 3 years (HR=0.69, 
95%CI:0.58-0.82). Similar results were obtained when treatment variables were included in 
the Cox regression model. No interaction between histological type and other risk factors were 
statistically significant for the risk of a recurrence. Results from the complete case analyses 
were comparable to the multiple imputation analyses.
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Table 3 Multivariable analyses for disease-free survival within 3 years after surgery and more than 3 years after surgery
Disease-free survival ≤ 3 years Disease-free survival>3 years
Complete case analysis*
Multiple imputation 
analysis†
Complete case analysis*
Multiple imputation 
analysis†
HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Histology
Ductal 1 1
Lobular 0,95 0.75 - 1.19 0,649 0,91 0.78 - 1.06 0,224 0,99 0.75 - 1.31 0,944 1,06 0.88 - 1.29 0,531
Age
≤50 1
>50 0,85 0.73 - 0.97 0,02 0,83 0.75 - 0.93 0,001 0,76 0.62 - 0.93 0,008 0,86 0.74 - 1.00 0,057
Tumor size
<=2cm 1
>2and<=5cm 1,67 1.45 - 1.92 <0.001 1,7 1.53 - 1.89 <0.001 1,36 1.12 - 1.65 0,002 1,47 1.27 - 1.70 <0.001
>5cm 1,92 1.48 - 2.49 <0.001 2,11 1.74 - 2.56 <0.001 1,73 1.12 - 2.68 0,014 1,41 1.00 - 2.00 0,052
Lymph node status
Negative 1
1-3 positive 1,89 1.61 - 2.21 <0.001 1,94 1.73 - 2.19 <0.001 1,65 1.32 - 2.07 <0.001 1,57 1.32 - 1.85 <0.001
>3 positive 3,42 2.80 - 4.19 <0.001 4,43 3.83 - 5.14 <0.001 3,98 2.92 - 5.41 <0.001 3,41 2.70 - 4.29 <0.001
Grade 
I 1
II 2,03 1.55 - 2.64 <0.001 2,2 1.79 - 2.70 <0.001 2,56 1.89 - 3.47 <0.001 2,2 1.75 - 2.77 <0.001
III 3,13 2.37 - 4.12 <0.001 3,42 2.75 - 4.25 <0.001 3,55 2.55 - 4.95 <0.001 2,65 2.06 - 3.42 <0.001
Multifocal
No 1
Yes 1,28 1.10 - 1.48 0,002 1,27 1.10 - 1.46 0,001 1,01 0.80 - 1.28 0,928 1,09 0.88 - 1.34 0,435
Hormone receptor status
ER- PR-* 1
ER+ PR- 0,68 0.54 - 0.85 0,001 0,69 0.58 - 0.82 <0.001 1,75 1.26 - 2.42 0,001 1,16 0.91 - 1.48 0,237
ER+PR+ 0,38 0.31 - 0.47 <0.001 0,42 0.36 - 0.49 <0.001 1,11 0.82 - 1.50 0,5 0,77 0.61 - 0.98 0,031
Residual tumor
No 1
Yes 1,22 0.92 - 1.61 0,163 1,21 0.98 - 1.48 0,071 0,92 0.58 - 1.46 0,727 0,9 0.64 - 1.27 0,545
Surgery + radiotherapy
BCS≠ +RT¥ 1
Amputation +RT 1,56 1.28 - 1.90 <0.001 1,2 1.04 - 1.39 0,014 0,91 0.66 - 1.26 0,571 1,09 0.87 - 1.37 0,451
Amputation -RT 1,47 1.26 - 1.70 <0.001 1,37 1.23 - 1.53 <0.001 1,28 1.05 - 1.56 0,015 1,19 1.02 - 1.38 0,025
Chemotherapy
No 1
Yes 0,71 0.61 - 0.83 <0.001 0,64 0.57 - 0.72 <0.001 0,54 0.43 - 0.68 <0.001 0,56 0.47 - 0.66 <0.001
Endocrine therapy
No 1
Yes 0,65 0.54 - 0.78 <0.001 0,64 0.57 - 0.73 <0.001 0,69 0.54 - 0.87 0,002 0,85 0.71 - 1.01 0,071
Analyses based on only those individuals for whom all variables were available (< 3 years n=13,506, > 3 years n=11,271). † Analyses based on all individuals 
with missing data imputed (n=25,336). * ER Estrogen receptor, PR Progesterone receptor. ≠ BCS Breast conserving surgery. ¥ RT Radiotherapy. Bold 
indicates statistical significance.
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Discussion
This study of nationwide population based data with nearly complete follow-up data about 
the location of breast cancer recurrence and vital status found comparable proportions of 
incidence for IDC (82%) and ILC (11%) as reported in the literature.1-3 The large size of the 
study cohort, the nationwide and, therefore, multi-institutional nature of the study population 
and the nearly complete 5 year follow-up period (1.8% loss due to incomplete follow-up 
information), strengthen the reliability and generalizability of the results obtained. 
Consistent with previous studies, our results show that patient and tumor characteristics 
are significantly different for ILC compared to IDC. Patients with ILC are, on average, older 
1,5,6,8,19-21, have a larger tumor size 1,5-8,22, are better differentiated 4-8,11,20,22,23 and are slightly more 
multifocal.24,25 Interestingly, we found that ILC is associated with more positive lymph nodes.6,21 
Findings on nodal status are not consistent, and other studies have found that lymph node 
status was comparable between patients with ILC and IDC 1,5,8 or even that ILC was less likely to 
be associated with positive lymph nodes.26 As expected, ILC was less often hormone receptor 
negative.1,4-8,11,19,21,22 
Although there is evidence that breast conserving surgery (BCS) in ILC is not associated with 
worse survival compared to mastectomy 6,27,28, ILC was more often treated by mastectomy 
compared to IDC.1,6,8,19,21 This may be related to the increased difficulty of determining tumor 
extension and achieving tumor-free margins after BCS. In fact, previous studies reported that 
ILC is associated with a higher risk of positive margins after BCS compared to IDC.29,30 Since 
ILC patients were more often hormone receptor positive, a greater proportion of ILC patients 
than of IDC patients received endocrine treatment. The fact that patients with ILC are less 
frequently treated with chemotherapy may be because a positive hormone receptor status has 
previously been associated with a lower chance of response to primary chemotherapy 21, or 
because the gain in DFS and OS after chemotherapy is limited for older patients with an early 
stage or ER+ tumors.31,32
As in other studies comparing the metastatic patterns of ILC and IDC, our results showed that ILC 
was less likely to metastasize to the lung 1,7,8,10,33, CNS 1,10 and lymph nodes.1 However, a higher 
risk of spread to the gastrointestinal organs 1,10,11,33 and bones 8,10,33 was observed. Interestingly, 
similar observations have been made comparing ER positive versus ER negative patients, 
with metastases to the bones being more common in ER positive patients and metastases to 
visceral organs being more common in ER negative patients.12-14 We found a similar pattern, 
with estrogen negative tumors more likely to metastasize to the CNS, lung and lymph nodes, 
while ER+ tumors were more likely to metastasize to the bones (p<0.001). Analyzing the site of 
metastasis by histological type within hormone receptor subgroups showed that there was still 
a difference for metastasis to gastrointestinal organs in the ER+PR+ and ER+PR- patients and for 
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metastasis to the lymph nodes and lung in ER-PR- patients. However, for metastasis to bones, 
CNS, liver and skin no longer differences were observed between histological type. 
The numerous published series reporting and discussing the recurrence patterns of breast 
cancer, showing a first peak between 1 and 2 years after diagnosis for LRR and DM 34,35, did 
not consider possible differences in the pattern due to histological type.26,34-36 The results in 
our study show a first peak at 1.5 years after surgery for IDC. However, for ILC no clear peak 
was found and risks for DM and LRR were lower than for IDC patients. This may be because 
ILC is more likely to be ER+PR+ so the pattern of LRR and DM is more related to the pattern of 
hormone receptor status. In fact, clear differences in risk patterns between histological type 
are no longer seen within hormone receptor subgroups. Other studies have reported similar 
results for patterns of recurrences between ER positive and PR negative patients, with highest 
risks among ER negative patients during the first three years.36,37 Comparable risk patterns 
have been observed for breast cancer death between ER positive and ER negative patients, 
showing higher rates within the first 7 years for ER negative patients and lower rates thereafter 
compared to ER positive patients.38 Most studies found no significant survival difference 
between IDC and ILC patients during the first 5 years after diagnosis1,5,7,11,22, while others found 
an advantage in overall survival for ILC.4,19-21,23 However, most of these studies did not correct 
for hormone receptor status. Pestalozzi et al 8 showed an advantage for ILC in the first 10 years 
and thereafter an advantage for the IDC cohort, independent of ER status. Unfortunately, the 
follow-up period in the present study was too short to meaningfully assess survival, in order to 
determine whether histological type is an independent risk factor. 
In addition, multivariable analysis showed that type of histology is not an independent prognostic 
factor for DFS. Although the risk of recurrence tended to be lower for ILC during the first 3 
years, a difference was no longer seen after 3 years. However, the present study was limited 
by a relatively short follow-up period (5 years) and disease-free survival between histological 
and hormone receptor subgroups may change after this period. Pestalozzi et al 8 found an early 
advantage (within 6 years) in DFS for the ILC cohort, followed by a significant late advantage 
for the IDC cohort, independent of hormone receptor status. Other studies found a better DFS 
or no difference between ILC and IDC, although it is unclear whether outcomes were biased by 
non-proportionality. Our results showed an advantage in DFS for ER+PR- patients during the 
first 3 years after diagnosis. After 3 years, a difference in DFS was no longer observed. Several 
other studies found that the risk of recurrences by hormone receptor status is not constant 
over time and reported higher risks among ER negative patients during the first 3-7 years after 
diagnosis, followed by a higher risk for ER positive patients thereafter.36,37,39
Because Her2 status was missing for 71% of the patients, Her2 status was not included in 
the analyses.1,5 Other studies found that patients with ILC were more often Her2 negative. 
Probably due to the large number of missing values for HER2 status, these studies did not 
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include Her2 status in multivariable Cox regression analyses to define prognostic factors for 
the risk of recurrences. However, it is known that a positive Her2 status is associated with 
increased risk of recurrences.40,41 Since these studies did not include histological subtype, the 
relation between Her2 status and histological subtype remains unclear.  
The percentages of missing data in multifocality (35%) and hormone receptor status (33%) are 
moderate. Multiple imputation is a state-of-the-art technique because it improves accuracy 
and statistical power relative to other missing data techniques and, in simulation studies, it 
has been shown that, even in cases of large percentages of missing data (50-75%), multiple 
imputation under fully conditional specification leads to confidence intervals with good 
coverage properties.42 Here, the influence of this imputation model on the parameter estimates 
of hormone receptor status is moderate to large (fraction of missing information ranging from 
0.22 to 0.33) so, to verify the results obtained in STATA, the analyses (multiple imputation and 
multivariate Cox regression models) were rerun in R with the package “mice”18, leading to 
similar results even when the imputation model was slightly varied.
Conclusion
The results from this population based study show that ILC has distinctive patient and tumor 
characteristics compared to IDC. However, histological type was not found to be an independent 
factor for the risk and risk pattern of recurrences. On the other hand, hormone receptor status 
appears to be the dominant factor with a time dependent effect on the risk and pattern of LRR 
and DM and of metastatic dissemination. 
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Abstract
Background
This study examined the risk of third cancer of non-breast origin (TNBC) among women with 
bilateral breast cancer (BBC; either synchronous or metachronous), focussing on the relation 
with breast cancer treatment. 
Patients and Methods
Risk was assessed, among 8,752 Dutch women diagnosed with BBC between 1989 and 2008, 
using standardised incidence ratios (SIR) and Cox regression analyses to estimate the hazard 
ratio (HR) of TNBC for different treatment modalities.
Results
Significant increased SIRs were observed for all TNBCs combined, haematological malignancies, 
stomach, colorectal, nonmelanoma skin, lung, head and neck, endometrial, and ovarian 
cancer. A 10-fold increased risk was found for ovarian cancer among women younger than 
50 years (SIR=10.0, 95% confidence interval (CI)=5.3–17.4). Radiotherapy was associated 
with increased risks of all TNBCs combined (HR=1.3; 95%CI=1.1–1.6, respectively). Endocrine 
therapy was associated with increased risks of all TNBCs combined (HR=1.2; 95%CI=1.0–1.5), 
haematological malignancies (HR=2.0; 95%CI=1.1–3.9), and head and neck cancer (HR=3.3; 
95%CI=1.1–10.4). After chemotherapy decreased risks were found for all TNBCs combined 
(HR=0.63; 95%CI=0.5–0.87).
Conclusion
Increased risk of TNBC could be influenced by genetic factors (ovarian cancer) or an effect of 
treatment (radiotherapy and endocrine therapy). More insight in the TNBC risk should further 
optimise and individualise treatment and surveillance protocols.
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Background
Breast cancer is by far the most frequent cancer in European and North American women.1 Due 
to earlier diagnosis and improved treatment, breast cancer survival has increased, increasing 
the risk of metachronous breast cancer, among the survivors.2 Women with a history of breast 
cancer have a 2-3 fold higher risk of developing a contralateral breast cancer as compared 
with the general female population.3-6 In a Dutch population based study 18% of breast cancer 
patients were diagnosed with a second breast cancer in the period 1989-2006.7 Similar results 
were observed among women at high risk, who either had an unilateral breast cancer or a 
twin sister with breast cancer, 9% to 18% experienced a breast cancer event after 20 years 
of follow-up.8 However, incidence declined since 1980 due to the increasing use of adjuvant 
therapy.9
Besides an elevated risk of contralateral breast cancer, several studies revealed that women 
with a primary breast cancer have an increased risk of developing a subsequent non-breast 
cancer. Increased risks were most consistently found for tumours of the ovary, endometrium, 
soft tissue and for leukaemia.3-6,10-15 Excess risks of melanoma of the skin and cancer of the bone, 
oesophagus, kidney and lung have also been reported, though less consistently.4-6,10-12,14,15 Risks 
of subsequent non-breast cancer appears to be associated with genetic and other risk factors 
that are common for both, breast cancer patients with primary breast cancer experienced an 
increased risk of lung cancer and soft tissue sarcomas that could be attributed to radiation. 
Increased risks of melanoma of the skin, uterine cancer and leukaemia were found to be 
associated with the use of chemotherapy for patients older than 50 years while the increased 
risk of endometrial cancer was related to endocrine therapy. At the same time chemotherapy 
was associated with a reduced risk of colon and lung cancer for women younger than 50 years.5
However, information about the risk of third cancer of non-breast origin (third non-breast 
cancer; TNBC) after synchronous or metachronous invasive bilateral breast cancer (BBC) is 
lacking. Patients with BBC may have been exposed to more carcinogenic or carcinoprotective 
cancer treatment. Moreover a higher risk could be expected for genetic, reproductive, or 
lifestyle-related cancers. More insight in these risks may further optimise and individualise 
surveillance protocols in women with BBC. Therefore we assessed in this study, the risks of 
TNBC after BBC in a nationwide study based on the Netherlands Cancer Registry (NCR). In 
addition we studied the associations of TNBC risk with breast cancer treatment. 
Patients and Methods
The cohort: Bilateral breast cancer patients 
Patients were selected from the population-based nationwide NCR that reached complete 
coverage of cancer incidence in The Netherlands since 1989.16 Patient registration is based on 
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notification on a weekly basis of all newly diagnosed malignancies by the automated national 
pathology archive and a yearly link with the national registry of hospital discharge diagnoses. 
In case of multiple primaries, the definition of a new primary tumour is a primary cancer that is 
not an extension, a recurrence, or a metastasis of a known tumour, located at another anatomic 
site, or when arising in the same anatomic site, belonging to a different histological subgroup 
or to a different behaviour subgroup (in situ vs invasive growth). Subsequently, information 
on patient and tumour characteristics and primary treatment, are retrieved directly from the 
medical records by specially trained registrars. Staging is coded according to the tumour, node 
and metastasis system (TNM) classification17, topography and histology are coded according to 
the International Classification of Diseases for Oncology (ICD-O).18 Basic treatment information 
was available: whether patients were surgical treated, received radiotherapy, chemotherapy 
or endocrine therapy. Data on vital status and migration are annually updated through 
linkage with the national population demographics registry of the municipal administrations 
(Gemeentelijke basisadministratie). Data quality is high 19 and data completeness is estimated 
to be at least 95%.20 
All women diagnosed with BBC, defined as invasive first breast cancer and a synchronous or 
metachronous invasive second contralateral primary breast cancer (without cancer before 
the first breast cancer or between the first and second breast cancer), diagnosed between 
1989 and 2008 in the Netherlands were selected (n=9,718). BBC patients were excluded with 
a metastasis at time of diagnosis of the first or second breast cancer (stage IV, n=909), with 
a sarcoma of the breast either for the first or second breast cancer (morphology code 8830-
9990, n=17), as well as patients who developed a third primary breast cancer after BBC (n=40). 
In total 8,752 women with BBC were included in our study. 
Statistical analysis
The patient and tumour characteristics are reported as frequencies and compared using 
χ2 test. To estimate the risks of TNBC after BBC Standardised Incidence Ratios (SIR) were 
calculated. The SIR is the ratio of the observed to the expected numbers of TNBC cases. 
Observed numbers are the TNBC cases diagnosed during follow-up period. Patients with zero 
follow-up time between second breast cancer and the TNBC or the end of study period, were 
excluded for the SIR calculation (n=6). To determine the expected numbers, person years at 
risk by 5-year age categories and 1-year calendar period categories were multiplied with the 
corresponding background cancer incidence in the general Dutch female population and then 
summed up. Person years at risk started at the second breast cancer diagnosis and ended at 
the date of TNBC diagnosis, date of death, or the end of the study period (e.g. 31 December 
2008), whichever came first. A SIR value higher than 1 implies an increased risk, while values 
lower than 1 suggest a decreased risk. Ninety-five percent confidence intervals (95%CI) were 
estimated assuming Poisson distribution of the TNBC occurrence. SIRs were computed for 
three age categories based on age at time of the second breast cancer diagnosis (<50, 50-64 
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and 65+ years) and for four follow-up intervals since the second breast cancer diagnosis (<1 
year, 1-5 years, 6-10 years and ≥11 years) and were plotted on a log scale. These subgroup 
analysis makes comparison with other studies possible and could give additional information 
in order to discuss and explain other outcomes. Tests for linear trend in relation to period of 
diagnosis were performed by incorporating a parameter in the relevant Poisson regression 
model with consecutive nonnegative integer values corresponding to increasing or decreasing 
levels of the factor and comparing the deviance statistic with that of a model without the 
relevant parameter. 
Multivariable Cox proportional hazard analysis was used to examine the effect of breast cancer 
treatment on the different TNBC risks. The follow-up time was defined as the time between the 
date of first breast cancer diagnosis and the date of TNBC diagnosis. Patients were censored 
at the date of death, migration or the end of the study period (e.g. 31 December 2008). 
Proportional hazards were tested for all entered variables using graphical (Kaplan Meier plots) 
and statistical methods. The interval between first and second breast cancer (BCFI) appeared to 
be a non proportional factor and therefore analyses were stratified by BCFI categories (<1 year, 
1-5 years, 6-10 years and >10 years) using the strata option in STATA. Factors included in the 
model were treatment of first breast cancer (radiotherapy (no, yes), chemotherapy (no, yes), 
endocrine therapy (no, yes)), age at first breast cancer (<50, 50-64, ≥65), year of first breast 
cancer incidence (continue variable). Second breast cancer treatment variables (radiotherapy 
(no, yes), chemotherapy (no, yes), endocrine therapy (no, yes)) were entered to the model 
as time dependent covariates, allocating patients to no second breast cancer treatment until 
second breast cancer occurrence. 
Statistical significance was defined as a 2-sided P value of less than 0.05. Statistical analyses 
were performed in SAS version 9.2.
Results
In the Netherlands, eligible 8,752 patients were diagnosed with invasive BBC between 1989 
and 2008, with a median time of 2.4 years between the first and second breast cancer (Table 
1). The patients accumulated 44,399 person years of follow-up since second breast cancer. 
Overall, 586 patients developed TNBC with a median follow-up time between the second 
breast cancer and TNBC of 3.9 years. Compared with patients without TNBC, patients with 
TNBC were significantly (Po0.001) more likely to be older than 65 years at first and second 
breast cancer diagnosis (respectively, 40% vs 47% and 59% vs 49%), had more often a stage I 
second breast cancer (61% vs 53%), were more often surgical treated for first and second breast 
cancer (respectively, 98% vs 95% and 96% vs 92%) and received less often chemotherapy for 
first and second breast cancer (respectively, 9% vs 19% and 9% vs 19%).
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Table 1 Patient and tumour characteristics of patients with bilateral breast cancer
Total With a TNBCa Without a TNBC
N % N % N % P valueb
Total 8,752 586 8,166
Age at 1st breast cancer <0.001
<50 years 2,245 26 106 18 2,139 26
50-64 years 2,993 34 206 35 2,787 34
≥65 years 3,514 40 274 47 3,240 40
Age at 2nd breast cancer <0.001
<50 years 1,470 17 65 11 1,405 17
50-64 years 2,922 33 175 30 2,747 34
≥65 years 4,360 50 346 59 4,014 49
Time between first and second breast cancer 0.552
Median (25-75% range) 2.4 (0.04-6.1) 2.2 (0.03-5.6) 2.4 (0.4-6.2)
<1 year 3,243 37 225 38 3,018 37
>1-5 years 2,687 31 186 32 2,501 31
>5-10 years 1,882 22 121 21 1,761 22
>10 years 940 11 54 9 886 11
Time between second breast cancer and TNBC
Median (25-75% range) NAc 3.9 (1.5-7.2) NA
<1 year NA 102 17 NA
>1-5 years NA 255 44 NA
>5-10 years NA 166 28 NA
>10 years NA 63 11 NA
Stage of first breast cancer 0.024
I 3,712 42 249 43 3,463 42
II 3,402 39 253 43 3,149 39
III 682 8 34 6 648 8
unknown 956 11 50 9 906 11
Stage of second breast cancer <0.001
I 4,664 53 359 61 4,305 53
II 2,832 32 170 29 2,662 33
III 618 7 25 4 593 7
unknown 638 7 32 5 606 7
Treatment
Surgery 
First breast cancer 8,303 95 573 98 7,730 95 0.001
Second breast cancer 8,063 92 565 96 7,498 92 <0.001
Radiotherapy 
First breast cancer 4,698 54 325 55 4,373 54 0,371
Second breast cancer 3,620 41 249 42 3,371 41 0,565
Chemotherapy
First breast cancer 1,640 19 50 9 1,590 19 <0,001
Second breast cancer 1,628 19 55 9 1,573 19 <0,001
Endocrine therapy
First breast cancer 2,638 30 171 29 2,467 30 0,600
Second breast cancer 3,417 39 209 36 3,208 39 0,083
aTNBC, third non-breast cancer; bP value χ2 test indicating differences between patients with and without a TNBC; cNA, not applicable 
Bold denotes statistical significance 
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Table2 Observed and expected numbers and standardised incidence ratios with 95% 
confidence intervals for third non- breast cancers after bilateral breast cancer 
Site of TNBCa Observed 
numbers
Expected 
numbers
SIRb 95% CIc
Head and neck 18 9 2 1.2 - 3.2
Thyroid 3 2 1.4 0.29 - 4.6
Oesophagus 5 6 0.84 0.27 - 2.1
Stomach 25 12 2.1 1.4 - 3.2
Pancreas 15 12 1.2 0.67 - 2.0
Liver, intrahepatic bile ducts and 
biliary tract
7 5 1.5 0.6 - 3.2
Colorectal 91 74 1.2 0.99 - 1.5
Digestive organs, other 5 3 1.6 0.52 - 3.9
Lung 77 35 2.2 1.7 - 2.8
Soft tissue 8 2 3.6 1.5 - 7.3
Melanoma of skin 25 18 1.4 0.89 - 2.1
Non-melanoma skin 80 50 1.6 1.3 - 2.0
Ovarian 33 14 2.3 1.6 - 3.4
Endometrial 58 22 2.6 2 - 3.4
Cervix uteri 5 5 0.97 0.31 - 2.4
Vulva 5 4 1.1 0.36 - 2.8
Female genitalorgans, otherd 6 1 4.6 1.7 - 10.4
Urinary bladder 19 15 1.3 0.78 - 2.0
Kidney 20 8 2.4 1.5 - 3.8
Brain 2 4 0.5 0.06 - 2.1
Haematological 48 33 1.5 1.1 - 1.9
All TNBCse 582 363 1.6 1.5 - 1.7
aTNBC, third non breast cancer; bSIR, standardised incidence ratio; cCI, confidence interval; d Included, not otherwise 
specified and vagina; e Included others than the specific sites denoted: renal pelvis (2 observed cases), thymus (1 
observed case), eye (3 observed cases), other or unspecified sites (4 observed cases), primary sites unknown (10 
observed cases) and benign brain tumour (7 observed cases); Bold denotes statistical significanc
Risk of TNBC compared with the general female population
Table 2 shows the observed and expected numbers of TNBC and SIRs for TNBC by cancer site. 
The risk of all TNBCs combined after BBC was 1.6 (95%CI=1.5–1.7). Elevated risks were seen 
for head and neck, stomach, lung, soft tissue, non-melanoma skin, ovarian, endometrial, 
other female genital organs and kidney cancer, and haematological malignancies. The risk 
of TNBCs overall was highest among women younger than 50 years at diagnosis of second 
breast cancer (SIR=2.8, 95%CI=2.1–3.5; Figure 1). Differences between age groups were 
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especially large for ovarian cancer, with a relative risk of 10 (95%CI=5.3–17.4) in women 
younger than 50 years at second breast cancer diagnosis. Relative risks for endometrial, 
stomach and kidney cancer were highest for patients older than 65 years (respective SIR=3.4; 
95%CI=2.3–4.5, SIR=2.3; 95%CI=1.4–3.6 and SIR=2.9; 95%CI=1.6–4.9). Overall, the risk of 
TNBCs tended to slightly increase with longer follow-up time since second breast cancer 
diagnosis (Figure 2). Increasing SIRs over time were seen for lung and ovarian cancer and 
haematological malignancies. For kidney and head and neck cancer, the SIRs tended to 
decrease with time. No significant trends with follow-up time were found.
Risk of TNBC compared within the cohort
Table 3 shows the independent effects of cancer treatment on the risk of developing TNBC. 
Except for lung, ovarian and head and neck cancer, the risk of TNBC was highest in the older 
age patients. For lung, ovarian and head and neck cancer, a decreased risk was seen for 
patients older than 65 years of age (respective hazard ratio (HR)=0.47; 95%CI=0.23–0.95, 
HR=0.13; 95%CI=0.03–0.49 and HR=0.07; 95%CI=0.11–0.39). Chemotherapy for the first 
breast cancer was associated with a decreased risk of all TNBCs combined (HR=0.63; 
95%CI=0.45–0.87). After radiotherapy for the second breast cancer, increased risks were 
found for all TNBCs combined (HR=1.3; 95%CI=1.1–1.6). After endocrine therapy for the 
second breast cancer, risks increased for all TNBCs combined (HR=1.2; 95%CI=1.0–1.5), 
haematological (HR=2.0; 95%CI=1.1–3.9) and head and neck cancer (HR=3.3; 
95%CI=1.1–10.4).
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Table 3: Multivariate Cox regression analyses for the association of risk of selected third non-breast 
cancer (>10 cases, increased SIRa overall) with breast cancer treatment.
All TNBCsb Stomach Colorectal Lung
Non-melanoma 
skin
HRc (95% CId) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
No. of patients 583 25 91 77 80
Age at first BCe diagnosis (years)
 <50 1 1 1 1 1
 50-64 1.3 (1.0-1.7) 2.5 (0.45-13.5) 3.5 (1.3-9.2) 1.0 (0.58-1.8) 1.9 (0.82-4.2)
 65+ 1.8 (1.4-2.3) 8.1 (1.5-43.8) 6.4 (2.4-17.1) 0.47 (0.23-0.95) 4.6 (2.0-10.6)
Incidence year first BC 1.1 (1.0-1.1) 1.0 (0.91-1.1) 1.1 (1.0-1.2) 1.1 (1.0-1.2) 1.1 (1.1-1.2)
First BC
Radiotherapy 1.1 (0.87-1.3) 1.8 (0.71-5.0) 0.69 (0.42-1.2) 0.93 (0.56-1.6) 1.5 (0.88-2.5)
Chemotherapy 0.63 (0.45-0.87) 0.32 (0.03-3.2) 0.40 (0.11-1.5) 0.49 (0.21-1.2) 1.4 (0.61-3.3)
Endocrine therapy 1.0 (0.82-1.3) 1.2 (0.43-3.5) 0.63 (0.34-1.2) 1.2 (0.66-2.3) 0.69 (0.37-1.3)
Second BC
Radiotherapy 1.3 (1.1-1.6) 1.6 (0.63-4.2) 1.4 (0.8-2.4) 1.5 (0.89-2.5) 1.1 (0.68-1.9)
Chemotherapy 0.93 (0.67-1.3) 2.3 (0.38-14.0) 0.80 (0.25-2.6) 0.58 (0.25-1.4) 0.55 (0.19-1.6)
Endocrine therapy 1.2 (1.0-1.5) 0.66 (0.22-2.0) 1.5 (0.87-2.5) 1.08 (0.61-1.9) 1.6 (0.94-2.7)
Endometrial Ovarian Kidney Haematological Head and Neck
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
No. of patients 58 33 20 49 18
Age at first BCe diagnosis (years)
 <50 1 1 1 1 1
 50-64 2.1 (0.82-5.1) 0.63 (0.29-1.4) 1.2 (0.32-4.8) 1.6 (0.66-3.9) 0.45 (0.14-1.4)
 65+ 3.2 (1.2-8.3) 0.13 (0.03-0.49) 1.9 (0.46-8.1) 2.2 (0.87-5.6) 0.07 (0.11-0.39)
Incidence year first BC 1.0 (0.93-1.1) 0.93 (0.84-1.0) 1.0 (0.88-1.1) 1.1 (1.01-1.2) 1.0 (0.91-1.2)
First BC
Radiotherapy 0.69 (0.37-1.3) 1.4 (0.60-3.1) 1.6 (0.58-4.3) 1.6 (0.82-3.1) 2.9 (0.87-9.9)
Chemotherapy 1.1 (0.41-3.2) 0.24 (0.05-1.1) 0.28 (0.03-2.4) 0.82 (0.29-2.3) 0.13 (0.01-1.2)
Endocrine therapy 1.4 (0.70-2.7) 1.2 (0.38-3.5) 1.7 (0.60-5.0) 0.62 (0.27-1.4) 2.0 (0.54-7.3)
Second BC
Radiotherapy 1.3 (0.69-2.4) 1.8 (0.82-4.0) 0.90 (0.33-2.5) 1.1 (0.56-2.1) 0.74 (0.26-2.1)
Chemotherapy 0.95 (0.31-2.9) 0.95 (0.33-2.7) 2.1 (0.48-8.8) 0.70 (0.22-2.2) 0.54 (0.10-2.8)
Endocrine therapy 1.5 (0.81-2.9) 0.57 (0.20-1.7) 2.3 (0.86-6.1) 2.0 (1.1-3.9) 3.3 (1.1-10.4)
aSIR Standardised Incidence Ratio; bTNBC: third non-breast cancer; cHR: Hazard Ratio; dCI: confidence interval; e BC: breast cancer; 
Bold denotes statistical significance
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Discussion 
This is the first population-based study reporting the risks for TNBC in patients with BBC. 
Results showed an elevated risk for all TNBCs combined and a more than twofold increased risk 
of head and neck, stomach, lung, soft tissue, ovarian, endometrial, other female genital organs 
and kidney cancer was found for women with BBC compared with women without cancer. The 
risk was highest for women with BBC younger than 50 years at time of their second breast 
cancer. Especially marked was the ten-fold increased risk of ovarian cancer among young BBC 
patients. Interestingly, chemotherapy was associated with a reduced risk of all TNBC combined.
 
Studies among patients with primary breast cancer reported a 23%-40% increased risk of 
subsequent cancer.4,11,15 Our results showed an elevated risk of all TNBC combined after BBC 
(SIR=1.6; 95%CI=1.5-1.7), and even higher risks (SIR=2.8) were found in women younger than 
50 years at second breast diagnosis. Other studies support higher risks for subsequent breast 
cancer after primary breast cancer in young women with SIRs varying from 1.3 until 5.5.4,6,14,21,22 
The high risk of TNBC in young women overall is influenced by the marked ten-fold increased 
risk of ovarian cancer among women younger than 50 years (SIR=10). This is likely related to 
BRCA mutations. Women with BRCA1 or BRCA2 are prone to early age breast cancer, multiple 
breast cancers and have a higher risk of developing an ovarian cancer.23
Radiotherapy is widely used for treatment of breast cancer. Over time modern radiation 
techniques reduce the exposure of normal tissue around the breast. Increased risks after 
radiation exposure of subsequent cancers of the oesophagus, lung, thyroid gland, soft tissue 
and leukaemia have been earlier reported.3,5,10,13,15,22,24,25 Our study showed excess risk of all 
TNBC after BBC for patients treated with radiotherapy for the second breast cancer. Although 
increased risk of lung cancer was expected among women with previous radiotherapy10,24,25, 
we observed no significant relation between radiation and lung cancer. We found elevated 
risks for lung cancer after a longer follow-up period (SIR=3.1 after 5 years of follow-up). From 
literature it is known that there is at least a 5 year lag period between radiation exposure 
and cancer induction.26 Furthermore, Kaufman et al.27 found no elevated risks for lung cancer 
among non smoking breast cancer patients after radiotherapy. However among ever-smokers 
without radiotherapy and ever-smokers treated with radiotherapy the risk of lung cancer was 
significantly increased (odds ratio (OR)=5.9 and OR = 18.9 respectively). Unfortunately no 
information about smoking was available in this study, hence it remains important to study the 
effect of radiotherapy on lung cancer taking smoking in to account. 
Due to its radio sensitivity, also ovaries though further located from the breast are prone to 
biological changes related to radiation.28 Two large studies found a relation between radiation 
of the breast and higher risk of subsequent ovarian cancer.10,13 Although other studies found no 
relation15,22 or even an adverse effect for women older than 50 years treated with radiotherapy.5 
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We found a non significant increased risk of ovarian cancer after radiotherapy for the second 
breast cancer. 
Our results showed a decreased risk after chemotherapy for the first breast cancer for all TNBC 
combined and it may have a protective effect for colorectal, lung, ovarian and head and neck 
cancer. In addition, younger BBC patients had a higher risk of lung, ovarian and head and neck 
cancer than those older than 65 years of age. Schaapveld et al.5 showed a protective effect of 
chemotherapy only among women younger than 50 for all second non breast cancers combined, 
colon and lung cancer. The study of Andersson et al.22 found in univariable analyses a protective 
effect of chemotherapy for bladder cancer. Rubino et al.15 found no risk differences of TNBC 
after primary breast cancer treated with or without chemotherapy, however information on 
chemotherapy was lacking in this study. An explanation for the protective effect might be that 
TNBCs undergo a growth delay from the use of chemotherapy. Especially for colon cancer 
fluorouracil containing chemotherapy could be effective.
Acute myeloid leukaemia (AML) is considered as a (anthracycline containing) chemotherapy-
induced cancer, which can present within a few years after breast cancer diagnosis.29-31 We 
observed no association between chemotherapy and increased risks for haematological 
malignancies. Probably because this group not only contains AML but also (non) Hodgkin’s 
lymphoma and other types of leukaemia. Surprisingly, we found a significant higher risk of 
haematological malignancies for patients treated with endocrine therapy. As far as we now 
this association was not earlier reported and we could not found a clear explanation for this 
association. 
Since 1975 tamoxifen is used for the treatment of postmenopausal breast cancer in patients with 
positive oestrogen receptor. Tamoxifen is linked to a 1.3–7.5-fold increased risk of endometrial 
cancer.32-34 Although no significant relation was found between endocrine treatment and the 
risk of endometrial cancer within the group of BBC patients, we found a twofold elevated risk 
for endometrial cancer after BBC compared to the general female population, particularly 
for women older than 65 years at second breast cancer diagnosis and women treated with 
endocrine therapy (results not shown). However, in line with other studies, the SIR for 
endometrial cancer was also increased for women who received no endocrine therapy (results 
not shown).5 Therefore, other shared risk factors like family history, reproductive factors (e.g. 
parity, hormone replacement treatment) or high body mass index probably contribute to the 
increased risk of endometrial cancer.35-38
Some strengths and limitations of our study should be considered. The strengths of this study 
include the large population based cohort with nearly complete follow-up data for vital status 
and TNBC, which enables us to provide reliable estimates of TNBC risk after BBC and effects 
of treatment. However, information of other risk factors such as lifestyle factors, including 
Risk of third primary cancers among women with bilateral breast cancer
118
smoking, alcohol consumption and body mass index were not available as well as genetic 
information. 
Treatment information was restricted. No information was available about the specific type 
of radiotherapy and the doses. We found no significant differences in TNBC risks between 
patients treated with radiation for the first or the second breast cancer. Because we included 
BBC patients, radiotherapy was given on different sites of the body so a cumulative effect could 
be expected for ovary and endometrial cancer and leukaemia, because of the equal distant to 
both sites and the radio sensitivity. Furthermore information of specific endocrine therapy was 
not available in our database. Apart from tamoxifen also aromatase inhibitors or luteinising 
hormone-releasing hormone (LHRH) agonists have been administered. Therefore the effect of 
endocrine therapy could be slightly underestimated. 
Risks were estimated for the first and second breast cancer treatment. Patients with 
synchronous breast cancer could have received chemotherapy or endocrine therapy for both 
breasts, however in fact they received only one dosage. Although the cox regression model 
was corrected for BCFI and variables for second breast cancer treatment were incorporated as 
time dependent covariates, outcomes need to be interpreted with caution. 
Conclusion 
Women with BBC had a 1.5 times higher risk of all TNBC combined. Young women had a 2.8 
times higher risk of all TNBC combined and a ten-fold higher risk of ovarian cancer, compared 
to the general population, which is probably related to genetic factors. Chemotherapy was 
associated with a decreased risk of all TNBC combined, while radiotherapy and endocrine 
therapy were associated with a increased risk. Next to the relations between treatment and 
the risk of TNBC and the possible role of genetics, shared environmental factors are likely to be 
involved for most elevated risks. Therefore follow-up care should also be focussed on improving 
healthy lifestyle. This study gave more insight in the risks of TNBC and results could further 
optimise and individualise treatment and surveillance protocols in (young) women with BBC.
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Abstract
Background
Hormone receptor (HR) status, an important prognostic factor for patients with metastatic 
breast cancer (MBC), is well known to be correlated to other prognostic factors, but information 
about the interaction between HR status and other prognostic factors is scarce. The aim of this 
study was, therefore, to evaluate prognostic factors for MBC survival in relation to HR status.
 
Patients and Methods
Dutch women diagnosed with breast cancer in the period 2003–2006 treated with curative 
intent who developed MBC within 5 years of follow-up were selected from the Netherlands 
cancer registry (N=2,001). Independent prognostic factors for survival after metastatic 
occurrence were determined by multivariable Cox survival analyses stratified by HR status. 
Interactions between HR status and prognostic factors were determined. 
Results
Median survival for patients with a negative HR status (HR-) was 8 months, compared to 19 
months for HR-positive (HR+) patients. A positive HR status, longer metastatic-free interval 
(>24 months), low grade, younger age, HER2 positive status, bone metastasis, surgical 
metastatic treatment and systemic treatment for MBC were found to be significant positive 
prognostic factors for survival. The prognostic value of lymph node status, HER2 status, 
endocrine treatment for primary tumour and chemotherapy for MBC was dependent on HR 
status. HR- patients with 1-3 positive nodes had poorer survival compared to patients without 
positive nodes, and no significant association was found for HR+ patients. More prominent 
better survival was observed for HR- patients compared to HR+ patients when they had a HER2 
positive tumour or were treated by chemotherapy for MBC. HR+ patients had a poorer survival 
if they had received adjuvant endocrine treatment.
Conclusion
This study underscores the aggressiveness of MBC and shows that the prognostic value of 
different factors depends on HR status. This information may help physicians to determine 
individual prognostic profiles and therapeutic strategies for MBC patients.
Chapter  8
125
8
Background 
Metastatic breast cancer (MBC) is considered an incurable disease. Although prognosis has 
improved during the last two decades1,2, it remains poor, with a median survival between 
18 and 30 months3,4, and actual survival varying widely, from just a few months to several 
years. Several prognostic factors have, however, been identified in patients with MBC. A 
negative hormone receptor (HR) status of the primary tumour, a short metastatic-free-interval 
(MFI), high histological grade, large tumour-size, positive lymph nodes, and older age are all 
associated with poor survival, and metastases to the bones and soft tissue are associated with 
better survival.3-8 Many of these prognostic factors are related to HR status. Compared to HR- 
tumours, HR+ tumours often develop in older patients, have a longer MFI, are more likely to 
be low grade and have a tendency to metastasize to bone, rather than to visceral organs.7 
Whether the prognostic value of the respective factors is similar in patients with HR+ and HR- 
tumours is uncertain.
Mainly due to their small sample size, previous studies on prognostic factors for MBC have 
rarely studied the interaction between the factors. Only Largillier et al.4 found a different 
prognostic effect for initial tumour size between HR+ and HR- tumours, with size being related 
to a poor outcome in HR-, but not in HR+ tumours. The aim of the present study was therefore 
to evaluate prognostic factors for survival in relation to HR status in MBC.
Patients and methods 
Patients were selected from the nationwide population-based Netherlands Cancer Registry, 
which registers data about all newly diagnosed in situ and invasive tumours since 1989. Trained 
registration clerks extract information on patient characteristics, tumour characteristics, 
treatment and follow-up directly from patient files. Tumour sites and histology were coded 
according to the International Classification of Diseases for Oncology (ICD-O)9, and staging 
according to the tumour, node, and metastasis system (TNM) classification.10 Hormone 
receptor status has been registered since the beginning of 2003, with tumours with at least 
10% positive tumour cells for estrogen receptor (ER) or progesterone receptor (PR) defined 
as having a positive receptor status: ER+ and/or PR+, respectively. Her2-Neu expression has 
been registered since the beginning of 2005 and considered positive in case of Her2-Neu 3+ 
(strong and complete membranous expression in >30% of tumour cells) or Her2-neu 2+ (weak 
complete membranous expression in >10% of tumour cells) confirmed with positive in situ 
hybridization (ISH).
Women diagnosed with primary invasive breast cancer (pT stage 1-3) between 2003 to 2006, 
without evidence of distant metastasis at the time of initial diagnosis and treated with curative 
intent, were included in this study (N=31,438). Follow-up data was not available for patients 
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who received neo-adjuvant systemic therapy (n=1,701) and were therefore excluded. Women 
who had an ER- and PR+ tumour (n=249), or who were not tumour-free after initial treatment 
(n=104) were also excluded from this study. Information on the occurrence of recurrent MBC 
within five years after diagnosis was derived retrospectively from the patients’ files. For this 
study, only the first metastatic site was taken into consideration. Sites were categorized into 
six groups: liver, lung, bones, central nervous system (CNS), multiple sites, or other. Of the 
selected breast cancer patients, 2,668 developed MBC during the first 5 years of follow-up 
since diagnosis. In the end, 2,001 patients remained available for analysis, of whom 1,292 
(65%) had a HR+ tumour. 
Statistical analyses
Patient and tumour characteristics are reported as frequencies and compared using χ2 tests. 
Metastatic survival was defined as time between the date of diagnosis of MBC and the date 
of death, or the end of the study period (31 December 2012). Univariable survival analyses 
were performed by constructing Kaplan-Meier plots using the log-rank test for comparisons. 
Multivariable proportional hazard regression modelling was used to assess independent 
prognostic factors for survival. The analyses were also performed stratified on HR status. The 
prognostic factors in the multivariable model were selected based on statistical significance in 
univariable analyses (P<0.1). With regard to the primary tumour, the following variables were 
examined: histological type, grade, tumour size, axillary lymph node status and HER2 status 
according to pathology, surgery and adjuvant radiotherapy, endocrine- and chemotherapy. In 
addition, the following MBC-related treatment variables were included: MFI, site of distant 
metastasis, age at MBC diagnosis, surgery, first line palliative radiotherapy, chemotherapy and 
endocrine treatment (table 1). Only adjuvant and first line palliative treatment was available 
for analyses. Interaction between HR status and other prognostic factors was tested. Hazards in 
different subgroups of variables were tested for proportionality using graphical tools (Kaplan-
Meier and Hazard plots) and the Schoenfeld residuals test. 
A p-value of <0.05 was considered to be statistically significant. Analyses were performed using 
STATA version 12.
Results
Characteristics
A total of 2,001 breast cancer patients who developed metastatic disease during the first 5 
years of follow-up after treatment of primary breast cancer were analysed in this study. Table 
1 summarizes the patient and tumour characteristics by HR status. Patients with HR+ tumours 
(n=1,292, 65% of total) were more likely to present with lobular carcinoma, low-to intermediate 
grade, small tumour size (≤ 2cm), HER2 negative status, had a longer MFI (>24 months), were 
older and more likely to present with bone metastases compared to patients with a HR- tumour 
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Table 1: Patient and tumour characteristics by hormone receptor status
Total HR* negative HR positive
Primary tumour N % N % N % P value
Total 2,001 100 709 35.4 1,292 64.6
Year of diagnosis 0.217
2003 139 19.6 213 16.5
2004 352 17.6 209 29.5 371 28.7
2005 580 29 211 29.8 397 30.7
2006 608 30.4 150 21.2 311 24.1
Histologic type 461 23 <0.001
Ductal 639 90.1 1,029 79.6
Lobular 1,668 83.4 24 3.4 189 14.6
Mixed and other 213 10.6 46 6.5 74 5.7
Grade± 120 6 <0.001
I  128  6.4 12 1.7 116 9
II 717 35.8 133 18.8 133 45.2
III 1041 52 532 75 509 39.4
Unknown 115 5.8 32 4.5 83 6.4
Tumour size 0.001
≤2 cm 734 36.7 224 31.6 510 39.5
>2 and ≤5cm 1,102 55.1 411 58 691 53.5
>5cm 157 7.9 71 10 86 6.7
Unknown 8 0.4 3 0.4 5 0.4
Lymph node status 0.684
Negative 718 35.9 248 35 470 36.4
1-3 positive 604 30.2 209 29.5 395 30.6
>3 positive 669 33.4 249 35.1 420 32.5
Unknown 10 0.5 3 0.4 7 0.5
Her2-Neu 0.001
Negative 804 40.2 253 35.7 551 42.7
Positive 189 9.5 86 12.1 103 8
Unknown 1,008 50.4 370 52.2 638 49.4
Multifocal 0.24
No 1,409 17.1 519 73.2 907 70.2
Yes 364 18.4 126 17.8 240 18.6
Unknown 208 10.5 64 9 145 11.2
Surgery + radiotherapy 0.114
BCS≠ +RT¥ 770 38.5 251 35.4 519 40.2
BCS - RT 19 1 8 1.1 11 0.9
Amputation +RT 546 27.4 206 29.1 343 26.6
Amputation -RT 662 33.4 244 34.4 419 32.4
Chemotherapy <0.001
No 956 47.8 230 32.4 726 56.2
Yes 1,045 52.2 479 67.6 566 43.8
Endocrine treatment <0.001
No 1,094 54.7 692 97.6 402 31.1
Yes 907 45.3 17 2.4 890 68.9
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Table 1: continued
Total HR negative HR positive
Metastasis N % N % N % P value
Metastatic free interval <0.001
<= 24 months 872 43.6 430 60.7 442 34.1
> 24 months 1,129 56.4 279 39.4 850 65.9
Site <0.001
Bones 602 30.4 95 13.4 515 39.9
Multiple sites 658 33.2 279 39.4 385 29.8
Liver 251 12.7 95 13.4 159 12.3
Lung 201 10.2 105 14.8 97 7.5
CNS 105 5.3 68 9.6 37 2.9
Other 164 8.3 67 9.5 99 7.7
Age at metastatic diagnosis <0.001
<50 year 510 25.5 224 31.6 286 22.1
50-69 year 941 47 320 45.1 621 48.1
>=70 year 550 27.5 165 23.3 385 39.8
Median (range) 60  24-94 57 25-94  61 24-93 
Surgery 0.006
No 1,792 89.6 614 86.6 1,178 91.2
Yes 97 4.9 43 6.1 54 4.2
Unknown 112 5.6 52 7.3 60 4.6
Radiotherapy 0.001
No 1,300 65 480 67.7 820 63.5
Yes 589 29.4 177 25 412 31.9
Unknown 112 5.6 52 7.3 60 4.6
Chemotherapy <0.001
No 1,020 51 232 32.7 788 61.0
Yes 869 43.4 425 59.9 444 34.4
Unknown 112 5.6 52 7.3 60 4.6
Endocrine treatment <0.001
No 1,236 61.8 636 89.7 600 46.4
Yes 653 32.6 21 3.0 632 48.9
Unknown 112 5.6 52 7.3 60 4.6
Hospital type 0.292
Academic 89 4.5 31 4.4 58 4.5
Top clinical hospital 394 19.7 138 19.5 256 19.8
Other 626 31.3 204 8.8 422 32.7
Unknown 892 44.6 336 47.4 556 43.0
Hospital volume per year 0.374
<50 75 3.8 29 4.1 46 3.6
50-100 506 25.3 165 23.3 341 26.4
100-150 387 19.3 129 18.2 258 20.0
>150 142 7.1 51 7.2 91 7.0
Unknown 891 44.5 335 47.3 556 43.0
* HR: hormone receptor; ±low grade=grade I and II, high grade = grade III; ≠ BCS: breast conserving surgery; ¥ RT: 
radiotherapy. Bold indicates statistical significance.
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(P<0.001). Of the patients with a HR- tumour, a greater proportion had received adjuvant or 
first line palliative chemotherapy (P<0.001). 
Survival
We observed 1,627 deaths among 2,001 patients. The median survival after MBC diagnosis 
was 14 months, 8 months in HR- patients and 19 months in HR+ patients (P<0.001, figure 
1). Table 2 shows the hazard ratios for MBC survival for the total group and by HR status. A 
positive HR status, longer MFI (>24 months), low grade, younger age, positive HER2 status, 
bone metastases, surgery for MBC, first line palliative systemic treatment were all found to 
be significant positive prognostic factors for survival in the total group. Significant interaction 
was found between HR status and lymph nodes, HER2 status, adjuvant endocrine treatment 
and first line palliative chemotherapy. Stratified analyses showed that, among the HR- 
patients, those with 1-3 positive nodes had a significantly poorer survival than those without 
positive nodes (HR=1.42; 95%CI=1.16-1.74), whereas no poorer survival for this subgroup 
was observed among the HR+ patients (HR=0.87; 95%CI=0.73-1.05). Better survival for HER2 
positive compared to HER2 negative patients was much more prominent for the patients with 
HR- tumours (HR=0.57; 95%CI=0.44-0.76) than among those with HR+ tumours (HR=0.82; 
95%CI=0.62-1.06). For HR+ patients, the use of adjuvant endocrine treatment was associated 
with a worse survival (HR=1.26; 95%CI=1.05-1.52). The use of first line palliative chemotherapy 
was associated with a better survival in HR- patients (HR=0.31; 95%CI=0.24-0.38) but was less 
prominent in HR+ patients (HR=0.76; 95%CI=0.64-0.92).
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Fig. 1. Kaplan-Meier survival curve by hormone receptor (HR) status
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Discussion
This population based study of 2,001 breast cancer patients who developed MBC during the 
first 5 years of follow-up shows that the prognostic value of lymph node status, HER2 status, 
adjuvant endocrine treatment and first line palliative chemotherapy is different for HR- and 
HR+ tumours. There was a median survival of 14 months for the whole group of patients, and 
we found that HR status, MFI, grade, HER2 status, site of metastasis, age and surgical, first line 
palliative systemic therapy were statistically significant prognostic factors for overall survival.
 
Given the relatively short MFI of at most 5 years, the current study population represents an 
aggressive subgroup of MBC patients. Several earlier studies reported that MFI is a significant 
prognostic factor, with patients who develop metastatic disease more than 5 years after the 
primary tumour having a significantly better prognosis than those developing metastases within 
5 years.3-5,7 The worst survival rates were for patients with MFI’s shorter than 2 years.5,7 Largillier 
et al.4, however, reported no significant relation between MFI and survival in multivariable 
analyses, either for the whole group nor after stratification for HR status. 
As in earlier studies, we found that HR status is a prognostic factor for survival.3-5 Although 
the median survival of 19 months for HR+ patients is substantially better than the 8 months 
for HR- patients, it remains rather poor. We found that the lymph node status of the primary 
tumour is not a significant prognostic factor for the group of patients with MBC as a whole. 
However, when analysed on HR status, we found a significantly poorer survival for patients 
with 1-3 positive lymph nodes among patients with a HR- tumour compared to those with 
negative lymph nodes. Literature results about the prognostic effect of lymph node status vary, 
with some reporting that the number of lymph nodes involved is associated with reduced 
survival3,5,7, and others, like Largillier et al4, finding no significant relation between lymph node 
status and survival, neither after stratification on HR status. 
Histological grade of the primary tumour has been shown to be an important prognostic factor 
in patients with MBC, higher grade being associated with worse survival.4,11 In our study, lack of 
statistical interaction indicated that the prognostic effect of histological grade was independent 
of the HR status of the tumour. 
The HER2 status of the primary tumour has been established as an important prognostic factor 
in breast cancer, with patients having a poorer outcome when HER2 is overexpressed.12 Our 
results show better survival among patients with HER2 positive status in HR+ patients, even 
more prominently among the patients with HR- tumours. In this study, however, HER2 data 
is missing for the incidence years 2003 and 2004 and, unfortunately, data on the treatment 
with trastuzumab is lacking. Most studies had limited available data for HER2 status so could 
not study its prognostic effect.4,5 Since 2005 HER2 over-expressed breast cancer patients are 
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treated with adjuvant trastuzumab, the introduction of this anti-HER2 treatment may have 
neutralized the negative prognostic effect of HER2 over-expression.12 
In our study, age at MBC diagnosis was an independent prognostic factor. Previous studies 
showed that patients aged <50 years have a better survival after MBC than patients aged >50 
years.5,13 Thus, although younger women have a higher risk of developing distant metastases 
than older women, it is a favourable prognostic factor once the metastases have developed. 
This may be because postmenopausal women receive chemotherapy less often. Additional 
analyses of our data confirmed this, showing that HR+ patients receiving chemotherapy after 
MBC diagnosis where significantly younger (data not shown). Moreover, younger patients tend 
to have a better performance status, therefore medical specialist tend to offer more treatment 
options to younger patients. 
Previous studies found a relation between the HR status and the site of MBC, with metastases 
to the bones being more common in HR+ patients and metastases to visceral organs being 
more common in HR- patients.7,11,14,15 The present study showed comparable results, with 
only 13% of the HR- patients having bone metastases compared to 40% of the HR+ patients. 
Multivariable analyses showed that the site of metastasis is an important prognostic factor 
for survival. Largillier et al.4 showed that survival for HR+ patients was better than for HR- 
patients irrespective of the metastatic site, whereas Clark et al.7 showed that the prognostic 
effect of HR status differed according to metastatic site. For example, HR+ patients with bone 
metastases lived longer than HR- patients with bone metastases. However, these results were 
based solely on univariable analyses. Although our results showed no significant interaction 
between metastatic site and HR status, HR- patients with multiple sites may have a more 
prominent poorer survival compared to patients with bone metastasis, than HR+ patients. This 
underscores the aggressiveness and explosive growth of the disease for especially HR- patients 
and the lack of treatment options, such as endocrine treatment, in this subgroup. 
As a consequence of the observational design and the lack of detailed information on 
performance status, co-morbidity and response to primary breast cancer treatment, results for 
treatment should be interpreted with caution. Still, some interesting results can be commented 
on. Adjuvant endocrine treatment for primary breast cancer provides a clear contribution to 
the chances of curing women with an early stage primary breast cancer.16,17 Dissemination of 
primary breast cancer while being treated with adjuvant endocrine treatment is associated with 
poor survival, probably due to the induction of drug resistance in remaining micro-metastases.17 
Consequently, women with MBC and a HR+ tumour have more treatment options when they 
have not yet received adjuvant endocrine treatment. This may explain why the HR+ patients 
with adjuvant endocrine treatment had a poorer survival than the ones without adjuvant 
endocrine treatment. In contrast to the association with adjuvant endocrine treatment, the 
use of first line palliative endocrine treatment was found to have a favourable effect on the 
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overall survival. The role of surgery for MBC remains uncertain, as patients with favourable 
prognostic factors are more likely to undergo surgical resection. Any comparison with surgically 
untreated patients will therefore be affected by serious biases18, and our results, showing 
that surgery is associated with a significantly better survival for patients with MBC, should be 
interpreted with care. The positive prognostic value of first line palliative chemotherapy was 
stronger for HR- patients than for HR+ patients. HR+ patients are often treated with adjuvant 
or first line palliative endocrine treatment, which could diminish the effect of first line palliative 
chemotherapy. Additional survival analyses showed that first line palliative chemotherapy for 
HR- patients gives better survival rates, irrespective of adjuvant chemotherapy. However, for 
HR+ patients only a positive effect of first line palliative chemotherapy was seen when patients 
did not receive adjuvant chemotherapy in patients who develop metastatic disease within 5 
years after diagnosis. 
While using population-based data from the Netherlands Cancer Registry has the advantage 
that it is a non-selected large, unselected and up-to-date cohort, including all breast cancer 
patients diagnosed between 2003 and 2006 with recurrent MBC, there are some limitations. 
Follow-up data was reported for a maximum duration of 5 years after initial treatment, resulting 
in a more aggressive subgroup with worse survival. In addition, HR status is based on the initial 
tumour while breast cancer metastasis may show receptor conversion.19,20 Hoefnagel et al.21 
showed that receptor conversion occurred for ER in 10% and for PR in 30% of the patients, 
mainly from positive to negative. These observations introduce a potential bias in our analysis.
Conclusion 
The present study underlines the aggressiveness of MBC for HR- patients with a negative 
HER2 status, a short MFI and multiple metastases. Furthermore, we showed the prognostic 
value of lymph node status, HER2 status, adjuvant endocrine treatment and first line palliative 
chemotherapy depends on HR status. Considering our results it seems that when first line 
palliative treatment options are available at MBC diagnosis and used, the better survival 
for MBC patients. This knowledge may help physicians to consider individual survival and 
therapeutic strategies. Further research is needed to assess the effect of different systemic 
treatment lines on survival in MBC patients.
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Due to increasing breast cancer incidence rates and better survival, the burden on follow-up 
care is increasing, and there is debate about the value, frequency and duration of follow-up, 
who should provide follow-up care and which diagnostic tests should be performed. Since 
1999, Dutch guidelines have described recommendations for breast cancer follow-up. While 
these recommendations did not change substantially until 2012, there is a lack of studies 
evaluating adherence to the follow-up guideline, and only a few studies have evaluated the 
opinions and preferences of both patients and health professionals (HP) on follow-up practice. 
Before changes can be made to optimise follow-up care, more knowledge is needed. Therefore 
the first part of this thesis aimed to evaluate current follow-up practice and opinions of patients 
and HPs on follow-up practice. 
The early detection of loco-regional recurrences and second primary tumours is an important 
purpose of follow-up care. While many studies identified prognostic factors for the risk of 
relapse, some findings remain unconvincing. The second part of this thesis therefore aimed to 
evaluate specific prognostic factors for the risk of relapse.
This final chapter is divided in three parts. First, the main research findings are briefly 
summarised. Then, in the second part, the strengths and limitations of the research conducted 
are discussed. Finally, the implications for clinicians, patients, policy makers and researchers 
are described. 
 
Part I: Main findings
Evaluation of current follow-up practice
The follow-up for breast cancer patients in daily practice is more intensive in terms of 
frequency and duration than guidelines recommend.
The research conducted showed overuse of breast cancer follow-up visits in the first 5 years 
of follow-up care in two Dutch hospitals (Chapter 2). This excess usage was related to adjuvant 
radiotherapy after surgical treatment, leading to follow-up visits by both the surgeon and the 
radiation oncologist. Furthermore, from the results of the interviews with patients and HPs, it 
appeared that patients not only receive more frequent follow-up visits, but also for a longer 
time period than recommended (Chapter 4). In addition results showed that patients were 
seldom referred to the general practitioner (GP) or the national screening programme after five 
years of follow-up, as is recommended in the guideline.
Health professionals frequently comply with patient preferences for (too) long follow-up.
Patients prefer intensive follow-up care for a long period (Chapter 4). The most frequently 
mentioned reason is reassurance that there has been no relapse. Although HPs indicated that 
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they offer patients a false security, they keep patients under observation more frequently and 
longer than guidelines recommend. Furthermore, patients prefer additional diagnostic tests 
like blood tests and whole body scans. Health professionals were not convinced about the 
additional value of these additional tests, and stressed the importance of better information 
for patients about the benefits of follow-up care and diagnostic tests.
Breast cancer follow-up becomes more intensive when more different health professionals 
are involved in primary breast cancer treatment.
Most patients were not only surgically treated but also received adjuvant radiotherapy, 
chemotherapy and/or endocrine therapy. This means that multiple disciplines are involved in 
the treatment of breast cancer patients, and each discipline prefers to see the patient during 
follow-up to evaluate treatment effects (Chapter 4). In the evaluation study, we found that 
when radiotherapy was given in addition to surgery, the frequency of follow-up visits increased 
(Chapter 2). Patient experience of different faces during follow-up period is not always as 
pleasant. Sometimes, insufficient communication between the different disciplines leads 
to inadequate information sharing and visits are not always well coordinated. This highlight 
the need for a patient-specific health care coordinator, as is now implemented in all Dutch 
hospitals, at instigation of the Health Inspection.
 
The Dutch reimbursement system does not encourage guideline adherence for follow-up.
The third reason for longer and more intensive follow-up care are financial incentives 
(Chapter 4). Each department receives an annual reimbursement for each patient visiting the 
department. This means that follow-up care by phone is not financially attractive. Besides, it 
is financially rewarding for each medical discipline to keep patients in follow-up care. Finally, 
while specialised nurses are enthusiastically introduced in follow-up care, in order to receive 
the annual fee for follow-up, the patient must be seen by a medical specialist.
Evaluation of prognostic factors for the risk of relapse
The web-based nomogram can support clinicians in counselling patients about the likelihood 
of requiring further surgery, allowing for a more patient-tailored approach.
One of the most important risk factors for local recurrence is the presence of positive 
surgical margins following lumpectomy. We developed a prediction model including clinical, 
radiological, and pathological variables (Chapter 5). A nomogram was developed as a graphical 
representation of the model and a web based application (http://www.breastconservation.
com) was built to facilitate the use of this nomogram in a clinical setting. This nomogram 
provides a valuable tool for identifying high-risk patients who might benefit from preoperative 
MRI and/or ablative surgery. 
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Histological type is not an independent prognostic factor for the risk and risk pattern of 
recurrences.
Although several studies found a relation between the risk of recurrences and histological type, 
we found that lobular type is not an independent prognostic factor for the risk and risk pattern 
of recurrences (Chapter 6). Hormone receptor status appears to be the dominant factor with 
a time-dependent effect on the risk and pattern of loco-regional recurrences and distant 
metastases and of metastatic dissemination.
Young women with bilateral breast cancer have a high risk of subsequent non-breast cancer, 
especially ovarian cancer.
In addition to the risk of recurrences, we found new evidence of the risk of third non-breast-
cancers (TNBC) (Chapter 7). Young women in particular had an increased risk of ovarian cancer, 
probably related to BRCA mutations. Furthermore, results show that chemotherapy was 
related to decreased risks for all TNBCs combined, possibly due to a growth delay resulting 
from the use of chemotherapy. Radiotherapy and endocrine therapy were related to increased 
risks for all TNBCs combined.
 
The prognostic value of different factors related to survival of patients with metastatic breast 
cancer depends on HR status. 
Several prognostic factors for survival have been identified in patients with metastatic breast 
cancer, many are related to hormone receptor (HR) status. Results in Chapter 8 show that 
the prognostic value of lymph node status, HER2 status, adjuvant endocrine treatment and 
first line palliative chemotherapy was dependent on HR status. HR- patients with 1-3 positive 
nodes had poorer survival compared to patients without positive nodes, and no significant 
association was found for HR+ patients. More prominent better survival was observed for HR- 
patients compared to HR+ patients when they had a HER2 positive tumour or were treated 
by first line palliative chemotherapy for MBC. HR+ patients had a poorer survival if they had 
received adjuvant endocrine treatment.  
Part II: Strengths and limitations of the study
Some strengths and limitations of the studies in this thesis: 
The inclusion of two Dutch hospitals provides important information for the evaluation of 
current follow-up practice.
The two studies in this thesis (Chapter 2 & 4) were based on data from two hospitals in 
the eastern part of the Netherlands with a relatively small sample size. Since the results 
may not therefore be representative for other hospitals, a comparison was made between 
the patient and tumour characteristics of the selection for the evaluation study (chapter 2) 
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to the national data. No significant differences were seen for age, stage, surgical treatment, 
given chemotherapy and radiotherapy. However, the selected women significantly more 
often had a hormone receptor positive tumour and were more often treated with endocrine 
treatment compared to national data. Recently, Geurts et al1 evaluated daily follow-up practice 
using a random sample of 144 patients in 15 hospitals. Results were comparable with our 
results: during follow-up years 2-5, at least 50% of patients underwent more visits than 
recommended. Furthermore, follow-up visits increased when more disciplines were involved 
in routine follow-up. We found an increase in follow-up visits when patients received adjuvant 
radiotherapy. Since only follow-up consults performed by a surgeon or radiation oncologist 
were registered for this study, we could not conclude whether receiving endocrine therapy, 
thus involvement of a medical oncologist, further increased the number of follow-up visits. 
Results from chapter 4 agree with results from other qualitative studies in the Netherlands 
exploring the preferences for breast cancer follow-up.2,3 However, opinions and preferences 
from patients and HPs from the eastern part of the Netherlands may differ from other 
regions in the Netherlands. In the eastern, rural, part people are probably more reserved 
and  acquiesce to the opinion of the doctor more often than in the western urban part of the 
Netherlands. Moreover, a complicating factor with qualitative studies is that patients usually 
have a preference for what they are most familiar with.4 Patients selected for this study were 
familiar with the current follow-up schedule but had no experience of follow-up by a GP or a 
less frequent follow-up schedule. Such alternative follow-up may therefore be less valued. 
Although results of our studies agree with the results of others, patient characteristics are 
comparable with national data, and both our studies provide valuable information about 
current follow-up practice, the findings need be interpreted with caution. 
The Netherlands Cancer Registry contains a wealth of information.
This thesis are mainly based on data from the Netherlands Cancer Registry (NCR), which contains 
high quality population based data from an unselected patient population.5 In the NCR, based 
on pathology notification through the PALGA (automated pathology archive) system, trained 
registration clerks gather data concerning patient, tumour and treatment characteristics from 
the patients’ files. Registration clerks have access to patients’ files and collect information 
about all cancer patients in all Dutch hospitals and a control system at national level monitors 
the quality of the data. 
The Netherlands Cancer Registry follow-up data has its limitations
A drawback of the NCR is that it contains follow-up information concerning relapse after 
breast cancer treatment over a relatively short follow-up period of 5 years. While most of 
the local-regional recurrences present within 5 years after treatment, about forty percent 
of distant metastases occur after a 5 year interval.6 Whether results for the first 5 years are 
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comparable with results for relapses after 5 years of follow-up, in particular for the risk of 
relapse in relation to HR status, is therefore not known. Several studies have found that the 
risk of relapse by hormone receptor status is not constant over time and reported higher risks 
among ER negative patients during the first 3–7 years after diagnosis, followed by a higher risk 
for ER positive patients thereafter.7,8
Another limitation of the data is that it does not contain information about the diagnostic 
tests performed and the follow-up visits. Additional data collection is therefore necessary to 
evaluate adherence to follow-up guidelines. Furthermore, information about performance 
status and co-morbidity, which could be competing causes of death, is lacking.  
Part III: Study implications and future research
Only recently, in 2012, was the Dutch guideline for breast cancer care revised and follow-up 
care schedules changed.9 The guideline recommends an annual follow-up visit during the first 
five years of follow-up. In addition, it recommends making a personal follow-up care plan 
with the patient during the first year. These modifications are made on account of the report 
‘Follow-up in oncology. Identify Objectives, Substantiate Actions’, published by the Health 
Council in 2007.10 The personal follow-up care plan describes the physical and psychological 
impact of the disease and treatment, how frequently the patient should receive a follow-up 
visit and which diagnostic test(s) should be performed during these visits. This plan is shared 
with the patient, the GP and other involved HPs. For the patient it should be clear who the 
primary contact person is.  
The personal follow-up care plan contains at least information about:
• Physical and psychosocial effects from the disease and treatment
• Desirability and facility of follow-up care
• Moment of review
• Possible late treatment effects
• Signals need to consult a doctor and
• Agreements on coordination and division of work between health professionals
Considering the non-adherence to previous guidelines, we do not expect that the revised 
follow-up guideline to automatically translate into clinical practice. Since implementation is 
likely to be more successful when barriers to implementation of the guideline are taken into 
account, this thesis provides insight into those barriers and describes several implications for 
clinicians, patients, policy makers and researchers. 
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Implications for clinicians 
The different disciplines involved in follow-up should agree on the frequency and content of 
visits for each patient and agree which discipline has to conduct the follow-up. 
Often, multiple disciplines are involved in the treatment of breast cancer patients and, in 
order to observe long-term treatment effects, they prefer to see the patient during a (long) 
follow-up period (Chapter 4). This preference is likely hinder the implementation of the revised 
guideline which instructs choosing one discipline to perform the follow-up care, depending on 
the treatment. For example, when a patient is treated by surgery and radiotherapy, only the 
surgeon or only the radiotherapist (or a specialised nurse on behalf of them) should conduct 
follow-up. To prevent more intensive follow-up, the different disciplines should also agree 
on the frequency of follow-up visits. Frequency and duration of follow-up should, ideally, be 
patient-tailored, based on patient, tumour and treatment characteristics (see below). Optimal 
collaboration among disciplines is needed. While a multidisciplinary follow-up visit, where 
the patient meets the involved HPs (surgeon, medical oncologist, radiation oncologist and 
specialised nurse) during one visit, may avoid suboptimal communication between the different 
disciplines and unnecessary hospital visits for the patient, it is not a cost-effective solution even 
though all medical disciplines are involved by follow-up care. A probably more cost-effective 
solution, in line with the guideline, is that the specialised nurse conducts follow-up care on 
behalf of the surgeon, radiation oncologist and/or medical oncologist. If necessary, patients 
can be referred to the medical specialist or other disciplines.
To prevent unnecessary health care expenditure, referral to the GP or screening programme 
should take place.
The guideline recommends that the duration of follow-up care should be determined jointly by 
the HP and patient. Moreover, it advises that patients older than 60 years should be actively 
referred to the GP or national screening programme after five years of follow-up. Several 
reasons were mentioned for maintaining in-hospital follow-up care: patient preferences, to 
observe long-term treatment effects and reimbursement schemes (Chapter 4). Furthermore, 
opinions about involvement of the GP in follow-up care vary among both HPs and patients. 
This prevents HPs referring patients after 5 years. Given the increasing burden on health 
care due to the increasing number of breast cancer survivors, patients need to be actively 
referred to the national screening programme or GP. To implement these recommendations, 
changes in the organisation of care and agreement of all disciplines are necessary. The revised 
guideline advises drawing up a personal follow-up care plan, together with the GP and HPs, 
with agreement about the frequency and duration of follow-up and reference to the GP or 
screening organisation if possible. This might improve guideline adherence by both patients 
and HPs. 
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Specialised nurses are highly valued by both patients and HPs and should have a prominent 
role in follow-up care for breast cancer patients.
Specialised nurses are highly valued for follow-up care by both patients and HPs because they 
are easily accessible, have more time and are more socially empathic to the patient, thus saving 
time for the specialists. They could play an important role in the contact with the different 
involved disciplines and the patients (case management), thus being more cost-effective 
(Chapter 4). However, reimbursement schemes hinder the deployment of independent 
specialised nurses (see below). Since the revised guideline recommends a personal follow-up 
care plan for all breast cancer patients, ideally a specialised nurse should be able to draw 
up such a personal follow-up care plan with the patient. In addition, as the nurses are easily 
accessible, women are likely to feel more comfortable speaking to them about physical and 
psychological problems. 
Implications for patients
Patients should be provided with a personal follow-up care plan with clear information 
about the benefits and goals of follow-up care, follow-up schedule, and diagnostic tests to 
be performed. 
This research show that patients have unrealistic expectations about follow-up care, often 
asking for additional diagnostic tests such as total body scans and they also prefer long term 
follow-up care. This highlights the need for information about the purpose and benefits of 
follow-up care. As recommended in the revised guideline, oral information about the benefits 
of follow-up care and the diagnostic tests should be provided to the patient during the first 
follow-up care visit. Furthermore, the physical and psychological effects of treatment and 
need for additional guidance should be discussed and agreement should be reached about the 
follow-up schedule, duration of in-hospital follow-up and referral to the GP or screening unit. 
The level of information detail should match the needs of the patient. All information should 
be summarized in the personal follow-up care plan made available to the patient, all involved 
HPs and the GP. At every follow-up visit, this plan should be reconsidered. Certain factors need 
to be taken into consideration. The literature describes critical barriers to implementation, 
including choosing a format and finding the time, personnel, and resources to complete each 
individual plan.11 Time investment is also a particular potential barrier, with the first follow-up 
care visit taking about an hour and another hour being required to complete the personal 
follow-up care plan.12,13 Although survivors and HPs are known to be keen on the personal 
follow-up care plan14, the burden on oncology practices may slow down the implementation 
of this intervention. 
As anyone else, patients with a history of (bilateral) breast cancer benefit from a more 
healthy lifestyle. 
Chapter 4 of this thesis showed that neither patients nor HPs mentioned lifestyle advice as 
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a goal of follow-up care, and the current guidelines only briefly mention the importance of 
a healthy lifestyle in later health complaints. Obesity and reduced physical activity, however, 
have a negative effect on prognosis after breast cancer treatment and should be taken into 
consideration. Obesity prevalence has increased worldwide, patients often gain weight 
because of decreased physical activity after breast cancer treatment15 and literature shows that 
pre- and postmenopausal women with a high body mass index (BMI) and low physical activity 
levels have a significant higher risk of recurrences and poorer disease free survival after breast 
cancer treatment. Also of interest are studies that have found that BMI has a greater effect 
on prognosis in younger women and less effect on older women16, that obesity is associated 
with an increased risk of contralateral breast cancer and second primary cancers, especially 
gynaecological tumours17 and that overweight women have a higher risk of developing co-
morbidities common to aging such as diabetes, hypertension, cardiovascular diseases and 
osteoporosis.18,19 Given the greater likelihood of overweight breast cancer survivors developing 
physical and psychosocial complaints, improvement in lifestyle is important as a healthy 
lifestyle reduces the risk of complaints of fatigue, anxiety and depression.20
Implications for policy makers
Health care insurers should invest in the evaluation of the cost-effectiveness of follow-up 
care by general practitioners.
Currently GPs are mainly involved in the diagnostic and terminal phase for cancer patients. 
The Health Council advised investigating the involvement of GPs in follow-up care. In 2011, 
the Dutch Cancer Society reported that primary care is still insufficiently adapted to this role 
and that, first of all, a change in attitude is needed for all involved HPs. When follow-up care 
shifts to primary care, specialists should focus more on the diagnostic and treatment phase. 
The personal follow-up care plan should improve communication between involved HPs. 
Expertise needs to be developed among GPs, both breast cancer specific as well as for generic 
and geriatric aspects and co-morbidity by cancer. Another important factor is the capacity of 
primary care. This thesis raises concerns about the involvement of GPs resulting from extra 
diagnostic tests and lack of time and expertise. Evaluation of the cost-effectiveness will provide 
more insight into whether the GP is a good alternative to in-hospital follow-up care. 
To stimulate adherence to recommended follow-up schedules and alternative follow-up 
care, the Dutch reimbursement system needs to change. 
Current reimbursement schemes compensate face-to-face follow-up visits by a medical specialist. 
Furthermore, for as long as necessary, each department receives a yearly reimbursement for 
each patient. This encourages follow-up by different medical specialists for a long period. 
According to the Dutch guidelines, patients older than 60 years can be referred to the GP 
or the national screening programme after 5 years of in-hospital follow-up.9 In the national 
screening programme, a standard biennial mammogram will be performed, and patients who 
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visit the GP will still make a biennial mammogram at the hospital. However, according to the 
current Dutch reimbursement schemes, a phone call about the outcome of the mammogram 
does not suffice so departments continue to invite patients for follow-up visits. Another 
disadvantage of the current reimbursement schemes is that specialised nurses or physician 
assistants cannot independently invoice follow-up visits: a medical specialist always needs be 
involved by follow-up care. However, specialised nurses play an increasingly important role in 
follow-up care and are well valued by both patients and HPs. Recognising these barriers, the 
Dutch healthcare authority advised the government to change reimbursement schemes. The 
government recently decided to extend the number of HPs who can invoice health care costs 
to physician assistants and specialised nurses from the year 2015. It is, however, not known 
whether the face-to-face principle will be dropped in 2015. If it is, it will encourage patient 
reference to primary care or the national screening program and allow alternative follow-up 
like telephone follow-up care by a specialised nurse.21 In addition, integrated funding will start 
in 2015, meaning that separate payments to providers for each of the individual services they 
provide to beneficiaries for a single illness or course of treatment will end. Instead, there will 
be bundled payment based on the care standard or clinical guideline, a payment that may lead 
to higher quality and more coordinated care.22 
Implications for researchers
Researchers should evaluate individualized follow-up according to breast cancer subtype and 
other prognostic factors and develop a model for optimal individualized follow-up.
Evidence about the optimal frequency and duration of follow-up is still scarce. Although patients 
are known to benefit from an early detection of recurrences and second primary breast cancer, 
many extra follow-up examinations are needed and the cost-effectiveness is doubtful. Geurts 
et al1 showed that 1,349 physical examinations and 262 mammography and/or MRI tests were 
performed in order to detect 1 preclinical relapse. While current follow-up guidelines advise 
an annual follow-up for at least 5 years, the guideline does not allow for individual differences. 
There is increasing evidence about prognostic factors for the risk of recurrences and second 
primary tumours, and it is known that recurrence risks are relatively high in the second and 
third year, in particular for HR negative patients (Chapter 6). A practical tool for generating 
the optimal follow-up schedule for each individual patient is not yet available, but could be 
useful for patients and HPs. The pros and cons of the revised follow-up schedule should first 
be evaluated for different patient groups. To predict the optimal follow-up schedule, as well as 
the risk factors (patient, tumour and treatment) for recurrences and new primary tumours, the 
sensitivity of diagnostic tests and cost-effectiveness should also be incorporated. 
Researchers should evaluate the long term pros and cons of alternative follow-up schedules.
Many alternative follow-up schedules with positive results for quality of live and short term 
outcomes have been described in literature. These include less frequent follow-up, nurse-led 
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or GP-led follow-up or telephone follow-up by a specialised nurse.21,23-25 However, the long term 
effects on quality of life and impacts on cost-effectiveness of most of these alternative follow-up 
schedules are unknown. Since this could hinder their implementation, more insight into long 
term outcomes is necessary. In addition, most studies did not take into account late treatment 
effects, the possible consequences of the treatment not directly related to manifestations 
of the breast cancer itself. These include: chemotherapy can cause infertility and premature 
menopause, resulting in vasomotor symptoms, sexual dysfunction, and osteoporosis, which 
are similar to the side effects of endocrine treatment in postmenopausal women; awareness 
of cardiotoxicity is needed since anthracyclines, trastuzumab, and radiotherapy can damage 
the heart.26 Since the number of breast cancer survivors continues to increase and since these 
women must cope with these late effects of breast cancer treatment, treatment needs to be 
taken into account when developing and evaluating alternative follow-up schedules. 
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Summary
Increased incidence of breast cancer, the most common cancer among women in the 
Netherlands, and better survival have increased the number of patients requiring follow-up 
care. This care consists of three elements: a) early detection of loco-regional recurrences or a 
second primary tumour in order to begin immediate potentially curative therapy and prolong 
survival; b) provision of information, guidance, addressing complaints and symptoms; c) 
evaluation of the medical procedure and its consequences. Despite guidelines existing, there is 
controversy about appropriate follow-up and the effectiveness of routine follow-up. Knowledge 
about the daily practice of follow-up care is also lacking. Consequently, before changes can be 
made to optimise follow-up care, more data are needed about the adherence to the current 
follow-up guidelines and opinions and preferences of patients and health professionals.
Evaluation of current follow-up practice
Since 1999, recommendations for follow-up care have been described in Dutch guidelines for 
breast cancer. Schedules for follow-up care did not change substantially until 2012: during the 
first year of follow-up, patients visit the hospital every 3 months, in the second year every 
6 months and, for at least the subsequent 3 years, annually thereafter. During these visits a 
physical examination is performed, complemented by an annual mammogram. 
Chapter 2 provides an evaluation of the adherence to follow-up guidelines for the first five 
years of follow-up in two teaching hospitals. A total of 198 women diagnosed with breast 
cancer in 2003 were selected from the Netherlands Cancer Registry (NCR). Compliance with 
the guideline was assessed by extracting follow-up care data from patients’ files. Differences 
between number of visits recommended and the actual number of visits were seen for every 
follow-up year. During the first year of follow-up, fewer follow-up visits were observed than 
recommended. However, during the subsequent years, almost double the number of scheduled 
follow-up visits were observed than guidelines advise. Multiple linear regression analyses 
showed that receiving radiotherapy was associated with more frequent follow-up visits. This 
led to the conclusion that follow-up care was more intensive in terms of the frequency of 
follow-up visits than guidelines recommend. Excess use was mainly seen for women who 
received radiotherapy in addition to surgical treatment, leading to follow-up visits by both the 
surgeon and the radiation oncologist.
Since 1999, the guideline has recommended that, after the first 5 years of follow-up, annual 
follow-up continues until the age of 60. Patients older than 60 should be referred to the general 
practitioner if treated with breast conserving surgery (a mammogram is performed biennially 
in the hospital), or to the national screening programme if treated with ablative surgery. In the 
national screening programme, women between 50 and 75 years of age undergo a standard 
biennial screening mammogram. For patients older than 75, no further follow-up care is 
recommended. Chapter 3 provides information about the relationship between in-hospital 
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follow-up care and the attendance to the national screening programme after breast cancer 
treatment. This study used NCR data of 11,227 women with breast cancer aged 50-74 years, 
treated for primary breast cancer between January 1996 and January 2007 in the Northern 
region of the Netherlands. Data were linked to the National Cancer Screening Programme, 
North region. Nineteen percent of the women attended the screening programme after breast 
cancer treatment, 4.4% within 5 years and 15.4% after more than 5 years after breast cancer 
treatment. Association with attending the screening within 5 years as well as 5 years after 
breast cancer treatment was positive for diagnoses of in-situ and screen-detected tumours, 
and negative for receiving adjuvant radiotherapy. Patients with a later year of diagnosis 
attended the screening less often during the first 5 years after treatment. The interrelation 
between outpatient follow-up and screening needs to be improved to avoid overlap and 
improve attendance in the screening programme after in-hospital follow-up. Breast cancer 
patients should be informed that attending the screening programme during the first 5 years 
of in-hospital follow-up is not necessary, and, if indicated after 5 years of follow-up, they should 
be informed about reference to the GP or screening programme.
Adherence to follow-up guidelines depends on the opinions of health professionals (HP) and 
patients. Chapter 4 examines the opinions and preferences from HPs and patients about the 
purpose, the duration and frequency of breast cancer follow-up, which examinations should 
be conducted, and by whom. For this purpose, semi-structured interviews were conducted 
in 2 hospitals with 23 patients and 18 health professionals. The results show that current 
follow-up is more intensive in terms of frequency and duration than guidelines recommend. 
HPs mentioned three major reasons: first, patients prefer prolonged and frequent follow-up; 
second, each discipline wants to observe the patient and the results of their therapy; third, 
financial incentives are involved. For patients and HPs, the most important purpose of follow-up 
was early detection of new malignancies. A highly valued aspect of follow-up mentioned by HPs 
was the psychosocial support, which was, interestingly, rarely mentioned by patients. Patients 
were satisfied with examination of the breast and with reassurance of the HP that everything 
is still fine. Patients’ expectations of the benefits of follow-up and additional examinations 
were sometimes unrealistic. Both patients and HPs were positive about nurse-practitioner-led 
follow-up, but less positive about general-practitioner-led follow-up. Results suggest that 
better information for patients about the benefits of follow-up care and diagnostic tests should 
be provided. In addition, the previously mentioned barriers to adherence to current guideline 
should be taken into account when implementing new and more individualised guidelines.
Evaluation of prognostic factors for the risk of relapse
The early detection of loco-regional recurrences and second primary tumours is an important 
goal of follow-up care. Although many studies have identified prognostic factors for the risk of 
relapse, some findings remain unconvincing. One of the most important risk factors for local 
recurrence is the presence of positive surgical margins following lumpectomy. 
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Chapter 5 validates a predictive model (a nomogram), which could be used as a preoperative 
tool for clinical decision-making, to predict the risk of positive margins after a lumpectomy. 
Patients with clinical T1-2N0-1Mx-0 histology-proven invasive breast carcinoma who underwent 
breast-conserving therapy (BCT) throughout the North-East region of The Netherlands between 
June 2008 and July 2009 were selected from the NCR (n = 1,185). Results from multivariable 
logistic regression analyses served as the basis for development of the nomogram. Nomogram 
calibration and discrimination were assessed graphically and by calculation of a concordance 
index respectively, and performance was validated on an independent dataset (n = 331) from the 
University Medical Center Groningen. Positive margins in lumpectomy were present in 19.7% 
and 24.5% of the patients in the modelling and validation group respectively. Factors associated 
with a higher risk of positive margins constituting the final model were micro-calcifications, 
absence of preoperative MRI, suspicion of multifocality, non-palpability, positive N-stage, T2-
stage, density of the breast, lobular histological type, high histological grade, positive ER status 
and presence of DCIS. Concordance indices were calculated of 0.70 (95% CI: 0.66-0.74) and 
0.69 (95% CI: 0.63-0.76) for the modelling and the validation group, respectively. Calibration of 
the model was considered adequate in both groups. A graphical representation of the model 
and a web-based application (http://www.breastconservation.com) was built to facilitate the 
use of our nomogram in a clinical setting. This nomogram is likely to assist clinicians identify 
high-risk patients who might benefit from preoperative MRI and/or ablative surgery.
Reported long-term clinical outcomes for invasive lobular carcinoma (ILC) versus invasive 
ductal carcinoma (IDC) vary. Inconsistent findings with regard to disease-free survival (DFS) 
are probably due histological type being related to hormone receptor status so Chapter 6 
examines whether histological type is an independent prognostic factor for DFS and whether 
it is a prognostic factor for the site of DM. The risk patterns over time of loco-regional 
recurrences and distant metastases (DM) were also determined. All Dutch women diagnosed 
between 2003 and 2005 with ILC (n = 2,949) or IDC (n = 22,378) were selected from the NCR. 
Results showed that, compared to patients with IDC, those with ILC were significantly older, 
were more likely to have more than three positive lymph nodes and to have larger, better 
differentiated, multifocal, and hormone receptor positive tumours. ILC was more likely to 
metastasize to the gastrointestinal organs and bones and less likely to the lung, central nervous 
system, and lymph nodes. Within the ER+PR+ and ER+PR- subgroups, ILC was still more likely 
to metastasize to gastrointestinal organs and less likely to the lung. The timing of recurrence 
was correlated to hormone receptor status, independent of histological type. Highest risks 
were observed among ER-PR- patients within 2 years of surgery. Multivariable analysis showed 
that histological type is not an independent prognostic factor of DFS for the first 3 years post-
surgery as well as thereafter. It was concluded that histological type should not be considered 
an important prognostic factor for the risk and risk pattern of recurrences during the first 5 
years of follow-up.
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Compared to the general female population, women with a history of breast cancer have a 
2-3 fold higher risk of developing a contralateral breast cancer. Breast cancer survivors also 
have an increased risk of developing subsequent non-breast cancer. Chapter 7 provides 
information about the risk of a third cancer of non-breast origin among 8,752 Dutch women 
diagnosed with bilateral breast cancer between 1989 and 2008 using standardised incidence 
ratios (SIR). Significant increased SIRs were observed for all third non-breast cancers combined, 
haematological malignancies, stomach, colorectal, non-melanoma skin, lung, head and neck, 
endometrial, and ovarian cancer. A 10-fold increased risk, probably related to genetic factors, 
was found for ovarian cancer among women younger than 50 years. Chemotherapy was 
associated with a decreased risk of all third non-breast cancers combined, while radiotherapy 
and endocrine therapy were associated with an increased risk. Besides treatment and possible 
genetic susceptibility, shared environmental factors are likely to be involved for most elevated 
risks. Consequently, follow-up care should also focus on a healthy lifestyle. These results could 
further optimise and individualise treatment and surveillance protocols in (young) women with 
bilateral breast cancer.
Although metastatic breast cancer is considered incurable, outcomes vary. Chapter 8 provides 
information about prognostic factors for survival of patients with metastatic breast cancer 
(MBC) in relation to HR status. 2,001 women diagnosed with breast cancer in the period 
2003–2006 who developed MBC within 5 years of follow-up were selected from the NCR. 
Patients with hormone receptor positive (HR) tumours (n=1,292, 65% of total) had a median 
survival of 19 months, survival was even poorer for HR negative patients (8 months). A positive 
HR status, longer MFI (>24 months), low grade, younger age, HER2 positive status, bone 
metastasis, surgical metastatic treatment, first line palliative systemic treatment were found 
to be significant positive prognostic factors for survival. The prognostic value of lymph node 
status, HER2 status, adjuvant endocrine treatment and first line palliative chemotherapy was 
dependent on HR status. HR negative patients with 1-3 positive nodes had poorer survival 
compared to patients without positive nodes, and no significant association was found for 
HR positive patients. More prominent better survival was observed for HR negative patients 
compared to HR positive patients when they had a HER2 positive tumour or were treated 
by chemotherapy for MBC. HR positive patients had a poorer survival if they had received 
adjuvant endocrine treatment. This information may help physicians to determine individual 
prognostic profiles and therapeutic strategies for MBC patients.
Since the revision of the guideline in 2012, follow-up visits for physical examination are restricted 
to an annual visit for the first 5 years. In addition, a personal follow-up care plan will be set 
up in the first year of follow-up, tailor-made to the needs of the patient. Chapter 9 discusses 
the main research findings and the strengths and limitations of the performed research. 
Considering the non-adherence to previous guidelines, we do not expect the revised follow-up 
guideline to automatically translate into clinical practice. Better collaboration between the 
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different involved disciplines is needed to implement the revised follow-up schedule. The 
specialised nurse may need to play a prominent role in performing follow-up care, informing 
patients about the benefits of follow-up care and the implementation of the personal follow-up 
care plan. Furthermore, the Dutch reimbursement system needs to encourage adherence to 
current and alternative follow-up schedules. Implementation might be more successful if these 
barriers are taken into account, and future research should investigate the feasibility and cost-
effectiveness of more individualized follow-up. 
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Samenvatting
Borstkanker is de meest voorkomende kanker onder vrouwen in Nederland. Door het 
toenemend aantal vrouwen met borstkanker en een betere levensverwachting neemt het 
aantal patiënten dat nacontrole behoeft toe. De nacontrole behelst 3 elementen: a) vroege 
detectie van terugkeer van de initiële tumor (een recidief genoemd)  of een tweede primaire 
tumor, zodat vroegtijdig, een in opzet genezende, behandeling gestart kan worden om de 
levensverwachting te verlengen; b) patiënten kunnen terecht met klachten en symptomen 
en worden geïnformeerd en begeleid; c) het medisch handelen en de mogelijke gevolgen 
hiervan worden geëvalueerd. Ondanks bestaande richtlijnen bestaat er controverse over 
optimale nacontrole en de effectiviteit van routinematige controles. Daarnaast is weinig inzicht 
in de manier waarop de nacontrole in de praktijk wordt uitgevoerd. Voordat veranderingen 
doorgevoerd kunnen worden om nacontrole te optimaliseren, is meer inzicht nodig in de 
navolging van de huidige richtlijn en de meningen en voorkeuren van zowel patiënten en 
zorgprofessionals hierin. 
Evaluatie van de huidige nacontrole in de praktijk 
Sinds 1999 staan aanbevelingen voor nacontrole beschreven in de Nederlandse richtlijn voor 
borstkankerzorg. De controleschema’s zijn niet wezenlijk veranderd tot 2012. Voor de eerste 
5 jaar nacontrole ziet het schema er als volgt uit: gedurende het eerste controlejaar bezoeken 
de patiënten het ziekenhuis elke 3 maanden, in het tweede jaar elke 6 maanden en daarna 
jaarlijks, voor tenminste de eerstvolgende 3 jaar. Tijdens deze bezoeken wordt lichamelijk 
onderzoek verricht, aangevuld met een jaarlijkse mammografie. Hoofdstuk 2 beschrijft een 
evaluatie van de navolging van de huidige nacontrolerichtlijn voor de eerste 5 jaar in twee 
topklinische ziekenhuizen. In totaal werden 198 vrouwen met de diagnose borstkanker in 
2003 geselecteerd uit de Nederlandse Kankerregistratie (NKR). Navolging van de richtlijn werd 
bepaald door gegevens over de controlebezoeken te verzamelen uit de patiëntendossiers. 
In ieder controlejaar werden verschillen tussen het geadviseerde aantal bezoeken en het 
daadwerkelijke aantal bezoeken gezien. Gedurende het eerste nacontrolejaar werden minder 
bezoeken gevonden dan geadviseerd. Gedurende de daarop volgende jaren, werd echter 
bijna het dubbele aantal bezoeken gezien dan de richtlijn adviseert. We zagen dat vrouwen 
die adjuvant behandeld werden met radiotherapie vaker werden gecontroleerd. Dit leidt tot 
controlebezoeken bij zowel de chirurg als de radiotherapeut. 
Sinds 1999 adviseert de richtlijn om na 5 jaar nacontrole de jaarlijkse bezoeken tot 60-jarige 
leeftijd te continueren. Vrouwen ouder dan 60 en borstsparend behandeld zouden verwezen 
moeten worden naar de huisarts (mammografische controle vindt tweejaarlijks plaats in het 
ziekenhuis) en vrouwen behandeld met een borstamputatie naar het bevolkingsonderzoek 
borstkanker. In het bevolkingsonderzoek krijgen vrouwen tussen de 50 en 75 jaar standaard 
een tweejaarlijkse mammografie. Voor patiënten ouder dan 75 wordt geen verdere nacontrole 
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geadviseerd. Hoofdstuk 3 geeft informatie over de relatie tussen nacontrole in het ziekenhuis en 
deelname aan het bevolkingsonderzoek na borstkankerbehandeling. Voor deze studie zijn NKR-
gegevens gebruikt van 11.227 vrouwen tussen de 50-74 jaar met borstkanker. Alle vrouwen zijn 
behandeld voor primaire borstkanker in de periode januari 1996 - januari 2007 in de noordelijke 
regio van Nederland. Gegevens zijn gekoppeld aan het bevolkingsonderzoek Noord. Negentien 
procent van de vrouwen bezocht het bevolkingsonderzoek na de behandeling voor borstkanker, 
waarvan 4,4% binnen 5 jaar. Vrouwen met een in-situ tumor of een via het bevolkingsonderzoek 
vastgestelde tumor bezochten het bevolkingsonderzoek relatief vaker, en vrouwen met 
adjuvante radiotherapie bezochten relatief minder vaak het bevolkingsonderzoek, zowel 
binnen als na 5 jaar. Patiënten met een later diagnosejaar bezochten het bevolkingsonderzoek 
minder vaak gedurende de eerste 5 jaar nacontrole. Afstemming tussen de nacontrole in het 
ziekenhuis en het bevolkingsonderzoek kan verbeterd worden om overlap te voorkomen en 
het bezoek aan het bevolkingsonderzoek te bevorderen na de nacontrole in het ziekenhuis. 
Patiënten moeten worden geïnformeerd dat het deelnemen aan het bevolkingsonderzoek 
gedurende de eerste 5 jaar nacontrole niet nodig is en wanneer geïndiceerd, dat na 5 jaar 
nacontrole verwezen wordt naar de huisarts of het bevolkingsonderzoek. 
Navolging van de richtlijn voor nacontrole hangt af van de voorkeur en mening van 
zorgprofessionals en patiënten. Hoofdstuk 4 bestudeert de meningen en voorkeuren van 
zorgprofessionals en patiënten over het doel, de duur en frequentie van controlebezoeken, 
welke diagnostische onderzoeken verricht moeten worden en bij wie. Hiervoor werden 
interviews afgenomen in 2 ziekenhuizen bij 23 patiënten en 18 zorgprofessionals. Resultaten 
laten zien dat de huidige nacontrole intensiever is qua frequentie en duur dan de richtlijn 
adviseert. Zorgprofessionals noemen drie belangrijke redenen: ten eerste hebben patiënten een 
voorkeur voor lange en frequente nacontrole; ten tweede wil iedere discipline de patiënt graag 
zelf terug zien om de behandeling te kunnen evalueren; ten derde vanwege financiële prikkels. 
Het belangrijkste doel van de nacontrole was voor zowel zorgprofessionals en patiënten, de 
vroege detectie van nieuwe maligniteiten. Volgens de zorgprofessionals was psychosociale 
begeleiding een belangrijk aspect van de nacontrole. Opmerkelijk werd dit zelden genoemd 
door patiënten. Patiënten waren tevreden over het lichamelijk onderzoek en de geruststelling 
van de zorgprofessional dat alles nog steeds in orde is. De verwachtingen van patiënten over 
de baten van nacontrole en diagnostische onderzoeken is soms onrealistisch. Zowel patiënten 
als zorgprofessionals zijn positief over de nacontrole door verpleegkundig specialisten. 
De resultaten laten zien dat betere informatie over de bijdrage van controlebezoeken en 
diagnostische testen nodig is. Verder is het van belang dat eerder genoemde knelpunten voor 
de navolging van de huidige richtlijn voor nacontrole in acht genomen moeten worden bij de 
implementatie van nieuwe en meer geïndividualiseerde richtlijnen. 
Evaluatie van prognostische factoren voor het risico op terugkeer 
Een belangrijk doel van nacontrole is de vroege detectie van een recidief of tweede primaire 
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tumor. Verschillende studies hebben prognostische factoren voor het risico op terugkeer van 
de ziekte onderzocht. Desondanks blijven enkele bevindingen niet overtuigend.
Een belangrijke risicofactor voor een lokaal recidief zijn positieve snijvlakken. Deze ontstaan 
wanneer de tumor niet volledig verwijderd is. Hoofdstuk 5 valideert een voorspellend model 
(een nomogram), welke gebruikt kan worden als een preoperatief beslismodel, om het risico 
in te schatten op positieve snijvlakken na borstsparende operatie. Voor het ontwikkelen 
van het nomogram werden gegevens gebruikt van 1.185 vrouwen met borstkanker die een 
borstsparende behandeling hebben ondergaan in de noordoost regio van Nederland tussen juni 
2008 en juli 2009. Het nomogram werd gevalideerd in een onafhankelijke dataset bestaande 
uit 331 vrouwen behandeld in het Universitair Medisch Centrum Groningen. Een grafische 
presentatie van het model en een webbased applicatie (http://www.breastconservation.com) 
zijn gebouwd om het gebruik van het nomogram in de klinische setting te faciliteren. Het 
nomogram kan de specialist assisteren bij het identificeren van hoog risico patiënten welke 
mogelijk baat hebben bij een preoperatief MRI of ablatieve chirurgie. 
Klinische uitkomsten op lange termijn voor invasief lobulair carcinoom (ILC: een tumor 
uitgaande van de melkklieren) versus invasief ductaal carcinoom (IDC: een tumor uitgaande van 
de melkgangen) verschillen. Wisselende bevindingen met betrekking tot ziektevrije overleving 
zijn mogelijk het gevolg van de relatie tussen histologisch type en hormoonreceptor (HR) status. 
Daarom bestudeert hoofdstuk 6 of het histologisch type een onafhankelijke factor is voor 
ziektevrije overleving en of het een prognostische factor is voor de plaats van afstandsmetastasen. 
Daarnaast zijn ook de patronen over tijd voor recidieven en afstandsmetastasen bepaald. Alle 
Nederlandse vrouwen gediagnosticeerd tussen 2003 en 2005 met een ILC (n=2.949) of IDC 
(n=22.378) werden geselecteerd uit de NKR. Resultaten laten zien dat ILC meer waarschijnlijk 
zal uitzaaien naar maag-darmstelsel en botten en minder waarschijnlijk naar longen, centraal 
zenuwstelsel en lymfeklieren. Binnen de HR positieve subgroepen was het nog steeds meer 
waarschijnlijk dat ILC zal uitzaaien naar het maag-darmstelsel en minder waarschijnlijk naar de 
longen. Het hoogste risico op terugkeer van de ziekte werd gezien binnen 2 jaar na operatie 
voor HR negatieve patiënten, onafhankelijk van histologisch type. Multivariabele analyses 
laten zien dat histologisch type geen onafhankelijke prognostische factor is voor ziektevrije 
overleving voor zowel de eerste 3 jaar na operatie als daarna. We kunnen concluderen dat 
histologisch type geen onafhankelijke prognostische factor is voor het risico en risicopatroon 
voor terugkeer van de ziekte in de eerste 5 jaar. 
Vergeleken met de algemene vrouwelijk populatie, hebben vrouwen met een geschiedenis met 
borstkanker een 2 tot 3 keer hoger risico op het ontwikkelen van contralaterale borstkanker. 
Daarnaast hebben zij een hoger risico op het ontwikkelen van een andere vorm van kanker. 
Hoofdstuk 7 geeft informatie over het risico op een derde kanker anders dan de borstkanker 
bij 8.752 Nederlandse vrouwen met de diagnose bilaterale borstkanker tussen 1989 en 2008. 
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Verhoogde risico’s werden gezien voor alle derde kankers samen, hematologische maligniteiten, 
maag-, colorectale-, huid- (anders dan melanoom), long-, hoofdhals-, endometrium- en 
ovariumkanker. Een 10-voudig verhoogd risico voor het krijgen van ovariumkanker werd 
gevonden voor vrouwen jonger dan 50 jaar, mogelijk gerelateerd aan genetische factoren. 
Chemotherapie werd geassocieerd met een verlaagd risico op alle derde kankers samen, 
terwijl radiotherapie en endocriene therapie werden geassocieerd met een verhoogd risico. 
Naast behandel- en mogelijke genetische factoren, zijn omgevingsfactoren redenen voor 
verhoogde risico’s. Daarom is het van belang dat tijdens de nacontrole aandacht is voor een 
gezonde levensstijl. Deze resultaten kunnen bijdragen in het optimaliseren en individualiseren 
van behandel- en surveillanceprotocollen voor (jonge) vrouwen met bilaterale borstkanker. 
Hoewel uitgezaaide borstkanker gezien wordt als ongeneeslijk, variëren uitkomsten. 
Hoofdstuk 8 geeft informatie over prognostische factoren voor overleving voor vrouwen 
met gemetastaseerde borstkanker, rekening houdend met de HR status. In totaal werden 
2.001 vrouwen met borstkanker in de periode 2003-2005 die gemetastaseerde borstkanker 
ontwikkelden in de eerste 5 jaar geselecteerd uit de NKR. Patiënten met een HR positieve 
tumor (n=1.292, 65% van totaal) hadden een mediane overleving van 19 maanden, overleving 
was nog slechter voor HR negatieve patiënten (8 maanden). Een positieve HR status, langere 
metastase-vrije interval (>24 maanden), goed gedifferentieerde tumor, jonge leeftijd, HER2 
positieve status, botmetastasen, chirurgische behandeling van de metastase, eerstelijn 
palliatieve systemische behandeling waren onafhankelijke positieve prognostische factoren voor 
overleving. De prognostische waarde van lymfeklierstatus, HER2 status, adjuvante endocriene 
therapie en eerstelijn palliatieve chemotherapie was afhankelijk van de HR status. HR negatieve 
patiënten met 1-3 positieve lymfeklieren hadden een slechtere overleving vergeleken met 
patiënten zonder positieve lymfeklieren, geen significante associatie werd gevonden voor HR 
positieve patiënten. Een meer prominent betere overleving werd gezien voor HR negatieve 
patiënten vergeleken met HR positieve patiënten wanneer zij een HER2 positieve tumor 
hadden of behandeld waren met eerstelijn palliatieve chemotherapie. HR positieve patiënten 
hadden een slechtere overleving wanneer zij behandeld waren met adjuvante chemotherapie. 
Deze informatie kan de specialist helpen bij het vaststellen van het individuele prognostische 
profiel en de behandelstrategie voor gemetastaseerde borstkankerpatiënten. 
Sinds de revisie van de richtlijn in 2012, wordt geadviseerd om het aantal controlebezoeken 
voor lichamelijk onderzoek te beperken tot 1 keer per jaar gedurende de eerste 5 jaar. Daarnaast 
wordt geadviseerd om in het eerste jaar een persoonlijk nazorgplan op te stellen, op maat naar 
behoeften van de patiënt. Hoofdstuk 9 bediscussieert de belangrijkste bevindingen, sterktes 
en zwaktes van de uitgevoerde onderzoeken. Gezien er veel afgeweken werd van de adviezen 
uit de vorige richtlijn, verwachten we niet dat de gereviseerde richtlijn automatisch wordt 
overgenomen in de dagelijkse praktijk. Voor de implementatie van deze gereviseerde richtlijn 
is betere afstemming nodig tussen de verschillende betrokken disciplines. De verpleegkundig 
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specialist zou hierin een grote rol moeten krijgen om de nacontrole uit te voeren, patiënten te 
informeren over de baten van nacontrole en de implementatie van het persoonlijk nazorgplan. 
Verder zal het Nederlandse zorgfinancieringsstelsel navolging van de richtlijn en mogelijke 
alternatieve nacontroleplannen moeten stimuleren. Implementatie heeft meer kans van slagen 
wanneer rekening gehouden wordt met de beschreven knelpunten. Onderzoek in de toekomst 
zal zich moeten richten op de haalbaarheid en kosteneffectiviteit van geïndividualiseerde 
controleschema’s. 
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Dankwoord
‘Is de datum voor je verdediging al bekend?’ is misschien wel de meest gestelde vraag tijdens 
mijn promotietraject. Ja het is zo ver, mijn boekje is af en de datum is bekend! Dan rest mij nu 
nog iedereen te bedanken die betrokken is geweest bij de totstandkoming van dit boekje en 
een aantal personen in het bijzonder.
Allereerst mijn promotor en co-promotor.
Beste Bart (Prof. dr. L.A. Kiemeney), ik wil je bedanken dat je mij de kans hebt gegeven om 
bij jou te kunnen promoveren. Ik heb het zeer gewaardeerd dat je me altijd op een kritische, 
maar vooral enthousiaste manier steeds weer hebt weten uit te dagen om tot dit proefschrift 
te komen. Om praktische redenen waren onze ‘promo-overleggen’ meestal op afstand, maar 
daarom niet minder waardevol! 
Beste Sabine (dr. S. Siesling), bedankt dat je me het laatste zetje hebt gegeven om aan dit 
promotietraject te beginnen. Het is fantastisch door iemand begeleid te worden met zoveel 
enthousiasme en die zoveel kansen en mogelijkheden ziet. Ons kennismakingsgesprek, voor 
een stageplaats bij het IKNO, sloten we al af met  paardenpraat en dat hebben we de zes jaren 
daarop volgehouden. Ik hoop dat we nog een keer de tijd vinden om samen een rit te maken 
en dan zal ik je niet eerst heel Markelo doorsturen, (links / rechts ;-)).
Leden van de manuscriptcommissie, prof. dr. J.H.W. de Wilt, prof. dr. J.B. Prins en prof. dr. E. van 
der Wall, bedankt voor het lezen en beoordelen van dit proefschrift. 
Artikelen schrijf je niet alleen. Ik wil Stans Drossaert,  Karin Groothuis-Oudshoorn, Joost Klaase, 
Sabine Linn, Marian Menke-Pluymers, Gabe Sonke, Adri Voogd, Harry de Vries en alle anderen 
bedanken voor de samenwerking en alles wat ik van jullie heb mogen leren op het gebied 
van patiëntenzorg, kwalitatief onderzoek, epidemiologie en statistiek. Rick bedankt voor jouw 
enthousiasme, ik heb met veel plezier met je samengewerkt. Lifang, de bezoekjes aan jou in 
Rotterdam maakten vaak weer veel duidelijk, dank voor de samenwerking.  
Uiteraard wil ik alle registratiemedewerkers bedanken. De Nederlandse Kankerregistratie was de 
basis voor bijna alle artikelen in dit proefschrift.  In het bijzonder wil ik de registratiemedewerkers 
uit de regio Enschede bedanken, die mij inzicht hebben gegeven wat goede registratie inhoudt 
en altijd bereid waren mijn vragen te beantwoorden. 
Natuurlijk wil ook mijn  (oud-)collega’s bedanken voor al het plezier dat we hebben tijdens het 
werk, vooral in de pauzes. Jullie hebben allemaal bijgedragen aan dit proefschrift, of het nu 
gaat om het regelen van een afspraak, een statistiekvraagje, het koppelen van databestanden 
of gewoon door de belangstelling en motiverende gesprekjes.   
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Mijn kamergenootje Nicol, met jou kan ik altijd even sparren of nu gaat over werk, dit 
proefschrift, hobby’s, eigenlijk over alles. Nu dit proefschrift is afgerond hoop ik dat we ons 
medaille-aantal kunnen gaan verdubbelen! 
Linda, samen naar Barcelona was een mooie ervaring, helemaal te gek dat onze poster daar 
nu een publicatie is geworden. Margriet, bedankt voor het delen van jouw kennis over de 
mammaregistratie en de adviezen die je mij hebt gegeven.  
Zonder de hulp van Marja was dit proefschrift nooit zo mooi geworden, dank daarvoor! Ook 
voor het vormgeven van alle posters de afgelopen tijd en voor de cappuccinotip. 
Vrienden en (schoon)familie bedankt voor jullie interesse en de nodige prettige afleiding de 
afgelopen tijd. Nu is het eindelijk tijd voor een feestje! 
Mijn paranimfen wil ik ook graag bedanken, fijn dat jullie mij willen bijstaan vandaag. 
Lieve Ilse, hoofdstuk 2 is het eindresultaat van jouw afstudeeropdracht waarbij ik je mocht 
begeleiden. Geweldig dat we daarna collega’s zijn geworden en voor verschillende projecten 
hebben samengewerkt. Ik waardeer je oprechte interesse in alles en iedereen en de gezellige 
momenten waarop we even bijkletsen. Lieve Inge, bewondering voor jouw bevlogenheid en 
passie voor de paarden. Je staat altijd voor mij klaar, ook al varieert de fysieke afstand nogal 
eens. Daar ben ik je erg dankbaar voor! Ik help je graag nog een keer verhuizen. 
Uiteraard wil ik ook mijn ouders, broertje en Ninke bedanken. Lieve pa en ma, goed voorbeeld 
doet goed volgen! Ik bewonder jullie om jullie doorzettingsvermogen en alles wat jullie hebben 
bereikt en wil jullie bedanken voor jullie onvoorwaardelijke betrokkenheid, steun en liefde. 
Lieve Jeroen, als wij samen zijn hebben we altijd veel lol. Dank voor al je hulp (ook niet-
proefschrift gerelateerd) en voor je nuchtere blik. Daar kan ik echt van genieten!  
Lieve Harmen, jij hebt als geen ander meegeleefd met mijn promotieonderzoek. Dank voor 
al je hulp en steun, vooral ook bij al die andere dingen in mijn leven. We hebben veel goede 
voornemens om samen leuke dingen te gaan doen, ik hoop dat we nog heel veel samen gaan 
beleven!
Annemiek
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Curriculum Vitae
Annemiek B.G. Kwast was born on April 6th, 1983, in Hengelo, the Netherlands. After graduating 
from high school at the Waerdenborch in Holten in 2001, she studied Nutrition and Dietetics at 
Hanze University Groningen, the Netherlands. In 2006 she obtained her Bachelor degree. From 
September 2006 to September 2008 she did her master in Nutrition and Health (specialisation: 
Nutritional and Public Health Epidemiology) at Wageningen University, the Netherlands. Her 
master thesis was entitled “Dietary energy density and weight status among elderly” and was 
supervised by prof. dr. E.J. Feskens. From 2008 to 2011 she worked at the Comprehensive 
Cancer Center North East (IKNO) as a researcher on various research projects including the 
European Cancer Health Indicator Project (EUROCHIP-3) and research on follow-up after breast 
cancer treatment. In October 2011, Annemiek officially started her PhD research described in 
this thesis at the department of Epidemiology, Biostatistics and HTA at the Radboud University 
Nijmegen Medical Centre under supervision of prof. dr. L.A. Kiemeney and dr. S. Siesling 
(department of research, Comprehensive Cancer Center the Netherlands (IKNL). Since June 
2012 she works as  advisor at the IKNL on various projects involving oncology and palliative 
care. 
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